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A manutenção da fidelidade durante o processo de síntese proteica é de 
extrema importância para a estabilidade das proteínas e o normal 
funcionamento dos processos celulares. Há erros que ocorrem durante este 
processo a uma taxa de 10-4, a um nível fisiológico, sendo tolerados pelas 
células. Quando a taxa de erro aumenta os mecanismos de controlo de 
qualidade de proteínas ficam sobrecarregados, levando à acumulação de 
proteínas aberrantes que podem agregar. O envelhecimento e 
neurodegeneração têm sido associados ao aumento de erros durante a 
síntese de proteínas, mas até agora pouco se sabe acerca dos mecanismos 
causa-efeito envolvidos nestes processos.  
De forma a entender como as células humanas se adaptam ao longo do tempo 
aos erros na síntese de proteínas, desenvolvemos uma metodologia que 
permite a incorporação errónea de aminoácidos de uma forma aleatória nas 
proteínas. Para tal, mutámos o anticodão de um tRNA de serina humano, de 
forma a incorpoporar serina em codões de outros aminoácidos. Para além 
disto, também sobre-expressámos o tRNA de Serina em células HEK293.  
As células que expressam estes tRNAs, acumularam proteínas ubiquitinadas e 
em alguns casos agregados proteicos. Apesar disto, não se observaram 
grandes alterações na proliferação e viabilidade destas células após várias 
passagens em cultura. Os mecanismos de controlo de qualidade de proteínas, 
nomeadamente o sistema ubiquitina-proteasoma, o sistema de resposta a 
proteínas aberrantes no retículo endoplasmático e os chaperones moleculares, 
foram activados de forma diferencial de acordo com o tipo de aminoácidos 
substituídos nas proteínas. Observámos também que a evolução destas linhas 
em cultura levou a alterações ao nível da expressão génica, como a sobre-
expressão de genes envolvidos na resposta ao stress do retículo 
endoplasmático e glicólise. A sequenciação do exoma das linhas celulares 
evoluídas permitiu-nos concluir que estas células acumularam poucas 
mutações comparativamente com a linha controlo. A maior parte dos genes 
mutados, ao longo do tempo, estão envolvidos em processos como a 
transcrição e ligação do RNA.  
Os nossos dados indicam, assim, que as células HEK293 se adaptam aos 
erros que ocorrem durante a síntese proteica, activando mecanismos de 
controlo de qualidade de proteínas e alterando a expressão génica. A 
activação destes mecanismos é dependente do tipo de erros translacionais e 
da passagem em que as células se encontram. Este estudo revela-nos um 
pouco mais acerca de como as células humanas se adaptam aos erros que 
ocorrem durante a síntese proteica.  
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abstract 
 
Protein synthesis fidelity is essential for proteome stability and for functional 
maintenance of cellular processes. Errors occur at frequencies around 10-4 
under normal physiological conditions and are tolerated by cells. If the 
frequency of these basal errors increases, the mechanisms of protein quality 
control become overload, leading to accumulation of misfolded proteins that 
may aggregate. Several conditions have been associated to this phenomenon, 
namely aging and neurodegeneration. But, the cause-effect mechanisms 
remain to be clarified in many cases. 
 
In order to elucidate how human cells respond to the accumulation of protein 
synthesis errors (mistranslation) throughout time, we have developed a 
methodology that allows for the random serine misincorporation in proteins on 
a proteome wide scale. The anticodon of a human serine tRNA was mutated to 
read non-cognate codons. HEK293 cells expressing these tRNAs accumulate 
ubiquitinated proteins and in some cases protein aggregates. Despite this, only 
slight alterations in proliferation and viability were detected after several 
passages in culture. Here we show that activation of quality control pathways, 
namely molecular chaperones, ubiquitin-proteasome system and unfolded 
protein response was dependent on the type of amino acid misincorporation. In 
addition, we observed that evolution of these cell lines in culture deregulates 
gene expression, for example genes involved in endoplasmic reticulum stress 
and glycolysis were upregulated. Whole-exome sequencing of evolved cell 
lines revealed that our cells accumulate a small number of mutations 
comparatively to the control cell line, in genes involved in transcription and 
RNA binding.   
 
Our data indicate that HEK293 cells adapt to protein synthesis errors mainly 
through activation of protein quality control mechanisms and other cellular 
processes depending on the type of amino acid substitution and cells passage 
number. This study reveals new insights on how human cells adapt to protein 
synthesis errors and the consequent accumulation of aberrant proteins.  
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Gln glutamine 
Glu glutamic acid 
Gly glycine 
GTP guanosine thriphosphate 
His histidine 
HSP heat shock protein 
I inosine 
Ile  isoleucine 
IRE-1 inositol-requiring enzyme 1 
JNK JUN N-terminal kinase 
Leu leucine 
Lys lysine 
Met methionine 
mRNA messenger ribonucleic acid 
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N nucleotide 
NH2 amino group 
OH hydroxide  
ORF open reading frame 
PABP poly(A)-binding protein 
PERK protein kinase RNA-like endoplasmic reticulum kinase  
Phe phenilalanine 
PPi inorganic pyrophosphate  
PQC protein quality control  
Pro proline 
RIDD regulated IRE1-dependent decay of mRNA 
RNA ribonucleic acid  
ROS reactive oxygen species 
rRNA ribosomal ribonucleic acid 
Ser serine 
sHSP small heat shock proteins 
T tymine 
Thr threonine 
tRNA  transfer ribonucleic acid 
tRNAi initiator transfer ribonucleic acid 
Trp tryptophan 
Tyr tyrosine 
U uridine 
UBD specific ubiquitin binding domains 
UPR unfolded protein response 
UPS ubiquitin-proteasome system 
UTR untranslated region 
Val valine 
XBP1 X-box-binding protein 1 
mTOR mammalian target of rapamycin 
AMPK AMP-activated protein kinase 
mt-tRNA  mitochondrial tRNAs 
  
  
  
 
Other abbreviations will be explained when used in the text. 
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1.1 The Genetic Code: a set of rules for mRNA translation  
 
The genome stores the genetic information of organisms in the form of 
deoxyribonucleic acid (DNA).  During cell division, daughter cells acquire identical copies of 
DNA of the mother cell, through the process of DNA replication. In this way, genetic 
information is faithfully transmitted to the next generation. Genomic information flows from 
DNA to messenger ribonucleic acid (mRNA), through the process of transcription and to 
proteins though protein synthesis (translation) (1–3). This flow of genetic information was 
incorporated in the “Central Dogma of Molecular Biology” by Francis Crick in 1958. Genomic 
studies in recent years unveiled many exceptions to this dogma, but the “Central Dogma of 
Molecular Biology” is still a framework for understanding the expression of genetic 
information in living organisms (3).  
The genetic code establishes the rules that govern the transfer of genetic information 
from nucleic acids to proteins and is based on nucleotide triplets (codons) that do not overlap 
along the mRNA (Figure 1-1). The 4 ribonucleotides (adenosine – A, guanine – G, uridine – U 
and cyclidine – C) form 64 possible codons (43): 61 specify individual amino acids and 3 stop 
codons (UAA, UGA and UAG), which are used to terminate RNA translation. Some amino 
acids can be specified by only one codon, which is the case of methionine (Met) and 
tryptophan (Trp) (AUG and UGG respectively), but most amino acids are specified by more 
than one codon. For example, leucine (Leu), serine (Ser) and arginine (Arg) are specified by 
six different codons, called synonymous codons. The genetic code is, therefore, degenerated 
(2,4).  
Synonymous codons are usually clustered in boxes rather than being randomly 
distributed throughout the code (Figure 1-1). Amino acids with two-codon boxes, i.e. tyrosine 
(Tyr) or four-codon boxes, i.e. glycine (Gly), differ only in the third position. Arg and Leu are 
exceptions, since they are specified by six codons, a four-codon box and two-codon box that 
differ in the first position of the code (4).  
Codons are decoded by transfer RNAs (tRNAs) in the ribosome. In general, organisms 
contain fewer tRNAs codons. Since wobble decoding (5) allows the first base in the first 
position of the anticodon to interact with more than one nucleotide in the third position of the 
codon. Also, according to the wobble hypothesis, pairing between codon and anticodon at the 
first two codon positions follows the Watson-Crick base pairing, but the last nucleotide of the 
codon can move slightly from its normal position to form a non-Watson-Crick base pair with 
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the anticodon. This explains how multiple codons that specify the same amino acid often differ 
at the third base position only (2,4). 
The distribution of amino acids in the genetic code is also biased toward amino acids 
polar properties. All codons with U in the second position specify amino acids with 
hydrophobic side-chains, while codons with A in the second position specify amino acids with 
polar side-chains (Figure 1-1) (6). Therefore, the genetic code is optimized to minimize the 
impact of mRNA decoding errors.   
 
 
Figure 1-1. The “Universal Genetic Code”. Colors in the figure indicate the chemical properties of the side 
chain of the amino acids. Orange indicates hydrophobic and the rest are hydrophilic aminoacids. Blue 
indicates polar, green basic and pink acidic amino acids. U – uridine; C – cyclidine; A – adenosine; G – 
guanine; Stop – stop codon [adapted from (6,7)]. 
 
 
1.2 tRNAs and aaRSs establish the genetic code   
 
The accurate decoding of the four-nucleotide of the mRNA language requires two 
important elements: transfer RNAs (tRNAs) and aminoacyl-tRNA synthetases (aaRSs). To 
produce proteins, cells link amino acids to tRNAs using a group of 20 enzymes called aaRSs. 
This reaction results in the formation of aminoacyl-tRNAs (aa-tRNAs). The anticodon of aa-
tRNA then pairs with codons in mRNA, so that the activated amino acid can be added to the 
growing polypeptide chain in the ribosome. It is this specific attachment of a given amino acid 
to a particular tRNA that establishes the genetic code (1,8,9).  
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1.2.1 tRNAs  
 
tRNAs are small, ubiquitous RNAs that function as “adapter” molecules matching 
codons to particular amino acids. They have two crucial properties: each tRNA accepts a single 
amino acid in its 3’- end and contains a trinucleotide, the anticodon, complementary to the 
codon in the mRNA assigned to that amino acid (1,9).  
In animal and plant cells there are between 50-100 different tRNAs. These numbers 
differ from the numbers of amino acids, because most amino acids have more than one tRNA 
to which they can attach. It also differs from the number of codons in the genome, because 
many tRNAs can pair to more than one codon (1). tRNAs with different anticodons that accept 
the same amino acid are called isoacceptors and their number varies between organisms. For 
example, minimal genomes of some bacteria have only one tRNA for each amino acid, while 
human cells have 49 different tRNAs isoacceptors (10,11).  
tRNAs are ~ 76 nucleotides long and, despite differences in the primary structure, all 
have a common “cloverleaf”  secondary structure  (Figure 1-2) (1,11,12). This structure is 
characterized by three stem loops (formed by base pairing complementarity) and four helices. 
The acceptor stem helix is formed by seven base pairs combining the 5’and 3’- end of the 
molecule. At the 3’-end, there is a conserved CCA sequence, that carries the aminoacyl residue 
via an ester link between the ribose 2’- or 3’-hydroxil (OH) group and the carboxyl group of 
the amino acid. The D stem loop, is formed by a helical region of 3-4 base pairs and a loop 
with 8-11 nucleotides. The loop contains two hydrouridine bases, hence the name 
dihydrouridine-stem-loop. The anticodon stem loop located in the opposite end to the acceptor 
stem, contains the anticodon triplet in the center of its loop. This loop has a universal length of 
7 nucleotides with a consensus sequence Py32-U33-XYZ-Pu(modified)-N38, where Py 
represents pyrimidine, U uridine (conserved in all tRNAs), XYZ the anticodon, Pu purine and 
N any nucleotide. The TψC stem loop also contains 7 nucleotides and the TψC sequence, 
where T is thymine, ψ pseudouridine and C cytosine. In addition to these defined stems, there 
is also a variable region between the TψC stem and the anticodon stem, whose length can vary 
from 4 to 24 nucleotides (1,11).  
tRNAs can be divided in two classes (Class I and II) according to the length of the 
variable loop. Class I tRNAs have a short loop, 4-5 nucleotides (most tRNAs), while Class II 
tRNAs have a long extra loop with at least 11 nucleotides. This class includes Leu and Ser 
tRNAs in eukaryotes and Tyr, Leu and Ser tRNAs in prokaryotes. The long loop may be 
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involved in the recognition of these tRNAs by their cognate aaRSs or in discrimination against 
non-cognate synthetases (11,13).  
In all tRNAs, the cloverleaf structure forms a tertiary L-shaped structure created by 
hydrogen bonding (Figure 1-2). In the L-shaped structure there are two functional domains 
with independent origins, namely the acceptor stem, at one end of the tRNA and the anticodon 
stem, at the other end of the structure. This structure is consistent with the role of tRNAs in 
protein synthesis as it allows the codon/anticodon interaction at the decoding center of the 
small ribosomal subunit and contacts of the aminoacyl-(peptidyl) residue with the peptidyl-
transferase center on the large ribosomal subunit (1,11,13).  
 
 
 
 
 
 
 
 
Figure 1-2. tRNA structures. A – tRNA secondary structure (cloverleaf). The acceptor stem is represented 
in red and has the CCA end and the 3’- terminal adenosine that accepts amino acids. Blue representes the D-
loop, green the anticodon loop, black the variable loop and grey the T-loop. B – tRNA tertiary structure (L-
shape). The cloverleaf secondary structure folds to the L-shaped tertiary structure. Both figures have 
corresponding colors [adapted from (12)]. 
 
 
aaRS recognize their cognate tRNAs through a limited number of nucleotide residues 
called identity determinants, which are commonly located in the tRNA anticodon, the acceptor 
stem and the associated “discriminator” base at position 73. Also, the variable stem can contain 
identity elements for tRNA recognition. Each tRNA family has its own discriminator base. For 
example, all Ser tRNAs have G73 and all Leu tRNAs have A73 discriminator bases. Along with 
tRNA identity determinants, the tRNA recognition system may also involve identity anti-
determinants which are responsible for preventing their recognition by non-cognate aaRS 
(13,14).  
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tRNAs are heavily modified during their maturation process. Over 100 known post-
transcriptional modifications have been reported, as well as, the enzymes responsible for 
catalyzing them. The number of modified bases varies among individual tRNA types, for 
example tRNAs of S. cerevisiae have an average of 11 modifications per tRNA, while 
mammalian tRNAs have an average of 13 to 14 modifications (15,16). Many examples of 
tRNA modifications include ribose/base methylations (Gm, Cm/m5C), base isomerization (U to 
pseudouridine ψ), base reduction (U to D; dihydro-uridine), base thiolation (s2C, s2U, s
4U) and 
base deamination (inosine). Some modifications are conserved in all tRNAs, for example, 
dihydro-uridine (D) residues in the D-stem or pseudouridine in the T-stem (11,17).  
Modifications in tRNAs are crucial for tRNA structure, function and stability and 
hypomodified tRNAs are targeted for degradation (18). Specific modifications in the anticodon 
loop affect directly translation efficiency. For example, modified bases at position 37 (adjacent 
to the anticodon) strengthen codon-anticodon interactions and prevent translational 
frameshifting (16,19). One example of a modified residue at position 37 is the 1-
methylguanosine (m1G) in tRNAs that decode codons starting with C (16,20). On the other 
hand, modifications at position 34, for example adenosine-to-inosine (A-to-I), are usually 
necessary for codon-anticodon wobbling to occur. These modified nucleosides in the anticodon 
loop and also in other positions can influence tRNA recognition of by aaRS and also function 
as identity or anti-identity determinants (16,18).  
In addition to the roles in translation, recent studies unveil new functions for tRNAs. 
For example, mitochondrial tRNAs may be involved in the control of apoptosis through 
binding to cytocrome c, promoting cell survival (21). Also, specific tRNAs genes can act as 
insulators in the human genome where they help separate actively transcribed chromatin 
domains from silent ones (17,22).  
 
 
1.2.1 aaRS 
 
aaRS are responsible for the aminoacylation of tRNAs with cognate amino acids, thus 
establishing the amino acid – trinucleotide relationships of the genetic code (11). Each aaRS 
recognizes and activates a single amino acid through a universally conserved two-step 
mechanism. In the first step (1) the amino acid (aa) is condensed with adenosine triphosphate 
(ATP) forming a tightly bound aminoacyl-adenylate and releasing inorganic pyrophosphate 
(PPi). In the second step (2) the activated amino acid is transferred to the 3’- end of the tRNA, 
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originating an aminoacyl-tRNA (aa-tRNA) and releasing adenosine monophosphate (AMP) 
(Figure 1-3) (23,24).  
(1) E+aa+ATPE(aa-AMP)+PPi 
(2) E(aa-AMP)+tRNAE+aa-tRNA+AMP 
 
 
Figure 1-3. The aminoacylation reaction. In the first step there is activation of the amino acid at the aaRS 
active site with ATP to form aminoacyl-adenylate. The amino acid is then transferred to the 3’-end of the 
tRNA. ATP – adenosine triphosphate; AMP– adenosine monophosphate; PPi – pyrophosphate [adapted from 
(24)]. 
 
 
aaRS are ancient enzymes, ubiquitously expressed and universally distributed across 
the phylogenetic three suggesting that they are among the oldest peptide families (23,25,26). 
All cells contain at least 20 synthetases (eukaryotic cellular organelles use an additional set of 
synthetases), one for each of the 20 amino acids of the genetic code (11). These 20 aaRS are 
divided in two classes (Class I and Class II), each class containing 10 enzymes. This division is 
based on the differences in the structural topology of their active sites. All the enzymes in each 
class evolved from one unique single-domain protein and there is no evidence for the existence 
of a common ancestor of the two classes (11,25,27).  
Class I aaRSs are generally monomeric and have in their catalytic domain a Rossman 
nucleotide binding fold composed of alternating β strands and α helices. Due to their structure, 
Class I aaRSs, approach tRNA molecules from the minor groove of the tRNA acceptor stem 
and aminoacylate the terminal adenosine (of the CCA-3’ terminal acceptor stem) at the 2’-OH 
position. Class II aaRSs are typically multimeric enzymes and their active sites contain seven-
stranded antiparallel β fold with flanking α helices. Enzymes present in Class II, approach 
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tRNAs from the major groove and charge the terminal adenosine at the 3’-OH position, based 
on studies carried out in E. coli  (11,23,25,28). 
The aaRS classes can be also divided into three subclasses, namely Ia,b,c (Class I) and 
IIa,b,c (Class II). Each subclass is thought to have evolved from the progenitor of the main 
class. The enzymes in the same subclass show a tendency to recognize amino acids that are 
chemically related. Subclasses Ia and IIa catalyze aminoacylation reactions of many of the 
hydrophobic amino acids, while subclasses Ib and IIb capture the carboxyl side-chain amino 
acids and the amidated (NH2) derivates. Subclasses Ic and IIc catalyze aminoacylation 
reactions for aromatic amino acids (Figure 1-4) (25).  
 
 
Figure 1-4. The two subclasses of aminoacyl-tRNA synthetases that evolved from two independent 
single-domain proteins. The ancestor three dimensional active-site domain is represented for each class 
[from (25)]. 
 
 
To ensure accurate aminoacylation, aaRSs have specific determinants that are crucial to 
recognize the cognate tRNAs. Generally, the conserved catalytic domain contains regions 
proximal to the active site responsible for binding of the acceptor stem, whereas the anticodon 
(when recognized) is bound by a separate divergent domain. Studies in E. coli revealed that the 
Rossman fold contains an acceptor binding domain composed of structural elements that 
specifically interact with a number of positions in the acceptor stem of the glutamine tRNA 
(tRNAGln). One example is the Leu-136 residue, where mutations in this site result in generally 
relaxed tRNA specificity leading to the mischarging of non cognate tRNAs (29,30).  
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aaRSs display an overall error rate of about 1 in 10,000 (10-4). This specificity is 
achieved, as described above, by the contacts between aaRSs and tRNAs, but also between 
aaRSs and amino acids. The discrimination by aaRSs of amino acids is potentially more 
problematic, since amino acids are considerably less complex than tRNA structures. To make 
sure that the correct amino acid is chosen, aaRSs possess a double-sieve mechanism. The 
active site serves as the first sieve, where the discrimination of amino acids based on size 
(larger amino acids are excluded) and chemical properties occurs. Despite this, misacylation 
can occur when the cognate amino acid displays high structural similarity to other non-cognate 
amino acid (for example the amino acids that differ by a single methyl group; valine (Val) and 
isoleucine (Ile)). To overcome this problem, some aaRSs possess an intrinsic proofreading 
activity in the editing site, which is the second sieve (Figure 1-5) (31). In the editing site, 
misactivated or mischarged amino acids are hydrolyzed, whereas cognate amino acids are 
rejected on the basis of size or hydrophobicity. Editing can potentially occur either before (pre-
transfer editing) or after (post-transfer editing) the misactivated amino acid is attached to the 
tRNA. Pre-transfer editing involves the hydrolysis of the misactivated aminoacyl-adenylate, 
aa-AMP, and post-transfer editing involves the hydrolysis of the aa-tRNA. All aaRSs have the 
capacity to hydrolyze non-cognate aa-AMPs (pre-transfer editing), but not all deacylate aa-
tRNA (post-transfer editing), as methionyl-tRNA synthetase (MetRS), lysyl-tRNA synthetase 
(LysRS) and seryl-tRNA synthetase (SerRS) (31,32).  
 
 
Figure 1-5. Pre-transfer and post-transfer editing of non-cognate amino acids by aaRSs. In pre-transfer 
editing AA-AMP is hydrolyzed directly, preventing the synthesis of a non-cognate aa-tRNA. In post-transfer 
editing the aa-tRNA is translocated to the editing site where the AA is removed. AS – active site; AA – 
amino acid; ATP – adenosine thriphosphate; ES – editing site; PPi – pyrophosphate;  
AMP – adenosine monophosphate [from (31)].  
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Editing decreases the frequency of errors during protein synthesis and is important for 
translational quality control, being considered an essential function (33,34). When this activity 
is compromised, a wrong amino acid can be incorporated into proteins (23). Several studies in 
bacteria, human cell cultures and mice suggest that defects in editing are toxic and can be 
associated to serious pathologies (33).  
In addition to protein synthesis, aaRS have long been known to participate in other 
cellular processes. They have been implicated in the regulation of expression of their own 
genes (30).  In both bacteria and eukaryotes, mRNAs of certain aaRSs encode short sequences 
that fold into the cloverleaf structure to mimic cognate tRNAs. aaRS in excess can bind to 
these “tRNA-mimicking elements” blocking translation of the aaRS mRNA, keeping the 
amount of specific aaRSs (35). Similar regulation occurs at the level of transcription. Other 
functions of aaRS include mediation of glucose and amino acid metabolism, regulation of the 
development of specific organs and tissues, triggering or silencing inflammatory responses and 
the control of cell death and stress responses that may lead to tumorigenesis (36–39).  
 
 
1.3 Protein synthesis in the ribosomes  
 
mRNA translation occurs in ribosomes that work in conjugation with tRNAs, amino 
acids, translational factors and aaRSs, in order to interpret mRNA information and catalyze the 
formation of peptide bonds (2).  Ribosomes contain several different ribosomal RNA (rRNA) 
molecules and more than 50 proteins. In eukaryotes, ribosomes are composed by a small 
subunit (40S) and a large subunit (60S), according to their sedimentation coefficients in 
Svedberg units (S). The small subunit contains one molecule of 18S rRNA and 33 proteins 
while the large subunit contains three rRNAs (28S, 5.8S and 5S) and 47 proteins. Both 
subunits contain three tRNA binding sites: the aminoacyl site (A site), the peptidyl site (P site), 
and the exit site (E site) (1,40). The A site accepts the aa-tRNA, the P site holds the tRNA that 
is bound to the nascent polypeptide chain and the E site holds the deacylated tRNA before it 
leaves the ribosome (1).   
There are three main steps in ribosomal translation: Initiation, Elongation and Termination. 
An extra step consists of ribosome recycling. During Initiation the 40S subunit joins the 
mRNA and searches for the initiation codon (AUG), using the initiator tRNA (tRNAi) as the 
searching tool. During elongation aa-tRNAs enter in the A site of the ribosome, where 
decoding takes place through base complementarity between anticodons of acylated tRNA and 
codons in the mRNA. The ribosome then translocates through the mRNA and catalyzes peptide 
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bonds between amino acids, forming a polypeptide chain. Termination occurs when the 
ribosome encounters a stop codon, which leads to dissociation of the newly synthesized 
polypeptide chain from the ribosome. In the recycling step, ribosomal subunits are dissociated, 
mRNA and deacylated tRNA are released and the components can be recycled for initiation of 
another round of translation (Figure 1-6) (41).  
The process of translation is conserved among of living organisms, despite some 
differences between bacteria and eukaryotes (1,42).  For the purpose of this work I will focus 
on the process of eukaryotic translation. 
 
 
 
Figure 1-6. The process of mRNA translation in eukaryotes showing the three main steps: Initiation, 
Elongation and Termination and the extra step: Recycling. During initiation 40S subunit joins mRNA 
and searches AUG codon using the eukaryotic initiator tRNA (tRNAMet). During the elongation amino acids 
are added to the growing peptide chain. When ribosome encounters a stop codon (UAG) translation 
terminates. Ribosomes and other translational components dissociate to be recycled and used in another 
round of translation. In blue is represented the open reading frame (ORF) [adapted from (41)]. 
 
 
1.3.1 Initiation  
  
 Before initiation of mRNA translation two events must occur. Firstly, the amino acid is 
attached to the tRNAs originating aa-tRNAs. Secondly, free ribosomes must dissociate in the 
two ribosomal subunits after each round of translation. eIF3 and probably eIF1 and eIF1A are 
three eukaryotic factors that participate in this process (Figure 1-7) (42,43).    
The first step of eukaryotic initiation is the assembly of the ternary complex 
eIF2.GTP.Met-tRNAi. The eIF2 binds GTP which is hydrolyzed to GDP during initiation. 
Because eIF2 has high affinity for GDP, another factor, eIF2B is needed to recycle GDP to 
GTP. The ternary complex binds to the small subunit 40S with the help of eIF1, eIF1A, eIF3 
and probably eIF5 originating the 43S pre-initiation complex (42–44).  
Natural 5’UTR possess secondary structures that require the cooperation of some 
factors to unwind the 5’cap of mRNA and allow ribosomal attachment. The 5’cap of mRNA is 
recognized by eIF4F complex (consisting of eIF4E, eIF4G and eIF4A). The eIF4E is a cap-
binding protein that recognizes the terminal 7-methylguanosine of the mRNA 5’end. The 
Unravelling the cellular networks that regulate proteotoxic stress  
24 
 
eIF4A is a DEAD-box RNA helicase. Finally, eIF4G acts as a “scaffold” that binds eIF4E, 
eIF4A, poly(A)-binding protein (PABP) and eIF3. The factors eIF4B and eIF4H bind to 
mRNA and enhance the activity of the eIF4A subunit RNA-helicase (42,43,45).  The giant 
heteromultimeric complex, eIF3 and PABP, which recognizes the 3’-poly A tail, help the 
assembly of the mRNA in the 43S complex. The eIF3 serves as a scaffold to alter the 
conformation of the 40S subunit, allowing easier access for mRNA, while PAB interacts with 
eIF4G leading to circularization of the mRNA, which is thought to stimulate translation (42–
44). The complex formed scans the mRNA from 5’-3’ direction, and stops when the Met-
tRNAi anticodon recognizes the initiation codon in the mRNA. The scanning process requires 
ATP hydrolysis, and the assistance of eIF4A, eIF4G and eIF4B. However, the mechanism by 
which these factors assist scanning is still poorly understood (42).  
The selection of the initiation codon (AUG) is facilitated by specific surrounding 
nucleotides which form a favorable sequence context (1,42). The best context contains a purine 
at position -3 and a G at position +4. Then, occurs hydrolysis of GTP bound to eIF2, a reaction 
facilitated by eIF5 a GTPase activating protein (GAP). eIF2.GDP releases the Met-tRNAi in 
the P-site of the small subunit (40S) and dissociates from the complex. Some other factors, like 
eIFs 1, 1A, 3 and 5, also dissociate at this stage (42–44).  
The large ribosomal subunit 60S joins to 40S.Met-tRNAi.mRNA complex and this 
requires hydrolysis of GTP bound to eIF5B. This factor stabilizes tRNAi and facilitates the 
joining of the two ribosomal subunits. This step is irreversible since the ribosomal subunits do 
not dissociate until the entire mRNA is translated and protein synthesis is terminated. 
eIF5B.GDP has low affinity for the ribosome so it dissociates from the complex. eIF1A also 
dissociates at this stage (Figure 1-7) (42,43).  
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Figure 1-7. Scheme of the first step in eukaryotic translation – Initiation. After ribosome recycling, there 
is formation of the eIF2 ternary complex. This complex joins the 40S subunit, eIF1, eIFA, eIF3 and probably 
eIF5 to form 43S pre-initiation complex. During mRNA activation, the mRNA cap-proximal region is 
unwound in an ATP-dependent manner by the helicase eIF4F and eIF4B. 43S joins this mRNA region and 
scans the 5’UTR in a 5’-3’ direction. When the initiation codon is recognized, eIF2-bound GTP is 
hydrolyzed. Finally 60S subunit joins 48S initiation complex with the concomitant displacement of eIF2-
GDP and several other factors [adapted from (43)]. 
Unravelling the cellular networks that regulate proteotoxic stress  
26 
 
1.3.2 Elongation 
 
Elongation starts with a peptidyl-tRNA in the P site and a vacant A site which accepts 
aa-tRNA carried in the form of a ternary complex with eEF1A.GTP (42). Only the cognate 
tRNA carrying the correct amino acid can enter the elongation phase to produce correct 
anticodon-codon interactions at the ribosomal A site. Binding of the cognate tRNA to the A 
site, triggers GTP hydrolysis, which promotes a conformational change in the ribosome that 
leads to tight binding of the aa-tRNA in the A site and the release of the eEF1A.GDP complex.  
The conformational change in the ribosome also positions the 3’ end of aa-tRNA in the A site 
in proximity to the 3’- end of peptidyl-tRNA in the P site (1,46). The ribosomal peptidyl-
transferase center then catalyzes the formation of the peptide bond between incoming amino 
acid and peptidyl-tRNA. The tRNA in the A site becomes deacylated and moves to the E site 
during ribosome translocation (42). This step is enhanced by eEF2 in combination with GTP 
hydrolysis (1,42). After translocation, the deacylated-tRNA is in the E site and the peptidyl-
tRNA in the P site. The A site is free to receive another aa-tRNA complexed with eEF1A.GTP 
and this cycle is repeated several times until a stop codon is found at the A site and the process 
of termination is initiated (Figure 1-8) (1,42,46). After the hydrolysis of GTP and the release of 
aa-tRNA, into the ribosome, eEF1A.GDP is released and recycled to its GTP-bound form to 
participate in successive rounds of polypeptide elongation. eEF1B is a multifactor complex 
that catalyses this exchange of GDP for GTP (42).  
 
 
1.3.3 Termination and Recycling  
 
The presence of a stop codon in the ribosome A site recruits translation termination 
factors that activate the hydrolysis of the ester bond that links the polypeptide chain to the P 
site tRNA. In eukaryotes, these are two protein factors: eRF1 and eRF3. The class 1 factor, 
eRF1, has similar structure to that of tRNAs, recognizes the three stop codons (UAA, UAG, 
UGA) in the A site and also promotes the hydrolysis of peptidyl-tRNA in the P site.  
The class 2 factor, eRF3, is a translational GTPase that stimulates the activity of eRF1. 
It also promotes the release of eRF1 from the ribosome following peptidyl-tRNA hydrolysis 
(Figure 1-8) (1,42,46). After termination, various components of the ribosome are recycled so 
they can be used in another round of translation. While in prokaryotes ribosomes appear to be 
recycled, in eukaryotes this step remains obscure. Little is known about how the ribosomal 
subunits are dissociated and how mRNA and deacylated tRNA are released. Some studies 
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showed that eIF3 can have an anti association activity due to induction of a conformational 
change in the 40S subunit, increasing the rate of subunits dissociation as well as lowering the 
rate of association. The close loop model of eukaryotic mRNAs suggests that the 40S subunit 
is not released back into the cytoplasm. Instead, it may be shuttled across or over the poly (A) 
tail back to the 5’- end of the mRNA allowing a subsequent round of translation in the same 
ORF (42,46).  
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Figure 1-8. Scheme of mRNA elongation, termination and recycling in eukaryotes. During elongation 
the A vacant site accepts the aa-tRNA.eEF1A.GTP complex. If correct base pairing is formed in the A site, 
ATP is hydrolyzed and eEF1A.GDP is released. Peptide bonds are then catalyzed by ribosomes. Deacylated 
tRNA moves to the E site during ribosome translocation due to GTP hydrolysis by eEF2. After translocation, 
deacylated tRNA is in the E site while peptidyl-tRNA is in the P site. A stop codon in the A site recruits 
releasing factors that lead to peptidyl-tRNA hydrolysis. Finally the various components of the ribosome are 
recycled [from (42)]. 
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1.4 Maintenance of mRNA translational accuracy  
 
Translation of a particular codon depends on both the nature and abundance of the 
respective tRNAs, particularly on the non- random use of synonymous codons and the 
availability of the respective isoacceptor tRNA (47). However, in cells there are non-cognate 
and near-cognate tRNAs that may participate in the discrimination process by aaRS and 
ribosomes. Furthermore, modifications in tRNAs, especially those targeting the anticodon loop 
region, affect the function of the tRNA and can influence translational accuracy (48).    
To facilitate accurate selection of amino acids or charged tRNAs, synthetases and 
ribosomes have kinetic discrimination mechanisms, driven by induced fit. In addition, to 
increase overall fidelity, there are quality control mechanisms in the two key events of mRNA 
translation: the synthesis of a correct aa-tRNA and the stringent selection of the aa-tRNA by 
the ribosome. The first one consists in the proofreading activity or editing in some aaRSs, a 
process already described in section 1.2.1 (49–51).  
In the ribosomes, translational fidelity is controlled at two basic selection steps: 
preferential rejection of incorrect ternary complexes prior to GTP hydrolysis in the initial 
selection stage and preferential rejection of incorrect (mostly near-cognate) aa-tRNAs in the 
proofreading stage after GTP hydrolysis. In the first stage, the A site is in a low affinity state, 
to allow sampling of codon-anticodon interactions based on Watson-Crick base-pairing, at first 
and second positions. Sometimes this base-pairing is not strong enough and some deviations to 
the genetic code can arise that must be corrected in the second stage. The ribosome controls the 
differences in the stabilities of the codon-anticodon complexes and specifically accelerates the 
rates of GTP hydrolysis by the elongation factor. After GTP hydrolysis, the elongation factor 
can release aa-tRNA to enter in the large subunit A site or it can be rejected from the ribosome 
(proofreading) (Figure 1-9) (47,52–54). An additional mechanism can contribute to high 
fidelity protein synthesis after peptidyl-transfer. In this quality control step, ribosome 
recognizes errors by evaluating the codon-anticodon helix in the P site, leading to reduced 
fidelity during subsequent tRNA selection and ultimately to premature termination by release 
factors (49).  
Over the past few years, many studies have documented the connection of ribosomes 
with mRNA and protein quality control processes (55–58). Ribosomes seem to be responsible 
for the recognition of defective mRNAs. Studies in yeast showed that the GTPase Ski7,  which 
is related to eRF3, interacts with ribosomes and is also a component of the cytoplasmic 
exosome, linking the process of recognition of nonstop mRNAs (do not have a stop codon) to 
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its decay (55,58). Defective proteins formed in the ribosomes can be rapidly degraded by co-
translational protein quality control processes (56,58).  
 
 
 
 
Figure 1-9. The two stages of quality control in the ribosome: Initial selection and Proofreading. Initial 
selection occurs by correct codon-anticodon pairing in the decoding center leading to GTP hydrolysis and 
conformational alterations. Once GTP is hydrolysed, the elongation factor releases aa-tRNA which can enter 
the A site (accommodation) form a peptidyl-tRNA or is rejected by the ribosome. 
P – P site; A – A site [adapted from (53)]. 
 
 
1.5 Errors during protein synthesis – mRNA mistranslation  
 
mRNA translation is a highly accurate biological process, however it is not error free. 
Errors can occur during the aminoacylation reaction or mRNA decoding in the ribosomes. 
Aminoacylation errors are mainly caused by failure of aaRS to differentiate between amino 
acids with similar structure or by the incorrect recognition of tRNAs. As already discussed, 
such errors are minimized by the aaRS editing mechanisms and by highly specific tRNA-aaRS 
interactions. In the ribosome, matching codons with anticodons is a tricky process that involves 
a certain amount of Watson-Crick wobble, to allow reading of all 64 codons with a minimal set 
of tRNAs. So, despite careful matchmaking, mistakes can occur. Four type of errors happen 
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during ribosome decoding namely; missence errors, which result in the substitution of one 
amino acid for another, nonsense errors, that cause readthrough of stop codons and produce 
proteins with extended C-termini; frameshifitng errors, that alter the mRNA reading frame, 
producing out-of-frame truncated proteins; and finally processivity errors, which cause 
premature termination (59–62).  
 The frequency of global translational error in vivo, in E. coli and mammalian cells is in 
the order of 10-4 (24,63–65). This physiological error is sustained due to protein quality control 
systems (PQC) which refold or destroy misfolded proteins after translation is finished. 
Environmental conditions (for example amino acid starvation) influence the fidelity of 
translation and the frequency of translation errors can increase significantly (60,64). Indeed, 
translational errors occur at a higher frequency than DNA replication errors. In E. coli, the 
typical mutation rate is approximately 10-9, meaning that perfectly replicated genomes are 
commonplace, but perfectly synthesized proteomes never occur. Some studies suggest that the 
same occurs in eukaryotes (66,67). Error rates above 10-3 per codon originate statistical 
proteomes, meaning that some proteins vary stochastically in their sequence and do not 
faithfully represent the respective genes (67).  
 mRNA mistranslation leads to the synthesis of altered proteins that may not properly 
fold and may have the propensity to form protein aggregates. For this reason errors in protein 
synthesis have been assumed to have negative consequences for cells and may even cause 
disease (41,68). For example in mice an editing defective alanyl-tRNA synthetase (AlaRS) 
leads to loss of Purkinge cells and consequent ataxia (69). Surprisingly, several studies suggest 
that organisms can tolerate mRNA mistranslation relatively well and in specific cases errors 
can even be advantageous (Figure 1-10). Little is known about how cells tolerate high level of 
translational errors, but mistranslation may generate advantageous proteome diversity. Since 
these studies have focused on one type of mistranslation, it is also likely that organisms might 
tolerate variation in error rates for one or a limited number of amino acids (65,67). For 
example, Candida spp. contain a Ser tRNA (tRNACAG
Ser) that can be atypically recognized by 
both SerRS and LeuRS and for this reason is aminoacylated with both Ser and Leu, leading to 
the ambiguous decoding of the CUG codon (70,71). Physiologically misincorporation of Leu 
for Ser at this codon occurs at rates around 3% (72). Experiments with a construct tRNA from 
Saccharomyces, showed that Candida albicans can tolerate up to ± 28% incorporation of Leu 
and ± 70% incorporation of Ser at CUG sites without compromising growth rate. In certain 
environmental conditions this high level of mistranslation is advantageous (72,73) as 
ambiguous cells survive better  in toxic environments containing cadmium, arsenate and 
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hydrogen peroxide (73,74). Increased mistranslation is also associated with major genome-
wide rearrangements (75).   
Another type of frequent mistranslation is the misincorporation of Met at various non-
cognate codons which is beneficial in mammalian cells (76). During immune response, 
following exposure of mammalian cells to virus particles and Toll-like receptors, there is 
tenfold increase in misincorporation of Met at non-cognate-sites. Since Met residues can 
protect proteins from reactive oxygen species (ROS) mediated damage, the ability to increase 
Met levels in proteins by inducing tRNA Met-misacylation provides a protective mechanism 
against oxidative stress (76,77). This phenomenon was later demonstrated either in bacteria 
and yeast (78,79). The deliberate synthesis of proteins with alterations, in this case, an increase 
of Met residues, was named “adaptive translation” (77).  
 
 
Figure 1-10. Consequences of protein synthesis errors in cells. Protein synthesis errors can be neutral 
having no effect (error containing proteins fold correctly), harmful (when errors lead to misfolding and 
aggregation) and beneficial (if the mutant protein acquires new functions). Misfolding proteins may also be 
beneficial if they trigger the stress response, creating pre-adaptation conditions that allow cells to survive 
better when exposed to stress.  
 
 
The benefits of enhancing protein mistranslation rates may be due to either direct or 
indirect mechanisms. Indirect mechanisms include activation of the heat shock response and 
other stressor proteins and activation of stress-induced mutagenesis or wide-spread genome 
rearrangements. Direct mechanisms are related to the alteration of the proteome pool, as for 
example the misincorporation of Met into proteins, or the acquisition of novel protein 
functions (67). The last mechanism can be particularly important if the new protein variant 
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results in a dominant phenotype. For example in Candida, increase in misincorporation of Leu 
resulted in higher cell adhesion (80).  
 
 
 
Figure 1-11. Mechanisms of adaptation to mRNA mistranslation. (A) Protein synthesis errors can cause 
stress-induced mutagenesis, which can increase the acquisition of drug resistance, (B) upregulation of stress 
responses such as heat shock proteins, (C) protection against oxidative stress by Met misincorporation and 
(D) acquisition of novel or altered functions by proteins [from (67)]. 
 
 
1.6 Protein misfolding  
 
In order to carry out biological functions, proteins must fold into specific 
conformational states (encoded in their sequence). Folding takes place in complex and highly 
crowded environments, with the assistance of several auxiliary proteins known as molecular 
chaperones, which protect incompletely folded polypeptide chains from non-productive 
interactions. There are also folding catalysts that are responsible for isomerization of peptide 
bounds and formation of disulphide bounds. The conformation of a protein is determined by a 
very large number of relatively weak non-covalent interactions like hydrogen and hydrophobic 
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interactions. Therefore, folding depends on the “correct” (native-like) contacts between 
residues, which are in average more stable than “incorrect” (non-native) interactions. It also 
depends on the size and complexity of proteins. For larger proteins, folding is more complex 
and involves partially folded intermediate states (68,81,82).  
Sometimes proteins cannot fold properly and are degraded or aggregate. DNA 
mutations, transcriptional errors, translational errors and erroneous post-translational 
modifications are important causes of protein misfolding. Environmental conditions and 
pathologies may exacerbate the errors perturbing protein folding beyond cellular repair 
capacity (83,84). 
Misfolded proteins expose hydrophobic regions and are prone to self association and 
subsequent aggregation (66,81). Even though the specific mechanisms by which misfolded 
proteins perturb cellular functions are not entirely understood, they can disrupt cell 
membranes, interact with normally folded proteins, overload PQC mechanisms, generate ROS 
and induce apoptotic and inflammatory responses (85,86).  
 
 
1.7 Protein Quality Control 
 
To minimize toxic effects of misfolded proteins, cells have evolved a variety of PQC 
mechanisms that maintain proteome homeostasis (87). There are four major PQC systems in 
eukaryotic cells; molecular chaperones, the ubiquitin-proteasome system (UPS), Endoplasmic 
Reticulum associated degradation (ERAD), unfolded protein response in the Endoplasmic 
Reticulum (UPR) and autophagy (Figure 1-12). These folding surveillance mechanisms, 
counteract aggregation and eliminate misfolded proteins (82). Molecular chaperones are the 
first line of defense against misfolded proteins due to their capacity to refold proteins in the 
cytosol, endoplasmic reticulum (ER) or mitochondria. Misfolded proteins in the cytosol or ER 
can be degraded by the UPS (82). ER stress activates the UPR to counteract accumulation of 
misfolded proteins and re-establish proteome homeostasis. Finally, misfolded proteins and 
aggregates can also be degraded by autophagy. 
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Figure 1-12. The four major mechanisms of protein quality control. 
 
 
1.7.1 Molecular Chaperones 
  
Molecular chaperones can recognize misfolded proteins, promote refolding or 
degradation via specialized proteases. They may also sequester proteins into specialized quality 
control compartments, to prevent the formation of toxic aggregates and regulate the inheritance 
of damage proteins (88). There are two compartments: the JUNQ (juxtanuclear quality control) 
and IPOD (insoluble protein deposit), that sequester different types of misfolded proteins. 
JUNQ compartment is associated with the cytosolic surface of the ER and contains 26S 
proteasomes and some chaperones. It concentrates soluble misfolded proteins that can either be 
degraded by the UPS or refolded by cytoplasmic chaperones. The IPOD contains insoluble 
aggregated proteins, and colocalizes with autophagy associated Atg8 (88). Since chaperones 
recognize selectively misfolded proteins, they are the first line of defense against toxic proteins 
(89).  
There are different classes of molecular chaperones, which are usually classified 
according to their molecular masses: Hsp100, Hsp90, Hsp70, Hsp60 and Hsp40 and small heat 
shock proteins (sHsps). Each class comprises multiple chaperone isoforms (88). Some are 
constitutively produced while others are induced by stress (90). Some chaperones such as 
Hsp70 and Hsp90 interact with cofactors which influence their ATPase activity (91,92). In 
addition to these features, chaperones are also responsible for de novo protein folding 
(chaperonin TRiC/CCT and some Hsp70s), while others assist conformational maturation and 
degradation (Hsp70s and Hsp90). Small heat shock proteins, for example Hsp27, have been 
observed to tightly associate with protein aggregates (88,93).  
Constitutively expressed (Hsc70) and stress-inducible forms of HSP70 are very 
important for proteostasis control, namely prevention of aggregation, promotion of folding to 
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the native state, solubilization and refolding of aggregated proteins, assistance in transport and 
degradation (94,95). In disease models Hsp70 is involved in preventing toxic aggregation (96–
98). It interacts with hydrophobic peptide segments in an ATP dependent manner, in a Hsp40 
dependent manner (91).  
Hsp90, also an ATPase dependent chaperone, is involved in stress tolerance and in 
normal physiological conditions, is associated with a wide array of proteins (known as clients), 
that depend on it to acquire their active conformations. These client proteins are involved in 
signal transduction, protein trafficking, receptor maturation, innate and adaptive immunity. 
Approximately 20 co-chaperones interact with HSP90 to guide its recognition of client 
proteins and modulate its biochemical activity (88,92).  
Chaperonins are large double-ring complexes of ~800kDa that enclose substrate 
proteins up to ~60kDa to accelerate folding and prevent aggregation. Hsp60 (also known as 
Group1 chaperonins) is largely, but not exclusively, compartmentalized in mitochondria and is 
responsible for folding and trafficking of pre-proteins (95,99).  
Small Hsps usually form dimmers and oligomers, bind to partially denatured proteins 
in an unstable state and minimize irreversible aggregation. Activity of sHsps is considered 
energy-independent although substrate affinity binding sites are potentially affected by ATP 
binding (100).  
 
 
1.7.2 The Ubiquitin-Proteasome System 
 
Proteins that cannot be refolded are eliminated by specific proteases. In eukaryotic 
cells, the proteasome is the primary selective protease, located mainly in the cytosol, but also 
detectable in the nucleus. It participates in cell quality control and is essential for the rapid 
destruction of key regulatory proteins that control cell cycle progression, signal transduction 
and several other cell processes (Figure 1-13) (82,101,102).  
The UPS involves the proteasome and a large number of proteins and is responsible for 
the identification, targeting and destruction of misfolded proteins. To be degraded by the 
proteasome, misfolded proteins must be covalently linked to polyubiquitin chains. This process 
is orchestrated by the concerted action of three enzymes; E1 (ubiquitin-activating), E2 
(ubiquitin-conjugating) and E3 (ubiquitin-ligating). The first enzyme (E1) uses ATP to form a 
high-energy thiolester bond with the C-terminus of ubiquitin (76 amino acid protein). Next, 
activated ubiquitin is transferred to a ubiquitin conjugating enzyme (E2) and then is conjugated 
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to target proteins in a process mediated by E3 ubiquitin ligase. The E3 ligase is an adaptor 
molecule that interacts with both the target protein and E2. From this interaction results the 
formation of an isopeptide bond between the C-terminus of ubiquitin and an ε-amino group of 
lysine residues in the target protein (Figure 1-13). Polyubiquitin chains are then formed after 
successive transfers of activated ubiquitin to lysine-48 of the previously conjugated ubiquitin 
molecule (102,103). Polyubiquitinated proteins bind to specific ubiquitin binding domains 
(UBD) located in the proteasome. Prior to degradation, chains of ubiquitin are disassembled to 
ubiquitin monomers by cysteine-protease and metalloprotease deubiquitinating enzymes 
(DUBs). Proteins to be degraded are unfolded and funneled through the narrow entrance of the 
proteasome (102,104).  
The proteasome is a macrocomplex formed by the assembly of several subunits that 
form the core particle (20S) and the regulatory particles (19S). The core particle exhibits a 
barrel-like structure in which 28 subunits form four seven-membered rings. The two outer 
rings are composed by seven α-subunits and the two inner rings are composed by seven β-
subunits. β-rings contain the proteolytic active sites with caspase-like, trypsin-like and 
chymotrypsin-like activities. α-rings control the entrance of the unfolded protein into the 
catalytic cavity. The 19S regulatory particle is responsible for the recognition, unfolding and 
translocation of the protein to the 20S core. It is composed by two subcomplexes: a base 
(adjacent to 20S) and a lid (on top of the base). The base contains six AAA-ATPases and three 
non-ATPases subunits. The lid is formed by eight subunits and is critical for the recognition 
and deubiquitination of proteins (Figure 1-13) (101,104–106).  
 An active proteasome can exist in several forms; 26S (20S core plus one 19S 
regulatory subunit) or 30S (20S core plus two 19S regulatory subunits). Although it is still 
unclear whether there are functional differences between the 26S and 30S proteasomes, the 
latter is the most abundant proteasome in cells and is believed to be the physiologically 
functional unit (104,105). The accession of proteins only through 19S particles safeguards the 
highly specific nature of the process and prevents non-specific protein degradation (107).  
Molecular chaperones cooperate directly with the UPS to redirect misfolded proteins to 
degradation. The mammalian cofactor of Hsp70 and Hsp90, called CHIP protein, shifts the 
mode of action of these two chaperones, binds to E2 and can also act as an E3 ubiquitin ligase 
during the ubiquitination of chaperone substrates. Several studies support the idea that CHIP is 
involved in quality control, in Parkinson’s and Alzheimer’s diseases, participating in the 
degradation of defective proteins (108–110).  
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1.7.3 Quality control in the ER  
 
The ER is involved in several cellular functions, namely, synthesis and sorting of 
secretory and membrane proteins, biosynthesis of phospholipids, cholesterol, steroids, 
degradation of glycogen, detoxification reactions and maintenance of intracellular calcium 
homeostasis. About one third of the proteins synthesized in eukaryotic cells are folded in the 
Figure 1-13. The ubiquitin-proteasome system (UPS). Degradation of proteins by the UPS is initiated 
with ubiquitin conjugation to the misfolded protein. First E1 (ubiquitin-activating enzyme) activates 
ubiquitin, in an ATP-dependent manner. Ubiquitin is then transferred to E2 (ubiquitin-conjugating enzyme). 
E3 (ubiquitin ligase) links ubiquitin from E2 to the target protein. This reaction is repeated to form a 
polyubiquitin chain. This polyubiquitin chain is recognized by the proteasome for degradation. Proteasomes 
are formed by a 20S particle (α-ring and β-ring) which constitutes the core and is responsible for the 
proteolytic activity and 19S regulatory particles (lid and base) that recognize ubiquitinated proteins. The 
proteasome is involved in a variety of cellular functions, such as quality control, stress response, signal 
transduction, immunity and cell cycle regulation [adapted from (101)]. 
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ER, and this process requires a myriad of chaperones and modifying enzymes. After the 
acquisition of native conformation, proteins leave the ER. They can be translocated to other 
organelles or secreted to the extracellular medium (111).  
If correct folding of proteins cannot be achieved, defective proteins are usually retro-
translocated to the cytoplasm to be degraded by the proteasome, a process called ER- 
associated degradation (ERAD). Misfolded proteins are recognized in the lumen of the ER and 
transported across the ER lipid bilayer into the cytoplasm. The substrate is then ubiquitinated 
by a membrane-associated ubiquitin ligase (E3). The ubiquitinated substrate is extracted from 
the membrane in an ATP-dependent manner and released in the cytosol for degradation by the 
proteasome (Figure 1-14). This is possible because, E3 ligase complexes are composed by 
proteins involved in substrate recognition and also retrotranslocation (111,112).  
 
 
Figure 1-14. ER- associated degradation (ERAD). E3 ligase complex recognizes, retranslocates and 
ubiquitinates misfolded proteins, releasing them into the cytosol to be degraded by the proteasome [from 
(112)]. 
 
 
Inefficient ERAD activation results in the accumulation of misfolded proteins in the 
lumen and membrane of the ER, a condition known as ER stress. This is detected by three 
sensors that face the ER lumen: inositol-requiring enzyme 1 (IRE-1 or ERN1), a protein kinase 
RNA-like endoplasmic reticulum kinase (PERK, also known as PEK or EIF2AK3) and 
activating transcription factor 6 (ATF6) (Figure 1-15). These sensors initiate ER-to-nucleus 
signaling cascades to trigger an adaptive response: the UPR that restores protein folding 
homeostasis. This is achieved by three main mechanisms: transient reduction in protein 
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synthesis, increase in the folding capacity and ERAD. Initiation of programmed cell death 
happens when ER stress cannot be resolved (111,113).  
Under non-stress conditions, binding immunoglobulin protein (BiP, also known as 
Grp78), the most abundant ER chaperone is associated with ER-luminal domains of the three 
sensors, keeping them inactive. Upon accumulation of unfolded or misfolded proteins BiP 
detaches from sensors to assist folding and these sensors become active. Alternatively, 
unfolded proteins can bind directly to IRE-1 (111,113).  
IRE-1α is a bifunctional transmembrane protein, harbouring in its cytoplasmic part 
both a serine-threonine kinase domain and a C-terminal RNase domain. Activation of IRE1 
involves its oligomerisation and trans-autophosphorylation of the kinase domains. 
Oligomerisation activates the RNase domain, responsible for the cleavage of X-box-binding 
protein 1 (XBP-1) mRNA at two stem-loop structures through an unconventional cytoplasmic 
splicing reaction. This reaction specifically removes an intron from unspliced or full length 
XBP-1 (XBP-1u) to generate sliced XBP-1 (XBP-1s). XBP-1s is a highly active transcription 
factor that activates genes that enhance ER protein-folding capacity (chaperones), degradation 
of misfolded proteins (ERAD) and also lipid biosynthesis (111,113). Studies showed that 
prolongation of IRE-1 signaling during ER stress can promote cell survival, being this adaptive 
mechanism important to match ER folding capacity with protein folding demand (111,114). 
Another mechanism proposed for IRE-1 is the degradation of mRNAs encoding proteins that 
transverse the secretory pathway, IRE-1 dependent decay (RIDD). Through this mechanism of 
protein synthesis attenuation ER stress is relieved (Figure 1-15) (115).  
PERK is a transmenbrane kinase that shares with IRE-1 approximately 20% similarity 
in its luminal domain. It phosphorylates eukaryotic initiation factor 2α (eIF2α), leading to 
inhibition of the guanine-exchange factor eIF2B that recycles eIF2 to its active GTP-bound 
form. This results in a delay in ternary complex formation and a reduction in cap-dependent 
translation (116). The block of initiation of translation is not total but reduces the protein load 
in the ER (113), and permits translation of certain transcripts with short upstream ORF in their 
5’-UTR regions, such as ATF4. ATF4 is a transcription factor responsible for induction of a set 
of genes involved in amino acid metabolism, antioxidant stress response and protein secretion 
(Figure 1-15) (113,117). It also directs the expression of a second transcription factor, C/EBP-
homologous protein (CHOP) and growth arrest and DNA damage-inducible protein 
(GADD34). CHOP is a proapoptotic factor, while GADD34 exerts a negative feedback in 
eIF2α phosphorylation. GADD34 associates with protein phosphatase 1 (PP1) and promotes 
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dephosphorylation of eIF2α. By this means, GADD34 promotes recovery from translation 
repression, helping cells to return to their normal function (113,118).  
ATF6 is a transmembrane protein with its carboxyl terminus facing the ER lumen and a 
transcription factor in its amino terminus. Upon ER stress, BiP dissociates from the luminal 
domain and ATF6 is transported to Golgi apparatus via coat protein COPII-covered vesicles, 
where is proteolytically cleaved. Site 1 and site 2 proteases (S1P and S2P, respectively) 
sequentially cleave ATF6 to release the amino-terminal transcription factor fragment pATF6-N 
from its membrane anchor. pATF6-N then moves to the nucleus and binds to promoters 
containing the ER stress response elements, thus inducing the expression of ER stress-induced 
genes such as chaperones and proteins involved in ERAD (Figure 1-15). XBP-1 expression is 
also induced by pATF6-N (113,119).  
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Figure 1-15. The three UPR sensors in mammalian cells. IRE-1 and PERK are activated by 
oligomerisation and trans-phosphorylation, upon release of BiP. IRE-1 cleaves XBP-1 mRNA to generate its 
active form, XBP-1s. This transcription factor is then translocated to the nucleus and induces expression of 
genes encoding chaperones, lipid synthesis and ERAD proteins.  IRE-1 also contributes to RIDD, 
degradation of mRNAs encoding proteins from the secretory pathway. PERK phosphorylates eIF2α leading 
to reduction in protein synthesis. Some mRNAs with small upstream open reading frames in their 5’UTR 
escape the translation block, namely ATF4. ATF4 triggers expression of CHOP, GADD34 and additional 
factors important for amino acid metabolism and redox homeostasis. Upon BiP release, ATF6 is translocated 
to the Golgi, where it undergoes cleavage by S1P and S2P. The ATF6 active fragment moves to the nucleus 
and coordinate the expression of genes encoding chaperones and proteins involved in lipid biosynthesis [from 
(113)]. 
 
 
As mentioned before, many components of the UPR trigger apoptosis under chronic 
stress. Induction of AFT4 and its downstream target CHOP lead to apoptosis possibly through 
the transcriptional up-regulation of several pro-apoptotic proteins of the BCL-2 family, known 
as BH3-only proteins (for example BIM) (120). One of the isoforms of IRE-1, IRE-1α when 
activated interacts with the adaptor protein tumor necrosis factor receptor-associated factor 2 
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(TRAF2) and leads to the downstream activation of apoptosis signal-regulating kinase 1 
(ASK1) and JUN N-terminal kinase (JNK), also contributing to cell death (121,122). Besides 
this, prolonged RIDD may reduce drastically the levels of proteins essential for survival 
participating in cell death (111). The molecular basis for the switch between prosurvival and 
proapoptotic UPR function is poorly understood. However, evidences suggest that UPR 
signaling can integrate stress intensity and duration information to promote cell adaptation or 
death (123,124). For example, in human cell lines exposed to ER stress over prolonged time, 
both ATF6 and IRE-1 are attenuated early, while PERK activity and CHOP expression persist 
until the death of the cells (114,125).    
Due to the broad spectrum of activities of the UPR in organ homeostasis, ER stress 
plays a role in the progression of protein-misfolding disorders and also several others such as 
cancer, diabetes and inflammation (123,126). For example, abnormal accumulation of the 
amyloid-β (Aβ) peptides in the brain, a hallmark of Alzheimer’s disease, leads to neuronal loss 
and cognitive deficits due to ER and oxidative stress (127). Elevated levels of eIF2α-P and 
ATF4 have also been observed in brains of people with Alzheimer’s disease and in mouse 
models of the disease (128). In agreement with these findings a recent study also demonstrated 
that decreasing the expression of two of the eIF2α kinases, PERK and general control non-
derepressible-2 (GCN2), improve cognitive function and synaptic plasticity in Alzheimer’s 
disease transgenic mouse models (129,130).  
ER stress and UPR activation have been documented in several human cancers (131). 
Because tumors arise and progress in a stressful environment, possibly transformed cells use 
UPR activation as a survival strategy. In fact, some studies demonstrate that UPR activation is 
required for oncogenic transformation, despite its known role in apoptosis. For this reason, 
UPR can also have a tumor-suppressing role depending on the tumor context (131,132). For 
example, in mice, Perk deletion delays Neu-dependent mammary tumor development and 
reduces lung metastases, whereas long-term PERK inactivation increases susceptibility to 
spontaneous mammary tumorigenesis (133). PERK activation can also promote MYC-induced 
cell transformation through autophagy, possibly due to the increase in ATF4, CHOP and 
factors that activate transcription of many autophagy genes (134,135). IRE1A and XBP1 
mutations have been identified in tumor cells from patients with multiple myeloma (136) and 
loss of function of XBP-1 promotes tumorigenesis in mouse models of intestinal cancer 
(137,138). On the other hand, increase XBP1 mRNA splicing was observed in human triple 
negative breast cancers, possibly indicating a requirement for XBP-1 in cancer stem-like cells 
(130,131,139). Since ER stress and UPR pathway are involved in the etiology of many 
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diseases, UPR pathways could be important therapeutic targets, particularly for anticancer and 
anti-dementia approaches (130).  
 
 
1.7.4 Autophagy 
 
Autophagy is the generic name used for any intracellular process that results in the 
degradation of cytosolic fractions, organelles and macromolecules inside lysosomes. This 
degradation system is activated in stress conditions, such as nutrient deprivation, DNA 
damage, hypoxia, oxidative stress or ER stress to support energy balance. In this way, 
autophagy plays an important role in PQC, being responsible for the selectively degradation of 
misfolded and aggregated proteins (101,140). 
Lysossomes are single-membrane vesicles that contain several hydrolases (proteases, 
lipases, nucleotidases and glycosidases), which need an acidic pH for optimal activity. In the 
case of protein quality control, the low pH in the lumen is responsible for the partial unfolding 
of substrate proteins allowing proteases to have access to internal peptides.  These proteases 
convert proteins to di- and tripeptides and free amino acids, which are released into the cytosol 
and recycled in protein synthesis (101,141).  
In mammalian cells, there are three main types of autophagy; macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA) (Figure 1-16). In 
macroautophagy, cytoplasmic portions are engulfed into double membrane vesicles or 
autophagosomes. Autophagosomes are then fused with lysosomes and sequestered material is 
degraded. Autophagy-related genes (ATG) encode proteins that organize into complexes, and 
are responsible for the regulation of the autophagic process. In microautophagy small 
components of the cytoplasm are directly engulfed by lysosomes. Finally, in chaperone-
mediated autophagy, specific cytoplasmic proteins are recognized by chaperones through a 
consensus sequence and transferred to lysosomes. Macro- and microautophagy participate in 
the degradation of both proteins and organelles, while CMA is only responsible for protein 
degradation (101,141).  
Several autophagic receptors respond to specific cellular insults, and recognize 
abnormally altered or aggregated proteins, targeting them for degradation. In macroautophagy, 
p62/SQSTM1, NIX and NBR1, recognize and facilitate the elimination of ubiquitinated 
proteins. These receptors simultaneously bind microtubule-associated protein light chain 3 
(LC3) in autophagosomes and ubiquitinated proteins to allow their inclusion into 
autophagosomes for subsequent degradation (142). CMA mediates the lysossomal degradation 
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of proteins that contain a consensus pentapeptide (KFERQ), which includes a substantial 
number of disease-causing aggregate-prone proteins. Hsc70 escorts proteins to the receptor 
lysosome-associated membrane protein type 2a (LAMP2A) (140,143).  
Mammalian target of rapamycin (mTOR) kinase and AMP-activated protein kinase 
(AMPK) are two master regulators of autophagy. mTOR integrates growth factor and nutrient 
signals and inhibits autophagy, whereas AMPK, senses and regulates cellular metabolism to 
maintain energy homeostasis and promotes autophagy. AMPK and mTOR regulate the 
phosphorylation of the mammalian homolog of Atg1, Ulk1 (144).  
 
 
 
Figure 1-16. Autophagic pathways. (A) In Macroautophagy, cytoplasmic regions are sequestered into 
autophagosomes that are then fused with lysosomes for cargo delivery. (B) In Microautophagy, the lysosomal 
membrane invaginates to trap regions of the cytosol that are internalized into the lysosome lumen as vesicles. 
(C) In CMA a targeting motif in the substrate protein is recognized by chaperones that are responsible for the 
delivery to the surface of the lysosome, where it binds to specific receptors that form translocation complexes 
[from (141)]. 
 
 
1.8 mRNA mistranslation and disease 
 
An extensive and growing catalogue of human diseases, caused by alterations in the 
components of protein synthesis machinery, have been discovered in recent years. Defects can 
be related to protein synthesis in the cytosol or can involve elements of mitochondrial protein 
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synthesis and have a broad spectrum of phenotypic outcomes, resulting in diverse diseases 
from neurodegeneration to cancer (41).  
Ribosomopathies are a class of diseases caused by mutations that affect the 
biosynthesis and/or functionality of the ribosome. They are characterized by pleiotropic 
abnormalities (birth defects, heart and lung diseases, anemia and ataxia) and in middle age 
patients present elevated cancer risk (30- to 40- fold compared with the general population) 
(145,146). Mutations in the ribosomal protein gene RPL10/uL16 were recently identified in 
patients with T-cell acute lymphoblastic leukemia (147). This ribosomal protein plays a role in 
catalysis and also 60S biogenesis. Mutant ribosomes have structural defects that affect 
translational fidelity, promoting elevated rates of -1 programmed ribosomal frameshifting and 
impaired recognition of termination codons (146).  
Ribosome frameshifting can also have a potential role in generation of aberrant 
proteins such as ubiquitin B (UBB+) and β-amyloid precursor protein (APP+) implicated in 
Alzheimer’s and other neurodegenerative diseases. These proteins called “+1 proteins” have 
carboxyl-terminal amino acids encoded by an alternative reading frame of the mRNA and 
inhibit the function of the proteasome, forming neurofibrillary tangles and neuritic plaques 
(148). 
Mutations in the editing domain of the mouse AlaRS, which allow the enzyme to 
charge tRNAAla with Ser or Gly are associated with rapid Purkinge cell loss in the cerebellum 
and development of ataxia (23,69,86). The misincorporation of these amino acids into proteins 
leads to toxic aggregates, increase in protein ubiquitination, formation of autophagosomes, 
induction of molecular chaperones (such as members of Hsp70 family) and upregulation of the 
UPR (induction of BiP and CHOP) (69). Also mutations in genes that encode GlyRS and 
TyrRS have been associated with the Charcot-Marie-Tooth (CMT) disease, characterized by 
muscular weakness and atrophy of the distal extremities (149,150). The disease causing 
mutations are dominant and the mutant proteins are fully active for aminoacylation, but do not 
interact efficiently with their cognate tRNAs (151). At least 11 distinct mutant alleles in the 
human population have been reported in GlyRS, while two missence mutations and one de 
novo deletion in TyrRS have been identified in unrelated families affected with the disease 
(23,149,150).  
Also mutations in tRNAs, particularly in mitochondrial tRNA genes, have been 
correlated with severe diseases, including fatal cardiopathies, encephalopathies, myophaties, 
diabetes and others (152). Over 200 mt-tRNA mutations have been linked to disease. The first 
report, in 1990, links a mutation in tRNALeu gene (MTTL1) with Mitochondrial myopathy, 
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encephalopathy, lactic acidosis and stroke (MELAS) (153). Eighty percent of patients with 
MELAS carry a maternaly inherited A>G mutation in the nucleotide 3243 in tRNAUUR
Leu that 
affects its stability, impairs charging efficiency with Leu and prevents taurine modification in 
the anticodon (in the wobble base position). A mutation in tRNALys (A8344G) was associated 
with Mioclonic epilepsy with ragged-red fibers (MERF). This mutation also affects 
aminoacylation and taurine modification in the anticodon (154,155).  
Deregulation of RNA polymerase (pol) III and its products (mainly tRNAs) have been 
reported in a wide range of transformed cells (156,157) and tRNAs are frequently 
overexpressed in breast cancer. Previous studies comparing cancer-derived versus non-cancer-
derived cell lines showed that nuclear-encoded tRNAs increase up to 3 fold and mitochondrial-
encoded tRNAs increase by up 5 fold. Also, in tumors versus normal breast tissue nuclear and 
mitochondrial-encoded tRNAs increased up to 10 fold (158). Recently, Goodarzi et al., 
identified two specific tRNAs (tRNAUUC
Glu and tRNACCG
Arg), that are upregulated in human 
breast cancer cells and promote breast cancer metastasis. Upregulation of these tRNAs 
enhances stability and ribosome occupancy of transcripts enriched for their cognate codons 
(159).  
Finally, growing evidences indicate that tRNA modifying enzymes may play important 
roles in cancer, type 2 diabetes, neurological disorders and mitochondrial-linked disorders (16). 
Human tRNA methyltransferase 1 (TRM1) gene encodes a methyltransferase that dimethylates 
guanosines (m22G) at position 26 of tRNAs and a frameshift mutation that inactivates this gene 
has been reported as a novel marker for recessive cognitive disorders (160). tRNA 
methyltransferase homolog 12 (TRMT12), the human homolog of yeast TRM12, is one of the 
enzymes involved in the formation of wybutosine at position 37 on tRNAPhe. In several breast 
cancer cell lines and breast cancer tumors this gene was overexpressed (161). CDK5 regulatory 
subunit associated protein 1-like 1 (CDKAL1) gene encodes for a methylthiotransferase 
involved in the complex 2-methylthio-N6-threonyl carbamoyladenosine (ms2t6A) modification 
at position 37 in tRNAUUU
Lys. Variantions in the CDKAL1 gene are associated with type 2 
diabetes (162). Evidences suggest that lack of ms2t6A modification leads to mistranslation of 
several proteins, including proinsulin, thus triggering the ER stress response. As it accumulates 
in an abnormal form, proinsulin cannot be converted into insulin, leading to glucose 
intolerance (16,163).  
Despite these alterations in the protein synthesis machinery it is still unclear how the 
above mutations cause disease.   
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1.9 Mutant tRNAs as strategy to induce protein synthesis errors and proteotoxic 
stress  
 
Many experimental strategies have been developed to study stress responses elicited by 
the accumulation of misfolded proteins. Incubation of cells with amino acid analogues, like 
azetidine carboxylic acid or canavanine, Pro and Arg analogues is commonly used. Amino acid 
analogues, due to chemical similarities to natural amino acids, can escape detection by the 
cellular protein synthesis machinery and become misincorporated into proteins. This leads to 
protein misfolding and aggregation. This strategy was extremely useful in the identification of 
components of the heat-shock response and UPS (164,165).  Another strategy is based on 
proteins that are prone to aggregation, such as Aβ and polyQ, which are used as models for 
Alzeimer’s and polyglutamine diseases, respectively. The expression of these proteins has been 
extensively used in human cells and animal models. For example, human cells and C. elegans 
models expressing of Aβ and polyQ were used to identify subnetworks of chaperones 
repressed or induced in aging and disease and also to clarify their roles in these situations 
(166).  
In 2010, Geslain et al., developed a new approach to destabilize the proteome and 
increase the level of misfolded proteins based on mutant tRNAs (165). They introduced 10 
different mutant tRNAs in a human cell line (HEK293) and in a vertebrate embryonic model 
(chick embryos). To construct mutagenic tRNAs, Geslain et al. took advantage of the 
recognition mechanism of tRNASer by SerRSs. Since this enzyme does not recognize the 
anticodon loop of Ser tRNAs, but rather the acceptor stem, D-arm and extra stem/loop (13), it 
was possible to alter the anticodon of this tRNAs without interfering with the serylation 
reaction. Mutant Ser tRNAs were aminoacylated with Ser, but translated codons 
complementary to the engineered anticodon, generating random proteome mutations XS  
(Figure 1-17).  
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Figure 1-17. Schematic representation of “chimeric” tRNAs that mutate the proteome. The wild-type 
anticodon of tRNASer is altered to decode codons of different amino acids. Despite alterations in the 
anticodon these tRNAs are aminoacylated with the amino acid Ser. Ser is incorporated into growing 
polypeptide chains, producing mistranslated proteins [from (165)]. 
 
 
The activity of those tRNAs was demonstrated using a gain-of-function mutation 
introduced in the fluorescent GFP reporter. GFP contains a critical Ser residue at position 65, 
altering the respective codon for codons corresponding to the anticodon of the mutant tRNAs 
allowed for monitoring Ser incorporation at position 65 of the mutant GFP. Fluorescence 
measurement showed that Ser misincorporation was dependent on the tRNA used (Figure 1-
18). Amino acid quantitative analysis of purified GFP and human epidermal growth factor 
receptor (EGFR), confirmed the misincorporation of Ser in the proteome. General parameters 
such as transcription, protein synthesis levels, growth rate and cell viability were also 
evaluated, showing different responses according to the type of error introduced in proteins 
(165).  
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Figure 1-18. Fluorescence recovery of GFP coded by a gene where serine-65 had been substituted by 10 
codons recognized by the engineered tRNAs [from (165)]. 
 
 
Similar experiments with mutant Ser tRNAs were carried out in zebrafish. Decoding 
activity of these tRNAs monitored using the GFP reporter showed that the tRNAs were 
functional. These Ser misincorporations into the proteome elicited a stress response in 
zebrafish embryos, resulting in the activation of the UPS and UPR and inhibition of protein 
synthesis (167).  
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1.10 Aims of the study  
 
The main aim of this PhD thesis was to study the stress response and adaptation 
capacity of human cells to protein synthesis errors (PSE). For this, we have created human cell 
lines (HEK293) that mistranslate a single codon in a controlled manner and also overexpressed 
the Wt tRNASer. Cellular responses were studied at a phenotypic and molecular level. This 
strategy unraveled adaptation and stress mechanisms that are important to understand the 
molecular basis of human diseases associated with protein synthesis errors.  
 
The main biological questions addressed in this thesis were the following:  
 
1 – Can human cells cope with increased level of protein synthesis errors? What are 
the phenotypic consequences?  
2 – How do these cells adapt and counteract proteotoxic stress to thrive in culture?  
3 – What are the transcriptional responses to mistranslation?  
4 – What is the impact of mistranslation on the genome? 
5 –Are HEK293 mistranslating cells a good model system to understand the 
molecular basis of human diseases associated with protein synthesis errors? 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unravelling the cellular networks that regulate proteotoxic stress  
52 
 
 
 
 
 
 
 
 
Chapter 2 – Adaptation of human cells to protein synthesis errors 
53 
 
 
 
 
 
 
 
 
 
 
2. Adaptation of human cells to 
protein synthesis errors 
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2.1 Abstract  
 
Protein synthesis is a highly-regulated process and maintenance of its fidelity is 
essential to life. Alterations in the components of the protein synthesis machinery, namely 
tRNAs, aminoacyl-tRNA synthetases (aaRS) or tRNA modifying enzymes, increase the level 
of protein synthesis errors (PSE), and are associated with several conditions, from cancer to 
neurodegeneration. Still, the cause-effect mechanisms remain to be elucidated in many 
conditions. We hypothesized that accumulation of PSE in human cells activate different 
protein quality control (PQC) mechanisms depending on the type of error and the duration of 
the stress stimulus. To address this issue, we modified the anticodon of a human serine transfer 
RNA (tRNASer), to incorporate the amino acid serine (Ser) at various non-cognate sites and 
overexpressed the wild type (Wt) tRNASer to evaluate the effects of tRNA misexpression. 
Stable HEK293 cell lines were produced and analyzed at different time points (cells passages). 
As expected, mutant tRNAs and tRNA pool deregulation led to accumulation of misfolded 
proteins. Activation of the ubiquitin-proteasome system (UPS) and the unfolded protein 
response (UPR) fully protected these cells from proteotoxic stress, maintaining viability intact. 
Evolution of these cell lines showed differential adaptation responses to different types of 
tRNAs’ misexpression. In some cases, adaption was mainly due to increased protein turnover, 
while in other cases, UPR activation with consequent protein synthesis inhibition was the main 
adaption mechanism. Our data provide new insight on how mammalian cells cope and adapt to 
proteotoxic stress induced by PSE. 
 
 
2.2 Introduction 
 
Tight control of protein synthesis is essential for cell functioning, nonetheless the high 
rate of ribosome decoding, which is required to maintain proteome homeostasis, affects the 
accuracy of mRNA translation and proteins are synthesized with some level of error. Indeed, 
lowering translation rate increases protein synthesis accuracy, but impacts negatively on 
growth rate and fitness (168,169). Protein synthesis errors (PSE) can arise during both 
aminoacylation of tRNAs and mRNA decoding by the ribosomes (60,66). The rate of 
eukaryotic protein synthesis error measured under normal experimental conditions, i.e., 
downstream of protein quality control (PQC) processes, is between 10-3 and 10-4 (63,66). Since 
most polypeptides containing erroneous amino acids are degraded, the real rate of amino acid 
misincorporation is much higher than those values, suggesting that defective PQC can have 
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catastrophic consequences for the cell. Similarly, stress conditions, in particular amino acid 
starvation, and metabolic deregulation associated with pathology and aging increase error 
frequency (88). In other words, a fraction of defective proteins is continually produced by cells 
making the existence of perfect proteomes an impossible task (67). 
Not surprisingly, deregulation of protein synthesis factors that maintain translational 
accuracy has been associated with human diseases (17,41). For instance, mutations in genes 
encoding the glycyl-tRNA synthetase (GlyRS), have been found in patients with Charcot-
Marie-Tooth neuropathy (23,151). Mutations in mitochondrial tRNALeu are linked to 
mitochondrial encephalomyophathy, lactic acidosis, and stroke-like episodes (MELAS) 
(152,154). Deregulation of the tRNA pool and tRNA modifying enzymes have been observed 
in cancer (16,158,161,170–172). In breast tumors there is strong upregulation (> 10 fold) of 
nuclear and mitochondrial encoded tRNAs (158). The tRNA modifying enzyme TRMT12 
(tRNA methyltransferase homolog 12, involved in the formation of wybutosine at position 37 
on tRNAPhe) is overexpressed in various breast tumors (16,161). Despite clear association with 
disease, how such deregulation and mutations causes disease are poorly understood. One 
possibility is that PSE may saturate PQC, leading to accumulation of misfolded and aggregated 
proteins (69,165,167,173,174). For example, molecular chaperones selectively recognize 
misfolded proteins and promote refolding or degradation via the ubiquitin-proteasome system 
(UPS) (88,175). Accumulation of misfolded proteins in the endoplasmic reticulum (ER) 
normally saturates ER chaperones (as GRP78/BiP), triggering the activation of the unfolded 
protein response (UPR) through its branches, namely ATF6, IRE1 or PERK (124). These 
pathways, regulate protein synthesis, decrease ER load, increase ER folding capacity and 
increase the degradation of misfolded proteins (176). In mice, a mutation in the editing domain 
of alanyl-tRNA synthetase (AlaRS), leads to the formation of toxic aggregates, an increase in 
protein ubiquitination, formation of autophagosomes, induction of molecular chaperones 
(members of Hsp70 family) and upregulation of the UPR (induction of BiP and CHOP). This 
ultimately leads to Purkinge cell death (69). Some cancer cells have increased growth rate, 
regulated by signals related to proliferation, metabolism and protein synthesis, explaining the 
global upregulation of tRNAs and tRNA modifying enzymes (177). This also induces ER 
stress and activation of UPR pathways (131,178), suggesting that protein misfolding, and 
eventually PSE, may be prevalent in cancer. 
The objective of this study was to clarify the poorly understood consequences of PSE 
in human cells. In particular, we wanted to elucidate how these cells cope and adapte to such 
errors and whether they affect cell viability, activate the UPR and produce phenotypes that are 
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common in diseases associated with deregulation of protein synthesis factors. To address these 
questions, we have created HEK293 cell lines expressing mutant tRNAs that randomly 
misincorporate serine (Ser) at alanine (Ala), leucine (Leu) and histidine (His) codon sites, on a 
proteome wide scale. A cell line expressing extra copies of the wild type (Wt) tRNAAGA
Ser was 
also produced to gain insight on the cellular consequences of tRNA imbalances; often observed 
in tumors. Cellular responses were studied at different time points (cells passages) to clarify 
how these HEK293 cells adapt to PSE.  
Our data show that immortalized cells cope relatively well with the presence of mutant 
tRNAs or overexpression of the Wt tRNASer. We observed accumulation of aggregated and 
ubiquitinated proteins and activation of the UPS and UPR, as expected. Activation of PQC 
mechanisms is differential according to the type of error introduced in proteins and to the cell 
passage. Additionally, the expression of mutant tRNAs decreased as cell passage increase, 
suggesting that human cells modulate expression of mutant tRNAs to decrease their 
destabilizing effect on the proteome. 
 
 
2.3 Results 
2.3.1 Human cell line models of PSE 
 
Previous studies from Geslain and colleagues reported a novel approach for the 
induction of stress responses to protein aggregation, based on engineered tRNAs in HEK293 
cells (165). This strategy allows the introduction of mutations of increasing severity randomly 
in the proteome. The decoding sequence (anticodon) of tRNASer was altered, not influencing 
the recognition by the seryl-tRNA synthetase (SerRS). The altered tRNA is aminoacylated 
with Ser, but will be used by the ribosome to translate codons complementary to the 
engineered anticodon. tRNAs produced by Geslain were tested for their ability to restore 
fluorescence of a GFP reporter, where the essential residue serine-65 (S65) had been 
substituted for the codons recognized by the engineered tRNAs, proving that mutant tRNAs 
are fully functional in HEK293 cells. Amino acid analysis of purified GFP from cells 
transfected with some of these tRNAs (tRNASer(Lys), tRNASer(His), tRNASer(Ile)) showed that 
the mutable residues had been replaced by serine (165). 
In the current study, and to induce PSE in HEK293 cells, we mutated the anticodon of 
the human Wt tRNAAGA
Ser to produce a set of tRNAs: tRNAAGC
Ser, tRNAAAG
Ser, tRNAGTG
Ser   
that misincorporate Ser at Ala, Leu and His codon sites, respectively (Figure 2-1).  
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Figure 2-1. Representation of the human tRNAAGASerand mutant tRNAs used in the study. 
 
 
These mutations do not interfere with serylation of the tRNAs by the SerRS, because 
this enzyme recognizes the extra-arm and discriminator base, rather than the anticodon of 
tRNASer (13,179). Participation of these tRNAs in protein synthesis leads to random 
incorporation of Ser at non-cognate sites, synthesis, misfolding, aggregation and degradation 
of the faulty proteins (Figure 2-2) (165,167).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2. Schematic representation of PSE incorporation by the mutant tRNAAAGSer. SerRS is not able 
to discriminate between endogenous tRNASer and mutant tRNAs and charges them equally, leading to Ser 
misincorporation at Leu codon sites. 
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We chose these alterations in the anticodon to have a broad spectrum of amino acid 
chemical differences. Ser is polar and hydrophilic and is normally present on protein surfaces, 
whereas Ala is nonpolar, hydrophobic and is found inside or outside proteins. Leu is 
hydrophobic and is generally buried in folded proteins, while His is a basic and polar residue 
(180). Therefore, Ser misincorporation severity should be higher in the case of 
misincorporation at Leu codon sites and much lower at Ala codon sites, depending also on the 
usage of those codons, the competition between endogenous tRNAs (tRNAAGC
Ala, tRNAAAG
Leu, 
tRNAGTG
His) in the ribosome, and the competition of endogenous tRNAAGA
Ser and mutant 
tRNAs for the SerRS. 
HEK293 cells were transfected with the plasmid pIRES2-DsRed containing one copy 
of each mutant tRNA. The resulting cell lines were denominated: tRNASer(A), tRNASer(L), 
tRNASer(H). Two additional cell lines were also produced: one was transfected with the empty 
plasmid; Mock (negative control) and another misexpressing the Wt tRNAAGA
Ser (tRNASer(S)). 
To gain insight on the long-term adaptation to PSE, three time points (P1, P15 and P30, 
corresponding to the number of cell passages after transfection and selection in geneticin 
containing media) were studied. Mutant tRNA expression in these cell lines was monitored by 
Sanger sequencing during evolution in culture. After P30, some of these cell lines presented 
additional mutations in the recombinant tRNA genes, namely in the acceptor arm, and for this 
reason cells were only studied till P30. Each cell line was compared with the control (Mock) of 
each passage, and for each cell line the values of the three passages (P1, P15 and P30) were 
compared among each other. 
 
 
2.3.2 Expression and copy number of mutant tRNAs and tRNASer in HEK293 cells  
 
Exogenous tRNA expression was determined using a primer extension reaction 
(SNaPshot analysis), which allowed to specifically detect the tRNAs with the altered 
nucleotide in the anticodon. We were able to detect in all cell lines, both the expression of the 
endogenous tRNASer (Figure 2-3 A) and each mutant tRNA (Figure 2-3 B). In the Mock cell 
line the expression of the endogenous tRNASer did not change from P1 to P30 (values around 5 
in arbitrary units (a.u.)), but the expression of tRNASer in the tRNASer(S) cell line (both the 
endogenous and the exogenous tRNA are detected) altered during our timeline (Figure 2-3 A). 
The expression of tRNASer increased slightly from passage P1 (8.9 a.u.) to P15 (12.7 a.u.) and 
then decreased from P15 (12.7 a.u.) to P30 (2.9 a.u.) (Figure 2-3 A), suggesting that increasing 
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the levels of the Wt tRNASer may be slightly advantageous at the beginning of the evolution, 
but becomes deleterious in the long term. Expression of all mutant tRNAs decreased gradually 
from P1 to P30 (Figure 2-3 B). In P1, in tRNASer(A) the levels of tRNAAGC
Ser were 0.58 a.u. 
(60% of the endogenous tRNASer expression) and in P30 declined to 0.1 a.u. (10% of the 
endogenous tRNASer expression). The relative levels of the tRNAAAG
Ser(in tRNASer(L) cells) 
and tRNAGTG
Ser(in tRNASer(H) cells) in P1 were 0.3 a.u. (30% of the endogenous tRNASer 
expression) and declined to 0.05 a.u. and 0.03 a.u. (5% and 3% of the endogenous tRNASer 
expression) in P30, respectively (Figure 2-3 B).  
 
A                                                                           B 
 
 
 
 
 
 
 
       
Figure 2-3. Quantification of tRNASer and mutant tRNAs expression. A – Detection of tRNAAGASer 
expression in Mock and tRNASer(S) cell lines, assessed by the SNaPshot assay. B – Expression of mutant 
tRNAs relative to the Wt endogenous tRNAAGASer determined by SNaPshot in tRNASer(A), tRNASer(L) and 
tRNASer(H) cell lines. tRNA values were normalized to an endogenous control, GAPDH. Data represents 
Average±SEM of one biological replicate and at least two technical replicates. 
 
 
To clarify if the gradual decrease in tRNA levels observed during the P1-P30 evolution 
were caused by differences in tRNA gene copy number we have also used the SNaPshot 
technique to detect tDNA insertion into the genome of HEK293 cells (Figure 2-4). The number 
of copies of the tRNASer in the genome of Mock and tRNASer(S) cell lines was not altered from 
P1 to P30. As expected, the copy number of tRNASer was higher in tRNASer(S) cells than in the 
Mock cell line, confirming incorporation of the plasmid into the genome (Figure 2-4 A). In the 
tRNASer(A) cell line the number of copies of the tDNA decreased from P1 (0.26 a.u., 26% of 
tRNASer copies) to P30 (0.15 a.u., 15% of tRNASercopies). In tRNASer(L) and tRNASer(H) cell 
lines the number of tDNA copies was maintained.  In tRNASer(L) cells, tDNA values were 
around 0.06 a.u. (6% of tDNASer copies) and in tRNASer(H) cells, tDNA showed values around 
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0.09 a.u. (9% of tDNASer copies). The tRNASer(A) cell line incorporated more copies of the 
respective tDNA, relative to tRNASer(L) and tRNASer(H) cell lines (Figure 2-4 B).  
Therefore, the expression of the tRNAs and respective tDNA copy number are well 
correlated indicating that the former may be due to transcriptional regulation by Pol III or 
tRNA degradation, rather than loss of tDNA copies during evolution. tRNASer(A) cell line, is 
an exception since the decreased mutant tRNA expression is accompanied by a decrease in the 
copy number. 
 
A                                                                            B 
 
 
 
 
 
 
 
 
Figure 2-4. Copy number of tRNASer and mutant tRNAs. A – tDNAAGASergenomic copy number in Mock 
and tRNASer(S) cell lines, assessed by SNaPshot. B – Genomic copy number of the mutant tDNA genes 
relative to the Wt endogenous tRNAAGASer, assessed by SNaPshot, in tRNASer(A), tRNASer(L) and 
tRNASer(H) cell lines. tRNA values were normalized to an endogenous control, GAPDH. Data represents 
Average±SEM of one biological replicate and at least two technical replicates.  
 
 
2.3.3 Phenotypic effects of PSE  
 
We have accessed cell viability, proliferation, number of anchorage-dependent colonies 
formed, protein synthesis rate and accumulation of insoluble proteins, as readouts of putative 
phenotypic effects produced by PSE emerging during evolution of our cell line models.  
We used the number of cell passages as landmark of time points during evolution. 
Since overexpression of Wt tRNASer and expression of mutant tRNAs did not affect doubling 
time of HEK293 cells (approximately 20h), we believed that all cells were approximately in 
the same generation along the experiment (Figure 2-5).  
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Figure 2-5. Doubling time of cells, assessed by cell counting with Tripan blue. Values represent 
Average±SEM of three independent experiments in triplicate. One-way ANOVA followed by Dunnett’s 
post-test was used to assess differences between the Mock cell line and cells misexpressing the Wt tRNASer 
(tRNASer(S)) and expressing mutant tRNAs (tRNASer(A), tRNASer(L), tRNASer(H)) (p>0.05). 
 
 
In order to test the toxicity of mutant tRNAs and increased copies of the tRNASer, cell 
viability was assessed using Tripan blue. Overall, viability was not compromised by the 
expression of mutant tRNAs or alteration in the tRNA pool (Figure 2-6 A). However, 
tRNASer(A) and tRNASer(L) cell lines showed an increase in viable cells (5.14% and 6.08% 
respectively), relatively to the Mock in P1 (Figure 2-6 A). This was coincident with the 
passage in which these mutant tRNAs were most expressed (Figure 2-3 B). During evolution, 
tRNASer(A) and tRNASer(L) cells showed the same pattern of viability, which decreased from 
P1 and P15 (93% in P1 and a 88% in P15 of viable cells), and recovered from P15 to P30, to a 
level of viable cells similar to that observed in P1 (~ 93% of viable cells) (Figure 2-6 B). 
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Figure 2-6. Percentage of viable cells in culture determined by cell counting with Tripan blue. A – 
Percentage of viable cells in comparison with the Mock in each passage (one-way ANOVA, Dunnett’s post-
test,**p<0.01 ) B – Percentage of viable cells in each time point in tRNASer(A) and tRNASer(L) cell lines 
(one-way ANOVA, Bonferroni’s post-test, *p<0.05;**p<0.01;***p<0.001). Values were normalized to the 
Mock cell line of each passage and represent Average±SEM of three independent experiments in triplicate. 
 
 
Regarding cell proliferation, assessed with a DNA synthesis–based cell proliferation 
assay (BrdU), in P1 comparatively to the Mock, there were no alterations (Figure 2-7). In P15, 
the tRNASer(A) cell line showed higher proliferation than Mock (1.43 fold), while tRNASer(H) 
cell line showed a decrease of proliferation (0.64 fold) relative to Mock (Figure 2-7 A). In P30, 
both tRNASer(S) and tRNASer(A) cell lines proliferated more than the Mock cell line (1.08 fold 
in both). The tRNASer(H) cell line, which showed decrease in proliferation from P1 to P15 
(0.33 fold), restored its proliferation values in P30 (1.03 fold) (Figure 2-7 B). The tRNASer(A) 
cell line, which showed an increase in proliferation from P1 to P15 (0.36 fold), in P30 
recovered the proliferation values observed in P1 (Figure 2-7 B). 
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Figure 2-7. Relative cell proliferation determined using a BrdU ELISA Kit. A – Cell proliferation in 
comparison with Mock in each passage (one-way ANOVA, Dunnett’s post-test, (*p<0.05;**p<0.01) B – 
Relative proliferation of tRNASer(A) and tRNASer(H) cell lines (one-way ANOVA, Bonferroni’s post-test, 
*p<0.05;**p<0.01;***p<0.001).Values were normalized to the Mock cell line of each passage and represent 
Average±SEM of three independent experiments in triplicate. 
 
 
Cell proliferation and survival was also assessed using anchorage-dependent colony 
formation assay, which consists in the ability of a single cell to grow into a colony. Only 
tRNASer(H) cell line had lower colony formation capacity relative to Mock cell line in P15, 
with an average 12.87 colonies for tRNASer(H) vs. 18.44 for Mock (Figure 2-8). This was 
consistent with proliferation data, as tRNASer(H) was the only cell line that displayed decreased 
proliferation, at this same passage. 
 
 
 
 
 
 
 
 
 
Figure 2-8. Number of colonies formed after 12 days in culture. Values were normalized to the Mock cell 
line of each passage and represent Average±SEM of three independent experiments in duplicate (one-way 
ANOVA, Dunnett’s post-test, *p<0.05) 
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Since these engineered cell lines are error prone at the level of protein synthesis, we 
questioned if protein synthesis rate could be affected during the evolution of these cell lines 
along 30 passages in culture. To measure protein synthesis rate, we took advantage of the 
SunSET method, based in the detection of puromycin incorporation into proteins, as described 
in the methods section (181). Protein synthesis rate increased in tRNASer(A) cells in P1 (1.23 
fold) and P15 (1.48 fold) relative to Mock, but decreased in the tRNASer(L) cells in P30 (0.61 
fold) relative to Mock (Figure 2-9 A). Despite showing increased protein synthesis rate relative 
to Mock, when we compare the three time points (P1, P15 and P30) of tRNASer(A) cell line, 
there was a decrease from 1.23 fold in P1 to 0.76 fold in P30. The same occurred in 
tRNASer(L) cells, in which protein synthesis rate decreased from 1.20 fold in P1 to 0.61 fold in 
P30 (Figure 2-9 B).  
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Figure 2-9. Protein synthesis rate determined by SunSET method adapted to immunoblot with anti-
puromycin. A – Top panel: Relative protein synthesis rate in comparison with Mock in each passage (one-
way ANOVA, Dunnett’s post-test, *p<0.05). Mock values for each passage were considered 1 and were not 
represented in the graph. Lower panel: Representative immunoblot images for each time point and cell line 
and β-tubulin. B – Relative protein synthesis rate during evolution of tRNASer(A) and tRNASer(L) cell lines 
(one-way ANOVA, Bonferroni’s post-test, **p<0.01;***p<0.001). Values were normalized to the Mock cell 
line of each passage and represent Average±SEM of at least three independent experiments in triplicate.  
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To test whether mutant and Wt tRNASer destabilized the proteome and lead to 
misfolded protein accumulation and aggregates formation, we have quantified the insoluble 
protein fraction in P1, P15 and P30. In P15, there was a tendency for increasing levels of 
insoluble proteins, but it was only statistically significant for the tRNASer(L) cell line (2.66 
fold) (Figure 2-10). This protein aggregation effect was also transient, as the level of insoluble 
proteins returned to control levels at P30. This result may be explained by the lower expression 
levels of the mutant tRNAs in P30, but it may also indicate that cells counteracted protein 
aggregation, through activation of PQC mechanisms. Interestingly, the level of insoluble 
proteins decreased from P15 (2.1 fold) to P30 (0.71 fold) in the tRNASer(S) cell line that 
misexpresses the Wt tRNASer (Figure 2-10 B).   
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Figure 2-10. Relative insoluble protein fraction. A – Top panel: Relative insoluble fraction in comparison 
with Mock in each passage (one-way ANOVA, Dunnett’s post-test, **p<0.01). Mock values for each 
passage were considered 1 and were not represented in the graph. Lower panel: Representative acrylamide 
gel after commassie staining of each time point and cell line. B – Protein insoluble fraction during evolution 
of the tRNASer(S) cell line (one-way ANOVA, Bonferroni’s post-test, *p<0.05). Values were normalized to 
the Mock cell line of each passage and represent Average±SEM of at least three independent experiments in 
triplicate. 
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2.3.4 The impact of PSE in the ubiquitin-proteasome system and molecular 
chaperones  
 
Eukaryotic cells encompass several mechanisms of PQC to avoid protein aggregation 
and to eliminate aggregates, if they accumulate. These mechanisms include molecular 
chaperones, the ubiquitin-proteasome system (UPS), the unfolded protein response (UPR), the 
endoplasmic reticulum associated protein degradation (ERAD) and autophagy (82,88,182). 
Since we did not observe significant accumulation of insoluble proteins, particularly in P30, 
we wondered if erroneous proteins could have been marked by ubiquitin for degradation by the 
UPS (101,106). We observed increased levels of ubiquitinated proteins in the tRNASer(H) cell 
line (1.43 fold) in P1 (Figure 2-11 A). In P15, all other cell lines, tRNASer(S), tRNASer(A) and 
tRNASer(L), also showed higher levels of ubiquitinated proteins (1.36, 1.37 and 1.48 fold 
respectively) (Figure 2-11 A). In P30, the amount of ubiquitinated proteins in all cell lines was 
similar to Mock in the same passage. Importantly, from P15 to P30 the amount of ubiquitinated 
proteins decreased in all cell lines, being statistically significant in tRNASer(S) (from 1.36 fold 
in P15 to 0.96 fold in P30) (Figure 2-11 B). The latter data indicates that these cells were able 
to somehow degrade all proteins targeted by ubiquitination. 
    
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 – Adaptation of human cells to protein synthesis errors 
69 
 
tRNA
Ser
(S) tRNA
Ser
(A) tRNA
Ser
(L) tRNA
Ser
(H)
0.8
1.0
1.2
1.4
1.6
P1
P15
P30
* *
**
*
R
e
la
ti
v
e
 p
ro
te
in
 u
b
iq
u
it
in
a
ti
o
n
P1 P15 P30 
0.8
1.0
1.2
1.4
1.6
tRNA
Ser
(S)
***
R
e
la
ti
v
e
 p
ro
te
in
 u
b
iq
u
it
in
a
ti
o
n
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure 2-11. Relative protein ubiquitination determined by immunoblot. A – Top panel: Relative 
protein ubiquitination in comparison with Mock in each passage (one-way ANOVA, Dunnett’s post-test, 
*p<0.05;**p<0.01). Mock values for each passage were considered 1 and were not represented in the graph. 
Lower panel: Representative immunoblot images for each time point and cell line plus β-tubulin are shown. 
B – Relative protein ubiquitination during evolution of the RNASer(S) cell line (one-way ANOVA, 
Bonferroni’s post-test, ***p<0.001). Values were normalized to the Mock cell line of each passage and 
represent Average±SEM of at least three independent experiments in triplicate. 
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We then checked whether proteasome activity was altered in the same cell lines and 
time points, using a proteasome activity assay that measures chymotrypsin-like activity. The 
tRNASer(L) cell line showed higher proteasome activity in P1(1.27 fold) (Figure 2-12 A), while 
tRNASer(A) cell line had higher activity relative to Mock in P15 and P30 (2.17 fold and 1.66 
fold, respectively) (Figure 2-12 A). However, proteasome activity decreased in the tRNASer(L) 
cell line from 1.85 fold in P15 to 0.97 fold in P30 (Figure 2-12 B). The accumulation of 
ubiquitinated proteins and insoluble proteins in P15, particularly in this cell line, was likely 
overwhelming for the proteasome, affecting its degradative capacity. On the other hand, in the 
tRNASer(A) cell line the accumulation of ubiquitinated proteins in P15 was concomitant with 
increased proteasome activity. tRNASer(S) and tRNASer(H) cell lines did now show significant 
alterations in proteasome activity. 
 
A                                                                          B 
 
 
 
 
 
 
 
 
Figure 2-12. Relative proteasome activity. A – Relative proteasome activity assessed by fluorescent 
measurement of the labeled substrate Suc-LLVY-AMC (one-way ANOVA, Dunnett’s post-test, 
*p<0.05;**p<0.01). Mock values for each passage were considered 1 and were not represented in the graph. 
B – Proteasome activity of the tRNASer(L) cell line (one-way ANOVA, Bonferroni’s post-test, *p<0.05). 
Values were normalized to the Mock cell line of each passage and represent Average±SEM of at least three 
independent experiments in triplicate. 
 
 
Finally, we checked the molecular chaperones branch of the PQC system. We assessed 
the expression of those chaperones that are known to play a critical role in protein folding 
during stress, and whose expression is frequently altered in human diseases, namely Hsp70, 
Hsp27, Hsp60, Hsp90α and BiP (183,184). Hsp70 (heat shock protein 70) binds to a wide 
range of nascent polypeptides in stress conditions and by shielding hydrophobic regions, 
prevents aggregation and promotes proper folding. It also recruits ubiquitin ligases, such as 
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CHIP (carboxyl terminus of Hsp70-interacting proteins) to tag proteins for proteasomal 
degradation (108). The expression of Hsp70 did not change in P1 and P15, but decreased in 
P30 in tRNASer(A), tRNASer(L) and tRNASer(H) cell lines: 0.67, 0.55 and 0.64 fold, 
respectively (Figure 2-13 A).   
In general, the expression of this molecular chaperone decreased during evolution until 
P30, being this decrease statistically significant in tRNASer(A) cells (from 1.02 fold in P1 to 
0.67 fold in P30) (Figure 2-13 B).  
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Figure 2-13. Relative HSP70 expression. A – Relative HSP70 expression and respective immunoblots (one-
way ANOVA, Dunnett’s post-test, *p<0.05;**p<0.01). Mock values for each passage were considered 1 and 
were not represented in the graph. B – Expression in the three different time points of HSP70 in tRNASer(A) 
cell line (one-way ANOVA, Bonferroni’s post-test, *p<0.05). Values were normalized to the Mock cell line 
of each passage and represent Average±SEM of at least three independent experiments in triplicate. 
 
 
Hsp27  minimizes protein aggregation, by destabilizing aggregates, bind to proteins 
and aids in the refolding processes, favors degradation of some ubiquitinated proteins by the 
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proteasome and is involved in apoptotic signaling pathways (185). Its expression increased in 
tRNASer(L) cells in P15 (1.69 fold) and decreased in tRNASer(L) and tRNASer(H) cells in P30; 
0.53 and 0.56 fold, respectively (Figure 2-14 A). In P15, the increase in Hsp27 levels in the 
tRNASer(L) cell line was consistent with the higher levels of insoluble proteins, which may 
indicate that Hsp27 is being recruited to destabilize aggregated proteins.  tRNASer(S) and 
tRNASer(A) cell lines showed increased Hsp27 during early evolution from P1 to P15 (from 
0.75 to 1.48 fold and from 0.74 to 1.35 fold, in tRNASer(S) and tRNASer(A) cells, respectively). 
However, from P15 to P30 the level of this chaperone decreased (from 1.49 to 0.96 fold and 
from 1.35 to 0.69 fold, in tRNASer(S) and in tRNASer(A) cells, respectively) (Figure 2-14 B). 
From P15 to P30, the decrease in the expression of Hsp27 was also statistically significant in 
tRNASer(L) (from 1.69 to 0.53 fold) and in tRNASer(H) cells (from 1.31 to 0.56 fold) (Figure 2-
14 C). These alterations in Hsp27 expression are consistent with the dynamics of increased 
protein ubiquitination in these cell lines in P15.  
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Figure 2-14. Relative Hsp27 expression.  A - Relative Hsp27 expression the respective immunoblot (one-
way ANOVA, Dunnett’s post-test, *p<0.05). Mock values for each passage were considered 1 and were not 
represented in the graph. B and C – Hsp27 expression during evolution line (one-way ANOVA, Bonferroni’s 
post-test, (*p<0.05;**p<0.01; ***p<0.001 ).Values were normalized to the Mock cell line of each passage 
and represent Average±SEM of at least three independent experiments in triplicate. 
 
 
Hsp60 (heat shock protein 60) is a mitochondrial chaperonin involved in protein 
refolding in the mitochondrial matrix under stress conditions. In our cell lines, the expression 
of Hsp60 increased in P15 in tRNASer(H) cell line (1.48 fold) and decreased in P30 in 
tRNASer(L) (0.69 fold) and tRNASer(H) cell lines (0.76 fold) relative to Mock (Figure 2-15 A). 
The expression of Hsp60 in these two cell lines, increased from P1 to P15 (from 0.83 to 1.4 
fold in tRNASer(L) cells and from 0.78 to 1.48 fold in tRNASer(H) cells), but decreased from 
P15 to P30 (from 1.4 to 0.69 fold in tRNASer(L) cells and from 1.48 to 0.76 fold in tRNASer(H) 
cells) (Figure 2-15 B), indicating that PSE may also affect protein folding in the mitochondria.   
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Figure 2-15. Relative Hsp60 expression. A - Relative Hsp60 expression the respective immunoblot (one-
way ANOVA, Dunnett’s post-test,*p<0.05;**p<0.01; ***p<0.001). Mock values for each passage were 
considered 1 and were not represented in the graph. B – Hsp60 expression during evolution (one-way 
ANOVA, Bonferroni’s post-test, *p<0.05;**p<0.01). Values were normalized to the Mock cell line of each 
passage and represent Average±SEM of at least three independent experiments in triplicate. 
 
 
Hsp90α is a molecular chaperone involved in the refolding of specific proteins 
(normally proteins involved in signal transduction, some of which are ER transmembrane 
kinases that participate in the UPR) (186). This protein displayed lower levels in tRNASer(L) 
(0.71 fold) and tRNASer(H) (0.69 fold) cell lines in P1, relative to Mock in the same passage 
(Figure 2-16). In tRNASer(S) cell line, Hsp90α increased in P30 (1.31 fold) (Figure 2-16).  
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Figure 2-16. Relative Hsp90α expression. Graphic and immunoblot image of Hsp90α expression. Values 
were normalized to the Mock cell line of each passage and represent Average±SEM of at least three 
independent experiments in triplicate (one-way ANOVA, Dunnett’s post-test, *p<0.05). Mock values for 
each passage were considered 1 and were not represented in the graph. 
 
 
Finally, we accessed the expression of BiP, a molecular chaperone of 70 KDa located 
in the lumen of the ER that senses ER stress and activates UPR signaling (187). Its expression 
was low compared to Mock in tRNASer(H) cell line (0.61 fold) in P1 and higher compared to 
Mock in the tRNASer(L) cell line in P30 (1.34 fold) (Figure 2-17 A). In tRNASer(L) there was 
upregulation of this chaperone (from 0.77 to 1.34 fold) from P1 to P30 (Figure 2-17 B), 
suggesting the presence of misfolded proteins in the ER. 
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Figure 2-17. Relative BiP expression. A – BiP expression relative to Mock and the corresponding 
immunoblots (one-way ANOVA, Dunnett’s post-test,*p<0.05). Mock values for each passage were 
considered 1 and were not represented in the graph. B – BiP expression during evolution in tRNASer(L) cell 
line (one-way ANOVA, Bonferroni’s post-test, *p<0.05). Values were normalized to the Mock cell line of 
each passage and represent Average±SEM of at least three independent experiments in triplicate.  
 
 
In this part of the study, we have observed accumulation of ubiquitinated proteins in all 
cell lines, but proteasome activity was only altered in tRNASer(A) and tRNASer(L) cells. While 
tRNASer(A) cells maintained high proteasome activity, tRNASer(L) cells did not. The 
expression of molecular chaperones changed depending on the cell line and throughout 
evolution. Hsp70 expression tended to decrease during evolution, while expression of Hsp27 
had a peak in P15, which could be correlated with higher levels of ubiquitinated proteins and 
insoluble proteins in some of the cell lines analyzed. Hsp60 expression was also increased in 
tRNASer(H) cells in P15, but its levels decreased in P30. Hsp90α and BiP presented a different 
pattern of expression as their expression increased from P1 to P30, in some of our cell lines.
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2.3.5 Effects of PSE in the UPR 
 
Accumulation of misfolded proteins in the ER leads to activation of the UPR, which 
consists in transcriptional activation of genes required for protein folding, ER expansion and 
ER-associated protein degradation (ERAD). Activation of UPR reduces ER stress, but 
prolonged activation leads to apoptosis and also the accumulation of reactive oxygen species 
(ROS) via UPR-regulated oxidative protein folding machinery in the ER, contributing in this 
way to cell death (188). To clarify whether constitutive PSE could lead to activation of the 
UPR, we studied some molecular markers of the UPR branches. Activation transcription factor 
6 (ATF6) is a transmembrane protein embedded in the ER. Following ER stress-induced 
proteolysis, it functions as a nuclear transcription factor (176). Although in P1 there were no 
alterations in the ratio of fragmented ATF6/total ATF6 among cell lines, compared to the 
Mock, tRNASer(S) cell line displayed an increase in P15 and tRNASer(A) an increase in P30 
(1.69 fold in both cases) (Figure 2-18 A). In tRNASer(S) cell line the ratio of fragmented 
ATF6/total ATF6 increased from P1 to P15 (from 0.72 to 1.69 fold) and decreased from P15 to 
P30 (from 1.69 fold to 0.67 fold) (Figure 2-18 B).  
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Figure 2-18. Relative ATF6f/ATF6t expression. A – ATF6f/ATF6t expression relative to Mock and the 
corresponding immunoblot (one-way ANOVA, Dunnett’s post-test,*p<0.05). Mock values for each passage 
were considered 1 and were not represented in the graph. B – ATF6f/ATF6t expression during evolution in 
tRNASer(S) (one-way ANOVA, Bonferroni’s post-test, **p<0.01). Values were normalized to the Mock cell 
line of each passage and represent Average±SEM of at least three independent experiments in triplicate.  
 
 
Another marker of UPR activation is the phosphorylation of the eukaryotic initiation 
factor 2α (eIF2α-P). In cases of ER stress, PERK phosphorylates and inactivates eIF2α, 
shutting down mRNA translation to reduce protein load in the ER (189). Only in P30 were 
observed diffrences in the ratio eIF2α-P/total eIF2α in our cell lines. The ratio eIF2α-P/total 
eIF2α decreased in tRNASer(A) (0.53 fold) and increased in tRNASer(L) (1.6 fold), comparing 
to Mock (Figure 2-19 A). In the latter, this happened gradually throughout evolution, from P1 
to P30 (from 0.8 to 1.6 fold) (Figure 2-19 B) and this decrease is consistent with the decreased 
protein synthesis rate in P30 (Figure 2-9). The decrease of eIF2α-P in the tRNASer(A) cell line 
made us wonder whether it was caused by downregulation of PERK, or upregulation of the 
eIF2α phosphatase PP1’s regulatory domain, GADD34. Our data showed an increase in 
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GADD34 expression only in tRNASer(A), in P30 (1.71 fold) (Figure 2-20 A) and from P1 to 
P30 (from 0.98 to 1.71 fold) (Figure 2-20 B). These results confirm that GADD34 plays an 
important role in the maintenance of protein translational rate in this particular cell line.  
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Figure 2-19. Relative eIF2αP/eIF2αt expression.  A – eIF2αP/ eIF2αt expression relative to Mock and the 
corresponding immunoblots (one-way ANOVA, Dunnett’s post-test,*p<0.05). Mock values for each passage 
were considered 1 and were not represented in the graph. B – eIF2αP/ eIF2αt expression during evoltution in 
tRNASer(L) cells (one-way ANOVA, Bonferroni’s post-test,*p<0.05). Values were normalized to the Mock 
cell line of each passage and represent Average±SEM of at least three independent experiments in triplicate. 
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Figure 2-20. Relative GADD34 expression. A – GADD34 expression relative to Mock and the 
corresponding immunoblots (one-way ANOVA, Dunnett’s post-test, **p<0.01). Mock values for each 
passage were considered 1 and were not represented in the graph. B – GADD34 expression during evoltution 
in tRNASer(A) cells (one-way ANOVA, Bonferroni’s post-test,*p<0.05). Values were normalized to the 
Mock cell line of each passage and represent Average±SEM of at least three independent experiments in 
triplicate. 
 
 
Therefore, different types of PSE activated different UPR pathways, probably due to 
differences in ER stress intensity. Indeed, in the tRNASer(A) cell line, where protein misfolding 
levels and ER stress are probably milder (Ser and Ala are chemical similar amino acids), there 
was an increase in fragmented ATF6, concomitant with increased accumulation of 
ubiquitinated proteins and proteasome activity. This is physiologically relevant since ATF6 is 
also responsible for protection against ER stress-induced apoptosis and cell survival (190). 
However, in the tRNASer(L) cell line, where the level of misfolded proteins and ER stress 
should be more intense due to bigger chemical differences between Ser and Leu, 
phosphorylation of eIF2α repressed protein synthesis. This did not happen in the tRNASer(A) 
cell line due to eIF2α dephosphorylation by GADD34, that maintained the levels of protein 
synthesis rate and allowed a balance between protein degradation and protein synthesis.  
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2.3.6 Transcriptional deregulation induced by PSE  
 
To obtain a better picture of PQC activation in our model, we have characterized our 
cell lines using cDNA microarrays. We focused our gene expression data analysis on UPR, 
UPS, autophagy, translational factors and ribosomal protein genes (Table 2-1). Regarding the 
UPR genes, ERN1(endoplasmic reticulum to nucleus signaling 1, IRE1), XBP1(X-box binding 
protein 1) and EIF2AK3 (eukaryotic translation factor 2 alpha kinase 3, PERK) were 
deregulated in our cells. In P1, ERN1 was downregulated 2.4 fold in tRNASer(S), 2.0 fold in 
tRNASer(A) and 1.8 fold in tRNASer(L) cells. On the contrary, XBP1 (wich correspondes to the 
unspliced transcript) was upregulated 1.5 fold in P1 and 1.8 fold in P15 in tRNASer(S) cells. 
ERN1 catalyzes the splicing of XBP1 mRNA. Probably, since ERN1 is downregulated in P1 in 
tRNASer(S) cells, there is an accumulation of XBP1u. The upregulation of XBP1 mRNA in 
P15, in  tRNASer(S) cells, is consistent with increased fragmented ATF6. ATF6 can induce not 
only the expression of ERAD genes, but also XBP1 gene (119). During evolution, EIF2AK3 
expression increased from -1.2 fold in P1 to 1.1 fold in P30, relative to Mock in tRNASer(L) 
and decreased in tRNASer(H) cells from 1.3 in P1 to -1.2 in P30. EIF2AK3 encodes the kinase 
responsible for eIF2α phosphorylation (PERK) and its upregulation is consistent with 
increased levels of eIF2α-P, in P30, in the tRNASer(L) cell line.  
The cDNA microarray data also confirmed activation of the UPS, as alterations in the 
expression of some ubiquitin ligases (UBE2Z, UBE2I and SMURF2) were observed over time. 
Overall, there was a tendency to increased expression in ubiquitin ligases in P15 in tRNASer(S), 
tRNASer(L) and tRNASer(H) cells, despite the values were below 1.5 fold. In tRNASer(S), 
UBE2Z expression decreased from P15 (1.3 fold) to P30 (-1.3 fold), while SMURF2 
expression increased from P1 (-1.2 fold) to P15 (1.3 fold). For the last one, in tRNASer(L), 
there was also an increase in expression from P1 (0.8 fold) to P15 (1.1 fold). In tRNASer(H), 
the expression of UBE2I decreased from P15 (1.1 fold) to P30 (-1.1 fold). Deubiquitinating 
enzymes (USP48 and USP36) were deregulated in tRNASer(S), tRNASer(A) and tRNASer(L) 
cell lines. USP48 was upregulated in tRNASer(L) in P30 (1.6 fold). USP36 was upregulated in 
tRNASer(S) in P15 (1.5 fold) and its expression decreased in tRNASer(A) cells from P1 (1.2 
fold) to P15 (-1.0 fold). Also, the expression of PSMC1 gene (proteasome 26S subunit, 
ATPase 1) suffered alterations during evolution, its expression decreased from P15 to P30 in 
tRNASer(S) (1.3 to -1.0 fold), tRNASer(A) (1.1 to -1.1 fold) and tRNASer(H) cells (1.2 to -1.1 
fold). tRNASer(S) cell line presented more alterations in UPS genes comparatively to the other 
cell lines. We could also observe that UPS related genes tended to be upregulated in P15, 
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concomitantly with the accumulation of ubiquitinated proteins in most cell lines, with 
exception for UPS48  in tRNASer(S) (upregulated in P30, 1.6 fold).  
Regarding autophagy, the microarray data showed upregulation of ATG16L1 during 
evolution in tRNASer(S) (from -1.0 fold in P15 to 1.3 fold in P30), tRNASer(A) (-1.1 fold in P15 
to 2.2 fold in P30) and tRNASer(H) cells (-2.2 fold in P1 to 1.6 fold in P30). ATG12 and ATG5 
expression also increased in the tRNASer(L) cell line, from -1.0 fold in P1 to 1.3 fold in P15 
and -1.2 fold in P1 to 1.1 fold in P15, respectively. These two genes encode proteins that form 
a complex involved in the formation of the autophagosomes and may be involved in the 
degradation of protein aggregates (191). These results indicate that autophagy was probably 
activated in our cell lines. The increase in ATG12 and ATG5 is consistent with the higher levels 
of insoluble proteins in the tRNASer(L) cell line.  
Beyond the above mentioned deregulations, a set of translational factors, namely 
EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1), EEF1A1 (eukaryotic 
translation elongation factor 1 alpha 1) and EEF2 (eukaryotic translation elongation factor 2), 
were also deregulated during evolution. EIF4EBP1 expression decreased in tRNASer(A) celss 
from P15 (1.3 fold) to P30 (-1.1 fold). The eIF4EBP1 interacts with eIF4E and inhibits 
initiation complex assembly with consequent translation repression (192). The decreased 
expression of EIF4EBP1 is in accordance with the translation derepression observed in this 
cell line. EEF1A1 expression decreased in tRNASer(S) and tRNASer(H) cells from 1.4 fold in 
P15 to -1.0 fold in P30 and from 1.0 fold in P1 to -1.2 fold in P15, respectively. Also, in 
tRNASer(S) cell line, EEF2 expression was downregulated from 1.0 fold in P15 to -1.5 fold in 
P30. These data suggest that translation elongation rate may also been affected during 
evolution, but our data was not able to reveal it. Also, these results may indicate that 
translation was remodeled for efficient translation of stress genes rather than for global 
translational repression. Indeed, the RPS6KL1 (ribosomal protein S6 kinase like 1) that 
encodes a member of the ribosomal S6 kinase family was upregulated during evolution from    
-1.3 fold in P15 to 1.0 fold in P30 in tRNASer(A) cell line. S6 kinases are part of the 
mammalian target of rapamycin (mTOR) pathway, which is a key regulator of cell growth via 
the regulation of protein synthesis. S6 kinases are activated by serine/threonine 
phosphorylation and phosphorylate ribosomal protein 6, increasing translation of a set of 
proteins, including ribosomal proteins (193). 
Altogether, the expression microarrays data are in accordance with our previous results 
and supported the idea that PQC mechanisms are being activated in a time dependent manner, 
and in response to mutant tRNAs or tRNA pool deregulation alone. UPR related genes were 
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upregulated (tRNASer(S) cell line), or showed increased fold change during evolution 
(tRNASer(L) cell line). UPS related genes were also upregulated in the same cell lines. 
Variation of expression through time in UPS genes, was observed in tRNASer(S), tRNASer(A) 
and tRNASer(H) cells. These gene expression alterations are different for each cell line, 
probably depending on the need for ubiquitinating or deubiquitinating enzymes during each 
passage. Autophagy seems to play a role in the response against misfolded proteins in our cell 
lines, since there was an increase in the expression of autophagy related genes through their 
evolution from P1 to P30. Alterations in translational factors were also seen, as well as a 
tendency to decreased expression though time in tRNASer(S) and tRNASer(A) cells, with no 
implications in the overall protein synthesis rate. Finally, also the expression of a ribosomal 
protein kinase (RPS6KL1) was altered in tRNASer(A) and tRNASer(H) cell lines.  
 
Table 2-1. Deregulation of PQC genes induced by protein synthesis errors.  
Red color represents upregulated genes, fold change above 1.5. Green color represents dowregulated genes, 
variation below -1.5 fold. Numbers in blue highlight changes in gene expression that occurred during 
evolution.  
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2.4 Discussion  
 
Our study demonstrates that HEK293 cells expressing mutant tRNAs or overexpressing 
the Wt tRNASer are highly tolerant to PSE, despite the accumulation of misfolded proteins over 
time. PQC mechanisms were activated in a time and stress dependent manner, allowing these 
cell lines to thrive, after several generations in culture. 
PSE destabilize protein structure and cause disease by overloading chaperones and the 
proteasome and inducing autophagy, increasing protein cleaning up energetic costs, altering 
cell signaling and metabolism, producing toxic protein aggregates, repressing protein synthesis 
and inducing major genomic alterations (75,167,194,195). Kalapis and Bezerra have 
demonstrated recently that a yeast strain misincorporating Ser at Leu sites could adapt to PSE 
by up-regulating protein synthesis, protein degradation and glucose up-take (196). 
Remarkably, clones that evolved for approximately 250 generations were able to reduce 
protein aggregates and recovered fitness to almost wild type levels, but at a high metabolic cost 
(196). Our data are in line with those data. Indeed, protein synthesis and degradation rates 
increased during evolution in tRNASer(A) cell line. In contrast, while mistranslation had a 
major negative initial impact on yeast growth rate and viability, no consequence at all were 
seen in HEK293 cells doubling time and an increase was even observed in the viability of 
tRNASer(A) and tRNASer(L) cell lines and proliferation of tRNASer(S) and tRNASer(A) cell lines 
(Figure 2-5, Figure 2-6 and Figure 2-7). 
Also, tolerance to mutant tRNAs increased in yeast during evolution, while in human 
cells the mutant tRNAs expression was strongly repressed throughout evolution. These data 
suggest that yeast adapted to mistranslation using error mitigation mechanisms, while human 
cells preferred error prevention. 
The decrease in protein aggregation levels observed during evolution in yeast and 
HEK293 cells (namely in tRNASer(L) cell line) has implications for understanding the biology 
of protein misfolding diseases. Protein aggregation studies use cell models where expression of 
aggregation prone proteins is induced and adaptation is not evaluated (197–199). Even in cases 
where these proteins are expressed constitutively the norm is to maintain cell passages as low 
as possible to avoid genomic instability (200). Considering our data on adaptation during 
evolution, human cell models of Alzheimer’s, Parkinson’s and other protein misfolding 
diseases should be studied to capture the full spectrum of metabolic and physiological changes 
induced by protein aggregation. Aggregates associated with neurological disorders are known 
to block proteasome activity and activate mechanisms that lead to the repression of protein 
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synthesis (41,201), suggesting that these cells are unable to tolerate and adapt to them 
(202,203). However, different types of human cells cope differently with protein aggregation, 
raising the question of whether adaptation to aggregation may follow different routes in 
different cell types. Recent studies showing that suppression of eIF2 kinases alleviates 
Alzheimer’s symptoms in mice (129) support this hypothesis.  
Different amino acid misincorporations in the proteome activated different cellular 
responses and led to differential adaption routes during the evolution of our cell lines. 
Interestingly, increased expression of the Wt tRNAAGA
Ser had phenotypic consequences that 
were clearly distinct from the Mock (control), suggesting that human cells are highly sensitive 
to tRNA gene copy number alterations and expression levels. It is known that increased 
expression of Wt tRNAs (which is common in cancer) alters translation rate, enhances 
expression of oncogenes and may also increase the level of protein errors, leading to 
accumulation of misfolded proteins (158,204). In P15, we observed accumulation of 
ubiquitinated proteins, UPS and UPR activation (Figure 2-21) confirming the hypothesis that 
misexpression of Wt tRNAs may have major physiological consequences due to activation of 
the stress response and translational deregulation of gene expression (159).  
In the tRNASer(A) cell line there was an initial (P1 to P15) increase in protein synthesis 
rate, followed by increased proteasome activity (P15 to P30), in other words increased protein 
synthesis and turnover, as occurred in yeast (Figure 2-21) (196). Previous studies show that 
short-living proteins have on average higher aggregation propensity and fewer chaperone 
interactions than long-living proteins and high protein turnover seems to be sufficient to 
prevent aggregation (205). Therefore, the Ser-to-Ala misincorporation model may be relevant 
to address the biology of PSE for instance in cancer, where PQC mechanisms are highly 
activated (206), but generalized protein aggregation is not commonly observed. Indeed, PSE 
have not yet been quantified in a systematic manner in cancer, and it is unclear whether it plays 
a relevant role, however chaperones are often uperegulated in tumors (207), suggesting high 
demand for protein folding/refolding, which is a hallmark of PSE.  
The tRNASer(L) cell line had higher proteasome activity (P1), but accumulation of 
aggregated proteins was also visible (P15) (Figure 2-21). Adaptation of this cell line to mutant 
tRNA expression and protein aggregation was more dependent on UPR activation, namely 
phosphorylation of eIF2α, and consequent inhibition of protein synthesis rate in order to 
alleviate ER stress, than other cell lines. At the protein synthesis level, phosphorylation of 
eIF2α promotes polysome disassembly resulting in the accumulation of untranslated messenger 
ribonucleoprotein particles (mRPs) that can form stress granules, and are responsible for 
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reprogramming mRNA metabolism and contribute to cell survival (208,209). Together with 
the decrease in protein synthesis rate, also dilution by cell division and autophagy may have 
contributed to the decrease in protein aggregates observed in P30, in this cell line.  
tRNASer(H) activated mainly PQC mechanisms in P1 and P15, while in P30, a decrease 
in molecular chaperones occurred (Figure 2-21). With exception of Hsp90α and BiP, there was 
a general decrease in molecular chaperones expression in our cell lines (Figure 2-21). Decrease 
in chaperones with aging have been already reported in several studies (210–213). Molecular 
chaperones are, usually, the first line of defense against misfolded proteins, and probably, other 
mechanisms can be more efficient to remove these proteins after prolonged proteotoxic stress.  
 
 
 
Figure 2-21. Summary of the PQC alterations identified in the different cell lines. Mutant tRNAs and 
misexpression of tRNASer led to accumulation of ubiquitinated proteins, suggesting increased levels of 
misfolded proteins.  PQC mechanisms were recruited in an error type and time dependent manner to 
counteract proteotoxic stress. Increase in protein turnover and decrease in protein synthesis seem to be two 
important mechanisms that cells used to thrive in culture after several generations accumulating errors in 
proteins. 
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2.5 Conclusion 
 
PSE have been extensively studied in E. coli and yeast, but little is known about their 
biology in human cells. We show here that experimental evolution provides an important tool 
to study such errors in human cells, although they have only been applied to microorganisms.  
HEK293 cells activated PQC mechanisms in order to respond to the accumulation of 
misfolded proteins caused by the introduction of mutant tRNAs or tRNA pool deregulation. As 
we expected, this activation depends on the cell passage and the type of proteome 
destabilization that we are creating. With evolution of the cell lines, we observed that there was 
a decrease in protein ubiquitination and in some cases protein aggregates with concomitant 
increase in UPR activation or protein degradation.  
Clearly, and in contrast to models of protein misfolding diseases, we did not observe 
significant effects on cell viability or proteasome inhibition suggesting that human cells cope 
better with PSE than with protein aggregation associated with Alzheimer’s, Parkinson’s and 
other neuropathies. Adaptation to PSE and protein aggregation may also suggest that protein 
synthesis and degradation rates are more relevant to mitigate and erase aggregates than 
chaperones or autophagy. In fact, expression of molecular chaperones was unchanged or 
decreased during evolution, an effect also observed in yeast, where chaperones expression 
increases initially but decreases gradually or is even repressed in some cases.  
 
 
2.6 Materials and Methods  
 
2.6.1 Cell culture 
 
Human embryonic kidney 293 (HEK293) cells were purchased from American Type 
Culture Collection (ATCC®CRL-1573). Cells were grown in Minimum Essential Medium 
(Gibco, Cat.41090-028) supplemented with 10% fetal bovine serum (FBS) (Sigma, 
Cat.F1051), 1% of Pen/Strep (Gibco, Cat.15070-063) and 1% of non-essential amino acids 
(Gibco, Cat.11140-050) in a humidified atmosphere at 37ºC in the presence of 5% CO2.  
 
 
2.6.2 Construction of mutant tRNA plasmids  
 
A DNA fragment of 248kb, corresponding to part of the gene encoding human wild 
type tRNAAGA
Ser (Chr6 tRNA#5) and its flanking region, was amplified by PCR. The primers 
Unravelling the cellular networks that regulate proteotoxic stress  
88 
 
used were the following: forward 5’- 
GCCGAATTCAGCTATTATTAAATCCCTAATAAAAGG-3’ and reverse 5’-
CGCCTCGAGTTGTAAAAGATCGAAAGCCTTTTTA-3’. The region amplified has the 
following sequence: 5’-
AGCTATTATTAAATCCCTAATAAAAGGAGTACAATATGTGATGTATGGAAACATG
TAAGACATTTAATAAGGTTTTTGGTATCTGTAGTCGTGGCCGAGTGGTTAAGGCGA
TGGACTAGAAATCCATTGGGGTCTCCCCGCGCAGGTTCGAATCCTGCCGACTACGG
CAGTGGGTTTTTGCATCTTCAAGCAGGTTTCATCCGACCGATCGATATTTCACGTG
TAAAAAGGCTTTCGATCTTTTACAA-3’. This region was cloned into the modified vector 
pIRES2-DsRed with new multiple cloning sites, using the enzymes EcoRI (Thermo Scientific, 
Cat.ER0271), XhoI (Thermo Scientific, Cat.ER0691) and T4 DNA ligase (Thermo Scientific, 
Cat.EL0011). To change the anticodon of the tRNAAGA
Ser, to other anticodons, we performed 
site-directed mutagenesis. The primers used were the following: forward to tRNAAGC
Ser (A) 5’-
GTTAAGGCGATGGACTAGCAATCCATTGGGGTCTCCC-3’; reverse to tRNAAGC
Ser (A) 
5’-GGGAGACCCCAATGGATTGCTAGTCCATCGCCTTAAC-3’;forward to tRNAAAG
Ser 
(L) 5’-GGTTAAGGCGATGGACTAAGAATCCATTGGGGTCTCCC-3’; reverse to 
tRNAAAG
Ser (L) 5’-GGGAGACCCCAATGGATTCTTAGTCCATCGCCTTAACC-3’;forward 
to  tRNAGTG
Ser (H) 5’-GGTTAAGGCGATGGACTGTGATCCATTGGGGTCTCC-3’; reverse 
to tRNAGTG
Ser (H) 5’-GGAGACCCCAATGGATTCACAGTCCATCGCCTTAACC-3’. 
Contruction of mutant tRNA plasmids was done by Patrícia Pereira in the RNA 
Biology Laboratory, Aveiro, Portugal, in 2007.  
 
 
2.6.3 Generation of mistranslating cell lines 
 
HEK293 cells with approximately 60% of confluency were transfected with 1µg of 
plasmid DNA using Lipofectamine2000 (Invitrogen, Cat.11668019), following manufacturer’s 
instructions. Cells were transfected with an empty vector (Mock), and with the plasmid 
carrying tRNAAGA
Ser(S), tRNAAGC
Ser(A), tRNAAAG
Ser(L) or tRNAGTG
Ser(H) genes. To establish 
stable cell lines, 72h after transfection, geneticin (Formedium, Cat.G4185) was added to the 
medium at a concentration of 800µg/ml and selection lasted for 1 month. Cells were kept in 
low concentration of geneticin (100µg/ml) after selection and during evolution in culture. 
Geneticin was not added to the medium when cells were plated for the experiments.  
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2.6.4 Evolution of cells in culture  
 
After transfection with the plasmids and selection, cells were kept in culture dishes 
(60mm) and subcultured ever 3 days using the same dilution (1/6) until passage 30. Cell 
culture conditions were the same during evolution. In P1, P15 and P30 cells were plated in 
100mm culture dishes, to have enough cells to perform the experiments and extract DNA, 
RNA and protein.  
 
 
2.6.5 Total RNA extraction  
 
RNA was extracted using Trizol®Reagent (Thermo Fisher Scientific, Cat.15596026). 
The content of one well from a 6 well plate, with around 5x105 cells, was collected for each 
experimental condition. Purification of RNA was done using DNaseI, Amplification Grade kit 
(Invitrogen, Cat.18068015), following manufacturer’s instructions. RNA was then precipitated 
with a standard Phenol/Chlorophorm/Isoamylalchohol (25:24:1) (Acros Organics, 
Cat.327111000) extraction protocol and conserved at -80ºC. RNA concentration was 
determined using NanoDrop1000 (Thermo Scientific). RNA quality was verified using Agilent 
2100 Bioanalyser.  
 
 
2.6.6 Quantification of tRNA expression and tDNA copy number 
 
The expression of the tRNAs was quantified by extracting total RNA from the 
transfected cell lines. 200ng of total RNA were used for cDNA convertion using NCode™ 
VILO™ miRNA cDNA Synthesis Kit (Invitrogen, Cat.A11193050), following manufacturer’s 
instructions. To determine the copy number of the Wt tDNASer and the mutant tDNA genes, 
genomic DNA was extracted using Wizard® Genomic DNA Purification Kit (Promega, 
Cat.TM050), following the manufacturer’s instructions. Amplification of the Wt and mutant 
tRNAs from cDNA (2µL) or DNA (200ng) was done by PCR using the following primers: 
forward 5’-CGTAGTCGGCAGGATTCGAA-3’ and reverse 5'-GTA GTC GTG GCC GAG 
TGG TT-3'. As an internal control, GAPDH was also amplified in the same PCR reaction, 
using the following primers: forward 5´-CTC CTG TTC GAC AGT CAG CC -3' and reverse 
5'-CCC ACT TGA TTT TGG AGG GA-3'.  
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PCR conditions for DNA amplification were: 95ºC for 15min, (95ºC for 30 sec, 62ºC 
for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 60ºC for 1 min 
and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 58ºC for 1 min and 30 sec, 
72ºC for 1 min and 30 sec, 30 cycles) and a final step of extension at 72°C for 10 min. 8µL of 
the PCR product was run on a 2% agarose gel to confirm the amplification of the two bands 
(Figure 2-23 A).  
PCR conditions for cDNA amplification were: 95ºC for 15min, (95ºC for 30 sec, 62ºC 
for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 60ºC for 1 min 
and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 58ºC for 1 min and 30 sec, 
72ºC for 1 min and 30 sec, 30 cycles) and a final step of extension at 72°C for 10 min. 5µL of 
PCR product were purified with 1µL of ExoI (Thermo Fisher Scientific, Cat.EN0581) and 1µL 
of FastAp (Thermo Fisher Scientific, Cat.EF0654) for 60min at 37ºC followed by 15min at 
85ºC. 2µL of purified PCR product were reamplified. PCR conditions were the same, with the 
exception of the number of cycles in the last amplification step (cycle 25). 8µL of the PCR 
product were run on a 2% agarose gel to confirm the amplification of the two DNA fragments 
(Figure 2-23 B).  
5µL of PCR products (from DNA or cDNA) were purified using 1µL of ExoI (Thermo Fisher 
Scientific, Cat.EN0581) and 1µL of FastAp (Thermo Fisher Scientific, Cat.EF0654) for 60min 
at 37ºC followed by 15min at 85ºC.  
SNaPshot reaction was performed using the following primers: 5’-
GGGAGACCCCAATGGATT-3’ for tRNAs and 5'-CCC ACT TGA TTT TGG AGG GA-3' 
for GAPDH and a SNaPshot Multiplex Ready Reaction Mix (Applied Biosystems, 
Cat.4323163). Reaction cycles for tRNAs were: 96ºC for 10 sec, 54ºC for 5 seconds and 60ºC 
for 30 sec, 25 cycles. Reaction cycles for GAPDH were: 96ºC for 10 sec, 64ºC for 5 seconds 
and 60ºC for 30 sec, 10cycles. SNaPshot products were purified with 1µL of FastAp (Thermo 
Fisher Scientific, Cat.EF0654) for 60min at 37ºC, followed by 15min at 85ºC. Samples were 
then sequenced and analyzed with Peak Scanner software (Applied Biosystems). The peak area 
corresponding to each mutant tRNA and Wt tRNASer was determined and a ratio calculated. 
GAPDH was quantified and used as a internal control to normalize tRNA expression levels 
(214,215).  
 
 
 
Chapter 2 – Adaptation of human cells to protein synthesis errors 
91 
 
2.6.7 Cell fitness assessment 
 
To measure cells doubling time, 3x104cells/well were plated in 6-well plates. After 
72h, cells were detached and counted in a Neubauer chamber with Tripan blue 0.4% (Lonza, 
Cat.17-942E). Population doubling time was calculated using the formula: Doubling 
time=duration*log(2)/(log(final concentration)-log(initial concentration)) (216). For viability 
assays, the number of viable cells in culture was determined with Tripan blue exclusion assay. 
3x104cells/well were plated in 6-well plates. After 72h, cells were counted in a Neubauer 
chamber using Tripan Blue 0.4% (Lonza, Cat.17-942E). For the quantification of cell 
proliferation, we used a colorimetric immunoassay ELISA, based on the measurement of BrdU 
incorporation during DNA synthesis (Roche, Cat.11647229001), following manufacturer’s 
instructions. 1x105cells/well were plated in a 96-well and analysis was performed after 48h. To 
access the ability of a single cell to grow into a colony we performed an anchorage-dependent 
colony formation assay. 100cells/well were plated in 6-well plates. The medium was renewed 
every 3 days. After 12 days, cells were fixed in ice-cold methanol and stained with 1% cristal 
violet (Sigma Aldrich, Cat.C6158) in 20% methanol to count the foci.  
 
 
2.6.8 Protein synthesis determination  
 
In order to determine protein synthesis rate, we took advantage of a non-reactive 
fluorescence-activated cell sorting-based assay, called SUnSET (181) with few modifications. 
2x105cells/well were plated in 6-well plates and after 48h, puromycin (Sigma Aldrich, Cat. 
07635) was added to each well in a final concentration of 10%. Cells were kept in the 
incubator for 10 min, washed twice with 1%PBS and returned to the incubator for 50 min. 
After protein extraction with Lysis Buffer (0.5% Triton X-100, 50mM HEPES, 250mM NaCl, 
1mM DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM PMSF, 1mM Na3VO4 supplemented 
with a cocktail of protease inhibitors (Complete, EDTA-free, Roche, Cat. 11873580001); as 
recommended by the manufacturer) and denaturation, 100 µg of protein were resolved in 10% 
SDS-PAGE and blotted onto nitrocellulose membranes (0.2µm) (GE Healthcare Life 
Sciences). Anti-puromycin, clone 12D10 (kindly given by Philippe Pierre) was used (1:5000 
dilution) to detect the incorporation of puromycin into proteins. IRDye800 goat anti-mouse 
secondary antibody (Li-cor Biosciences, Cat.400-33) was used (1:10000 dilution) and detected 
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in an Odyssey Infrared Imaging System (Licor Biosciences). Membranes were also probed 
with Anti-β-tubulin (Invitrogen, Cat.32-2600) (1:1000 dilution) as a loading control. 
 
 
2.6.9 Quantification of the insoluble protein fraction  
 
To quantify the insoluble protein fraction, 2x105cells/well were plated in 6-well plates. 
After 48h cells were detached and 100µL of Lysis Buffer (0.5% Triton X-100, 50mM HEPES, 
250mM NaCl, 1mM DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM PMSF, 1mM Na3VO4 
supplemented with a cocktail of protease inhibitors (Complete, EDTA-free, Roche, Cat. 
11873580001) as recommended by the manufacturer) was added to the cells’ pellet. Cells were 
sonicated with a probe sonicator in 5 pulses of 5 seconds, incubated on ice for 30min and 
centrifuged at 5000rpm for 15min at 4ºC. 10µL of the supernatant (total protein fraction) were 
stored to measure protein concentration with bicinchoninic acid (BCA) assay (Thermo Fisher 
Scientific, Cat. 23225). 80µL of supernatant were centrifuged again at 12000rpm for 20min at 
4ºC. The pellet (insoluble fraction) was then washed with 160µL of LB and 40µL of 
10%Triton X-100 (Sigma-Aldrich, Cat.X100) and centrifuged at 15000g for 20min at 4ºC. The 
pellet was solubilized in 50µL of LB. 15µL of samples were denaturated with loading buffer 
(6x) (0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 0.06% bromophenol blue) at 
95ºC for 5 min and resolved in a 10% SDS-PAGE. The gel was stained with 0.1% Comassie 
Brilliant Blue G solution (Sigma-Aldrich, Cat.B0770) for at least 2h. After destaining with a 
solution of 10% ethanol and 7.5% acetic acid, gels were scanned using Odyssey Infrared 
Imaging System (Licor Biosciences). Lane signals corresponding to each sample were 
quantified and normalized to the total amount of protein determined with BCA assay.  
 
 
2.6.10 Quantification of proteasome activity  
 
In order to test the activity of the proteasome, 2x105cells/well were plated in 6-well 
plates. After 48h cells were washed with 1%PBS and resuspended in 100µL of Lysis Buffer 
(1mM EDTA, 10mM Tris-HCl pH 7.5; 20% glycerol; 4mM DTT; 2mM ATP). Cells were 
sonicated with a probe sonicator in 5 pulses of 5 seconds, and centrifuged at 13000rpm for 
10min at 4ºC. The supernatant was diluted (1:20) and protein content was quantified using 
Bradford method (Sigma-Aldrich, Cat.B6916). 20µg of protein in Lysis Buffer were incubated 
with the substrate suc-LLVY-MCA (50µM) (Sigma-Aldrich, Cat.S4939) in the presence or in 
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the absence of the proteasome inhibitor MG132 (10µM) (Sigma-Aldrich, Cat.SML1135) in a 
medium containing 1mM EDTA, 10mM Tris-HCl pH 7.5; 2mM ATP (final volume 100µL). 
Substrate degradation was monitored every 5min during 1h at 37ºC in a fluorescence-
luminescence detector Synergy™ HT Multi-Mode Microplate Reader (Biotek), set to 380 and 
460nm, excitation and emission wavelengths, respectively.  Specific proteasome activity was 
determined by subtracting the values for each sample without MG132 to the values with 
MG132. Final activity was calculated as fluorescence emission at 0 min subtracted from 
fluorescence after 1h relative to control (Mock).  
 
 
2.6.11 Immunoblots  
 
2x105 cells were plated in 6-well plates. After 48h, cells were washed with 1%PBS and 
then lysed with protein Lysis Buffer (0.5% Triton X-100, 50mM HEPES, 250mM NaCl, 1mM 
DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM PMSF, 1mM Na3VO4 supplemented with a 
cocktail of protease inhibitors (Complete, EDTA-free, Roche, Cat. 11873580001) as 
recommended by the manufacturer). Cells were sonicated with a probe sonicator in 5 pulses of 
5 seconds. After centrifugation, 16000g for 30min, protein in the supernatants was quantified 
using the BCA assay (Thermo Fisher Scientific, Cat. 23225). Samples were denaturated with 
loading buffer (6x) at 95ºC for 5 min.  
Protein samples were separated by SDS-PAGE in 10% polyacrylamide gels (or 8% for 
molecular chaperones and ATF6), transferred to nitrocellulose membranes (0.2µm) and 
immunobloted. Membranes were incubated with primary antibodies overnight (4ºC), washed 
and incubated with secondary antibodies (1:10000 dilution, 2h at room temperature), 
IRDye800 goat anti-mouse (Li-cor Biosciences, Cat.400-33) or IRDye680 goat anti-rabbit (Li-
cor Biosciences, Cat.925-68070). Secondary antibodies were detected using an Odyssey 
Infrared Imaging System (Licor Biosciences). The following primary antibodies were used: 
anti-ubiquitin (1:1000 dilution) (Sigma-Aldrich, Cat.U0508), anti-Hsp70 (1:1000 dilution) 
(Stress Marq Biosciences, Cat.SMC-100B), anti-Hsp27 (0.5µg/ml dilution) (Stress Marq 
Biosciences, Cat.SMC-161A), anti-Hsp60 (1:1000 dilution) (Stress Marq Biosciences, 
Cat.SPC-105), anti-Hsp90α (1:1000 dilution) (Stress Marq Biosciences, Cat.SMC-147), anti-
BiP (1:1000 dilution) (Stress Marq Biosciences, Cat.SPC-180), anti-ATF6 (1:400 dilution) 
(Stressgen, Cat.70B1413.1), anti-eIF2α (1:1000 dilution) (Cell Signalling, Cat.9722), anti-
phosphorylated eIF2α (1:400 dilution) (Abcam, Cat.ab4837), anti-GADD34 (1:500 dilution) 
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(Thermo Fisher Scientific, Cat.PA1-12376), anti-β-tubulin (Invitrogen, Cat.32-2600). β-tubulin 
was used in all the immunoblots as a loading control. 
 
 
2.6.12 Gene expression microarrays 
 
Gene expression microarrays profiling was performed using the Agilent protocol for 
One-Color Microarray Based Gene Expression Analysis Low Input Quick Amp Labeling v6.9 
(Agilent Technologies). RNA quality determination was performed using 2100 Bioanalyser 
(Agilent Technologies) and the kit Agilent RNA 6000 Nano kit (Agilent Technologies, 
Cat.5067-1512). 100ng of total RNA were used to synthesize labeled cDNA (with Cyanine 3-
CTP) using Agilent T7 Promoter Primer and T7 RNA polymerase Blend (Agilent 
Technologies, Cat.5190-2305). cDNA was purified with RNAeasy mini spin columns 
(Quiagen, Cat.74104). Dye incorporation was quantified using Nanodrop 1000 
Spectophotometer. 600ng of labeled cDNA were hybridized in Sure Print G3 Human Gene 
Expression 8x60k v2 microarrays (Agilent Technologies, Cat.G4851B). Hybridizations were 
carried out using Agilent gasket slides in a rotating oven for 17h at 65ºC. Slides were then 
washed following manufacturer’s instructions and scanned in an Agilent G2565AA 
microarrays scanner.  
Probes signal values were extracted using Agilent Feature Extraction Software. Data 
were normalized using median centering of signal distribution with Biometric Research Branch 
BRB-Array tools v3.4.o software (217,218). Microarrays statistical analysis was carried out 
using Mev software (TM4 Microarray Software Suite) (219,220). T-test was performed to 
identify genes that showed differences in expression between control (Mock) and samples. 
Significant genes that present a fold change above 1.5 or bellow -1.5 were considered for 
downstream analysis.  
The microarray raw data was submitted to the GEO database and has been given the 
following accession number: GSE93854.  
 
 
2.6.13 Statistical analysis  
 
For all assays, our data represent at least 3 independent experiments and 3 replicates. 
Statistical analysis was performed using One-way ANOVA analysis of variance followed by 
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the Dunnett’s or Bonferroni’s post-tests, as indicated in the figures. In all cases, p-values<0.05 
were considered statistically significant.  
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2.7 Supplementary Figures  
 
Figure 2-22. tRNA amplification with primers for the plasmid and Sanger sequencing. 
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Figure 2-23. SNaPshot analysis – Agarose gels representative of the amplification of tRNA and 
GAPDH. A – Amplification from DNA of mistranslating cells; B – Amplification from cDNA of 
mistranslating cells.  
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Figure 2-24. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the respective control, 
GAPDH. Sequenced samples correspond to cDNA from P1. The primer extension (SNaPshot) reaction 
utilizes a multiplex kit that contains a reaction mix of four differentially fluorescently labeled ddNTPs, 
allowing the detection of the incorporated base correspondent to the last base of anticodons. In the case of 
tRNASer(S) cell line, expressing tRNAAGASer, the peak corresponds to the incorporation of T (red peak). For 
tRNASer(A) cells (expressing tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). For 
tRNASer(L) (expressing tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak corresponds to 
the incorporation of C (black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, the Wt tRNASer 
and mutant tRNAs were detected (upper panel). The peak area corresponding to each mutant tRNA and Wt 
tRNASer was determined for each cell line and a ratio was calculated. Amplification of GAPDH was used as 
an internal control to normalize the values (lower panel).   
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Figure 2-25. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the respective control, 
GAPDH. Sequenced samples correspond to cDNA from P15. For tRNASer(S) cell line (expressing 
tRNAAGASer), the peak corresponds to the incorporation of T (red peak). For tRNASer(A) cells (expressing 
tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). For tRNASer(L) (expressing 
tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak corresponds to the incorporation of C 
(black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, the Wt tRNASer and mutant tRNAs were 
detected (upper panel). The peak area corresponding to each mutant tRNA and Wt tRNASer was determined 
for each cell line and a ratio was calculated. Amplification of GAPDH was used as an internal control to 
normalize the values (lower panel).   
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Figure 2-26. SNaPshot peak of the endogenous tRNASer, mutant tRNAs and the respective control, 
GAPDH. Sequenced samples correspond to cDNA from P30. For tRNASer(S) cell line (expressing 
tRNAAGASer), the peak corresponds to the incorporation of T (red peak). For tRNASer(A) cells (expressing 
tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). For tRNASer(L) (expressing 
tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak corresponds to the incorporation of C 
(black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, the Wt tRNASer and mutant tRNAs were 
detected (upper panel). The peak area corresponding to each mutant tRNA and Wt tRNASer was determined 
for each cell line and a ratio was calculated. Amplification of GAPDH was used as an internal control to 
normalize the values (lower panel).   
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Figure 2-27. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the respective control, 
GAPDH.  Sequenced samples correspond to DNA from P1. For tRNASer(S) cell line (expressing 
tRNAAGASer), the peak corresponds to the incorporation of T (red peak). For tRNASer(A) cells (expressing 
tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). For tRNASer(L) (expressing 
tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak corresponds to the incorporation of C 
(black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, the Wt tRNASer and mutant tRNAs were 
detected (upper panel). The peak area corresponding to each mutant tRNA and Wt tRNASer was determined 
for each cell line and a ratio was calculated. Amplification of GAPDH was used as an internal control to 
normalize the values (lower panel).   
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Figure 2-28. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the respective control, 
GAPDH.  Sequenced samples correspond to DNA from P15. For tRNASer(S) cell line (expressing 
tRNAAGASer), the peak corresponds to the incorporation of T (red peak). For tRNASer(A) cells (expressing 
tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). For tRNASer(L) (expressing 
tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak corresponds to the incorporation of C 
(black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, the Wt tRNASer and mutant tRNAs were 
detected (upper panel). The peak area corresponding to each mutant tRNA and Wt tRNASer was determined 
for each cell line and a ratio was calculated. Amplification of GAPDH was used as an internal control to 
normalize the values (lower panel).   
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Figure 2-29. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the respective control, 
GAPDH. Sequenced samples correspond to DNA from P30. For tRNASer(S) cell line (expressing 
tRNAAGASer), the peak corresponds to the incorporation of T (red peak). For tRNASer(A) cells (expressing 
tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). For tRNASer(L) (expressing 
tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak corresponds to the incorporation of C 
(black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, the Wt tRNASer and mutant tRNAs were 
detected (upper panel). The peak area corresponding to each mutant tRNA and Wt tRNASer was determined 
for each cell line and a ratio was calculated.  Amplification of GAPDH was used as an internal control to 
normalize the values (lower panel).   
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3.1 Abstract 
 
In human cells, protein synthesis errors (PSE) activate several protein quality control 
(PQC) mechanisms that are highly dynamic and respond to type and duration of stress stimuli 
(Chapter 2). Transcriptome analysis revealed that PSE also induce mechanisms that protect 
cells against stress. For example, mistranslating yeast strains upregulate genes involved in 
protein folding, response to oxidative stress, carbohydrate and energy reserve metabolism 
(195).  
Many studies have characterized the cellular responses to PSE, but a global picture of 
how human cells respond and adapt in culture to PSE is still missing. To clarify this issue we 
have used the same cell lines created in the previous Chapter (Mock, tRNASer(S); tRNASer(A); 
tRNASer(L); tRNASer(H)) and profiled them using DNA microarrays. Our objective was to 
identify the transcriptional deregulation induced by PSE of cells in culture at different 
evolution time points (P1, P15 and P30). We also wanted to identify the transcriptome 
alterations that occur in each cell line throughout time, with an increase in the number of 
passages. 
As in the previous Chapter, transcriptional alterations were dependent on error type and 
cells passage number. Several genes that encode endoplasmic reticulum (ER) and ER stress 
proteins were upregulated. In addition, metabolic alterations (glycolysis/gluconeogenesis) and 
activation of signaling pathways (p53 and MAPK) were deregulated in our cell lines. These 
transcriptional alterations provide new insights to understand the pathways involved in the 
response to PSE.  
 
 
3.2 Introduction  
 
Eukaryotic cells have evolved sophisticated sensing mechanisms and signal transduction 
systems that can produce accurate dynamic outcomes in response to stress. This ultimately 
allows cellular stress protection, homeostasis and survival (221). The stress responses involve 
gene expression alterations that are essential for the slower long term adaptation and recovery 
of cells. Control of gene expression is tightly regulated and has fast response kinetics and 
controlled reversibility, which allow cells to change their transcriptional capacity within 
minutes in the presence of the stress (221). Thus, the transcriptome (set of all RNA molecules 
in a cell) is highly dynamic and reflects the homeostatic imbalances of cells (221,222). 
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Microarray-based transcriptome comparisons have been widely used to identify potentially 
adaptive expression changes to several stressors (223) or characterize disease states, such as 
cancer (224,225).  
PSE and accumulation of misfolded proteins in cells lead to the activation of PQC 
mechanisms, already described previouly. In Chapter 2, we have highlighted that increase or 
decrease in transcription and translation of PQC components fluctuate over time. 
Transcriptional responses of cells induced by PSE have already been characterized. For 
example, protein misfolding, caused by misincorporation of the proline analogue azetidine-2-
carboxilic acid (AZC) in S. cerevisiae leads to induction of heat shock factor-regulated genes 
and selective repression of ribosomal protein genes (226). In human HEK293FT cells, the 
misincorporation of AZC leads to the upregulation of specific genes related to the response to 
unfolded proteins, namely DDIT3 (a transcription factor activated by ER stress), DNAJB1 (a 
molecular chaperone that stimulates ATPase activity of Hsp70 heat shock proteins) and 
HSPH1 (a heat shock protein that prevents the aggregation of denatured proteins in cells under 
severe stress) (227). In yeast, the expression of a Ser tRNA that misincorporates Ser at Leu 
CUG codons sites, leads to the accumulation of misfolded proteins and upregulation of 
molecular chaperones, but also oxidative and general stress, carbohydrate and energy reserve 
metabolism genes. Genes encoding translational factors, ribosome biogenesis and assembly 
were downregulated (195). The deregulation of carbohydrate and energy metabolism genes 
shows that adaptation to PSE also prompts alterations in metabolism. These data show that 
upregulation of translation and metabolic processes occurs as an initial response to 
mistranslation, but such deregulation changes from positive to negative over time. Molecular 
chaperones are the first line of defense against misfolded proteins while downregulation of 
protein synthesis is a downstream adaptive event (195). Activation of different stress genes 
(so-called environmental stress response) plus those belonging to PQC, also confer stress 
cross-protection and increased thermotolerance, tolerance to oxidative and osmotic stress and 
also resistance to heavy metals and drugs, in yeast (73,228).  
In zebrafish embryos, the expression of tRNAs that misincorporate Ser at non-cognate 
protein sites, also leads to upregulation of molecular chaperones (such as hsp70l, hsp90a.2, and 
hspa5/bip), ER stress response related genes (such as eif2ak3/perk and xbp1), apoptosis and 
autophagy related genes. It was also reported downregulation of several mitochondrial genes 
that confer protection against ROS (167).  
Transcriptional tools have been essential to better characterize and understand the 
different effects (positive and negative) of PSE in cells. Yeast cells exposed for approximately 
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250 generations to PSE were characterized at the transcriptional level and alterations were 
identified in the evolved cell lines, relative to the ancestor. Genes belonging to ribosome 
biogenesis, rRNA processing and ribosomal large subunit assembly were upregulated while 
genes involved in glycogen biosynthetic processes were downregulated in the evolved cell 
lines (196).  
Despite all these studies, there is little data about transcriptional responses of human 
cells exposed to PSE. To address this issue, we have used the cell lines described previously, 
which express mutant tRNAs and overexpress the Wt tRNAAGA
Ser, and analyzed their 
transcriptional profile. Transcriptional alterations were identified in each cell line 
comparatively with the Mock in each passage and a comparison between the alterations in each 
cell line through time was also carried out. This, allowed us to complement our previous 
transcriptional analysis, from Chapter 2, which was focused on specific genes belonging to 
PQC processes.  
Although, there were a small number of deregulated genes in these mistranslating cell 
lines, we could correlate some of the deregulated Gene Ontology (GO) categories with the 
phenotypes that we have described previously. Transcriptional alterations were dependent on 
the type of the error introduced into proteins and cells passage. In all of our mistranslating cells 
there was upregulation of ER and ER stress response genes. In addition, in some cell lines 
(tRNASer(S) and tRNASer(A)) genes involved in metabolic pathways such as glycolysis and 
gluconeogenesis were deregulated. Signaling pathways, for example p53 and MAPK, were 
also deregulated. This study provides a comphreensive overview of the transcriptional 
alterations and permited the identification of putative adaptive pathways.  
 
 
3.3 Results  
 
3.3.1 The impact of PSE in gene expression deregulation  
 
In the previous Chapter, we have described phenotypic and molecular alterations of 
HEK293 cells expressing tRNAs that misincorporate Ser at non-cognate codon sites, namely, 
tRNAAGC
Ala, tRNAAAG
Leu and tRNAGTG
His, or overexpressing the Wt tRNAAGA
Ser. These cells 
could cope relatively well with those tRNAs despite the accumulation of misfolded proteins or 
accumulation of protein aggregates (tRNASer(L) cell line). Interstingly, tRNASer(L) cell line in 
particular was able to erase protein aggregates after several generations in culture.  
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Depending on the type of the misincorporated amino acid introduced into proteins 
and also cells passage number, there was differential activation of PQC mechanisms. The 
activation of PQC mechanisms was essential for cell survival in culture along with decreased 
expression of the mutant tRNAs. The phenotypes observed suggest that these cells may 
activate others stress pathways and adaptation mechanisms. In order to understand and identify 
those putative mechanisms involved in adaptation to PSE, cDNA microarrays were performed 
using 3 biological replicates for each of our created cell lines (Mock, tRNASer(S), tRNASer(A), 
tRNASer(L) and tRNASer(H)) at passages number, 1, 15 and 30. These studies allowed us to 
analyze the expression level of 26.083 genes encoded by the human genome. Only 
significantly deregulated genes were considered in our analysis (p<0.05) with a fold change 
above 1.5 or below -1.5.  
For this first analysis, each cell line (tRNASer(S), tRNASer(A), tRNASer(L) and 
tRNASer(H)) was compared with the control in the respective passage, thus the fold change was 
calculated relatively to Mock. Figure 3-1, shows the percentage of genes that were 
significantly deregulated with a fold change above 1.5 (upregulated genes) or below -1.5 
(downregulated genes), in each cell line in P1, P15 and P30.  
In P1, the tRNASer(S) cell line had the highest number of deregulated genes (7.4%), 
followed by tRNASer(A) cell line (5.5%). tRNASer(L) and tRNASer(H) cells, had 2.1% and 2.9% 
of deregulated genes, respectively (Figure 3-1 A). All of the cell lines in P1 had a higher 
number of downregulated genes (tRNASer(S)-5.1%; tRNASer(L)-1.8% and tRNASer(H)-1.8%) 
comparatively to the number of upregulated genes (tRNASer(S)-2.3%; tRNASer(L)-0.4% and 
tRNASer(H)-1.1%) with the exception of tRNASer(A) cell line, that had fewer downregulated 
(1.9%) than upregulated genes (3.6%) (Figure 3-1 A). 
 In P15, the cell line with higher number of deregulated genes was also tRNASer(S) 
(4.9%) (Figure 3-1 B). The remaining cell lines had similar levels of deregulation 
((tRNASer(A)-2.8%; tRNASer(L)-2.8% and tRNASer(H)-2.7%). For each cell line in P15, the 
percentage of upregulated and downregulated genes was similar (Figure 3-1 B).  
In P30, the tRNASer(S) cell line had the lowest percentage of deregulated genes, only 
1.3%, followed by tRNASer(A) with 2.3% (Figure 3-1 C). tRNASer(L) and tRNASer(H) cells 
showed the highest deregulation, 5.9% and 5%, respectively. In tRNASer(S) and tRNASer(L) 
cells there were more genes downregulated (0.8% and 4.6%, respectively) than upregulated 
(0.4% and 1.3%, respectively), while in tRNASer(A) cell line the levels of upregulated and 
downregulated genes was similar. tRNASer(H) cell line showed fewer downregulated (1.2%) 
than upregulated (3.8%) genes (Figure 1-3 C).  
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In all the three time points (P1, P15 and P30), the percentage of deregulated genes was 
low (always below 8%), showing that only a small set of genes is being deregulated in 
response to PSE in our cells.  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Percentage of deregulated genes for each cell line comparatively with the Mock in each 
time point. A – P1; B – P15; C – P30 
 
 
3.3.2 Ontology of the genes deregulated in response to PSE 
 
In order to understand in more detail the relevance of the above deregulation for 
adaptation to PSE, we annotated deregulated genes in GO Categories using DAVID 
Bioinformatics Resources 6.7. Even though the percentage of deregulation is low in these cells, 
many GO categories were significantly deregulated (p-value<0.05). Here, we only present GO 
categories that are theoretically more relevant for adaptation to PSE. The Categories chosen in 
the DAVID annotation tool were the following: OMIM_DISEASE, GOTERM_BP_FAT 
(Biological Process), GOTERM_CC_FAT (Cellular Compartment), GOTERM_MF_FAT 
(Molecular Function) and KEGG_PATHWAY and will be indicated in the following figures as 
well as the number of annotated genes and p-values for each category.  
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In P1, tRNASer(S) and tRNASer(A) cell lines had higher number of deregulated genes 
compared with the other cell lines (see above) and also higher number of deregulated GO 
categories (Figure 3-2 A,B). In tRNASer(S) cell line there was upregulation of categories 
related to the ER and the nuclear envelope-endoplasmic reticulum network. In these categories 
were annotated genes such as molecular chaperones (for example DNAJB11, which encodes an 
Hsp40), several ER enzymes and transporters, and elements of response to ER stress, namely 
HERPUD1, which encodes an inducible ER protein that is expressed under ER stress and plays 
a role in ERAD. Some genes involved in homeostatic processes (for instance, TEP1, a 
telomerase associated protein) and carbohydrate transport and biosynthesis (for example 
PCK2, which encodes an enzyme that participates in gluconeogenesis) were also upregulated. 
Categories related to cell adhesion processes and extracellular region were downregulated 
(Figure 3-2 A). On the contrary, in tRNASer(A) cells, also in P1, cell adhesion, migration and 
proliferation were upregulated (Figure 3-2 B). This result was in agreement with our previous 
data (Chapter 2), where we could see an increase in cell proliferation from P1 to P15 (Figure 2-
7 B). Genes involved in homeostatic process, several transcription factors and ER genes, 
namely the molecular chaperones encoded by DNAJB11 and HSP90B1 and a protein 
responsible for degradation of misfolded proteins, encoded by DERL3, were also upregulated.  
Downregulated categories in this cell line were involved in fatty acid metabolism and lipid 
binding (Figure 3-2 B).  
tRNASer(L) and tRNASer(H) cell lines deregulated genes that were annotated in fewer 
categories than tRNASer(S) and tRNASer(A) cell lines (Figure 3-2 C, D). Some genes 
upregulated in tRNASer(L) cells were membrane receptors and transporters annonated in 
intrinsic to plasma membrane GO category. Categories related to lipid biosynthesis and cell 
adhesion were downregulated in this cell line (Figure 3-2 C). In the tRNASer(H) cell line 
categories related to ER (where was included, once again the molecular chaperone encoded by 
DNAJB11 gene) and proteolysis were upregulated. Genes involved in transcription, 
macromolecule biosynthetic processes and constituents of the cytoskeleton were 
downregulated (Figure 3-2 D).  
In P1, upregulation of ER components occured in all of our cell lines, with the 
exception for tRNASer(L) cell line. This can be correlated with increased levels in misfolded 
proteins in these cell lines and consequent increase in ER capacity to fold and counteract 
protein aggregation. In fact, in these categories we could find some genes involved in the ER 
stress response. Cell adhesion and processes related to lipid biosynthesis seem to be common 
downregulated processes in our mistranslating cells. The tRNASer(A) cell line presented a 
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different transcriptional profile, which can probably explain its proliferating phenotype (Table 
3-1). 
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Figure 3-2. Functional class enrichment analysis (GO categories) of genes upregulated (red bars) and 
downregulated (green bars) in mistranslating cell lines in P1. A - tRNASer(S); B - tRNASer(A); C - 
tRNASer(L); D – tRNASer(H). p-values of each GO category are displayed in the graphs next to the respective 
bar. 
 
 
In our intermediary time point, P15, the tRNASer(S) cell line had the highest number of 
deregulated categories (Figure 3-3 A). Most of them are related to the response to misfolded 
proteins; UPS and ER stress: response to unfolded proteins, response to ER stress, proteasomal 
ubiquitin-dependent protein catabolic process, ER-nuclear signaling pathway, protein folding, 
unfolded protein binding, ER-Golgi intermediate compartment. The deregulation of these 
stress related categories is in line with our previous results of Chapter 2. The expression of the 
tRNASer was higher in P15, in this cell line, and consequently there was also an increase in 
protein ubiquitination and fragmented ATF6. This protein is known to activate the 
transcription of ER genes to alleviate ER stress, which can explain the upregulation of ER 
related categories. Interestingly, the deregulation of the endogenous tRNASer (in tRNASer(S)) 
also lead to upregulation of several aaRSs genes, namely AARS - AlaRS, NARS-AspRS, GARS-
GlyRS, IARS-IleRS, MARS-MetRS, WARS-TrpRS and YARS-TyrRS. Other upregulated 
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categories were mitochondrial lumen and pyruvate metabolism. The last one may indicate 
higher energetic requirement by these cells. Cell adhesion and peptidase inhibitor activity were 
downregulated (Figure 3-3 A).  
The tRNASer(A) cell line upregulated a GO category related to cell proliferation, as 
well as positive regulation of transcription factor activity and response to oxygen levels. 
Categories related to chromatin assembly, cytoskeleton regulation and cell adhesion were 
downregulated in P15 in this cell line (Figure 3-3 B). In tRNASer(L) cell line the ER GO 
category was upregulated. Also, genes annotated in the GO category chromosome were 
upregulated, namely genes that encode histones (HDAC8 and HIST1H3A) and centromere 
(CENPE) proteins and the telomerase associated protein-1(TEP1). Cell adhesion and 
components of extracellular matrix were downregulated in tRNASer(L) cells, in P15 (Figure 3-3 
C). The tRNASer(H) cell line upregulated genes belonging to the plasma membrane part, 
namely several G-proteins and ion channels. Cell differentiation and adhesion processes were 
dowregulated in this cell line (Figure 3-3 D).  
In P15, tRNASer(S) and tRNASer(L) cell lines upregulated GO categories related to ER 
stress and ER, respectively. In tRNASer(S) cells, a higher number of categories related to 
misfolding protein accumulation, proteotoxic stress and cellular metabolism and energy 
production were upregulated. This may indicate higher consumption of energy in these cells. 
Despite some specific alterations, cell adhesion was clearly a dowregulated category in P15 
(Table 3-1). 
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Figure 3-3. Functional class enrichment analysis (GO categories) of genes upregulated (red bars) and 
downregulated (green bars) in mistranslating cell lines in P15. A - tRNASer(S); B - tRNASer(A); C - 
tRNASer(L); D – tRNASer(H). p-values of each GO category are displayed in the graphs next to the respective 
bar. 
 
 
Although the percentage of deregulated genes was similar for the three time points, few 
processes were deregulated in P30. At this passage number, tRNASer(S) cells showed 
upregulation of genes involved in signal transduction and cell proliferation (Figure 3-4 A) and 
in fact, in Chapter 2 there was an increase in cell proliferation relative to Mock in this passage 
(Figure 2-7 A). Categories related to fatty acids and lipids metabolism were downderegulated 
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in tRNASer(S) cells (Figure 3-4 A). In tRNASer(A) cells, there was upregulation of genes 
involved in AMP catabolic process (Figure 3-4 B), which suggests metabolic alterations in 
these cells since AMP can function as an energy sensor (229). Genes involved in adhesion to 
the extracellular matrix belonging to the GO categories: focal adhesion, extracellular region 
and ECM-receptor interaction, were downregulated in tRNASer(A) (Figure 3-4 B). In 
tRNASer(L) cells, genes involved in transcription from RNA polymerase II promoter, negative 
regulation of cell proliferation and cell cycle arrest were up-regulated, while categories related 
to cell adhesion were downregulated (Figure 3-4 C). Finally, in tRNASer(H) cells, genes 
encoding extracellular proteins, namely collagen and laminin were upregulated. Genes 
involved in positive regulation of cell differentiation, extracellular matrix (ECM-receptor 
interaction) and positive regulation of organelle organization were downregulated in this cell 
line (Figure 3-4 D).  
Altogether these results show that genes involved in ER function and ER stress were 
upregulated in P1 and/or P15 in our cell lines, indicating that transcriptional responses to 
proteotoxic stress are very important during early adaptation to PSE, probably because mutant 
tRNA expression was higher (Table 3-1). The tRNASer(S) cell line is interesting because it 
activated carbohydrate biosynthesis and pyruvate metabolism suggesting that adaptation to 
PSE requires high leves of energy. The proliferating phenotype of the tRNASer(A) cell line, 
was confirmed since these cells upregulated genes related to proliferation and migration. Also, 
this cell line upregulated genes that respond to oxygen levels and others involved in AMP 
catabolic process and responders to metabolic alterations. Surprisingly no transcriptional 
responses to proteotoxic stress were observed in tRNASer(L) cells in P1, and only the ER 
category was upregulated in P15.  Despite this result, some individual stress genes may have 
been deregulated. Regarding dowregulated genes, they were mainly involved in cell adhesion 
or lipids metabolism. In tRNASer(H) cell line, in addition to cell adhesion, also genes annotated 
in the categories of cytoskeleton, cell differentiation and organelle organization were 
downregulated. Table 3-1 summarizes the main processes altered in each passage in our 
mistranslating cell lines.    
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Figure 3-4. Functional class enrichment analysis (GO categories) of genes upregulated (red bars) and 
downregulated (green bars) in mistranslating cell lines in P30. A - tRNASer(S); B - tRNASer(A); C - 
tRNASer(L); D – tRNASer(H). p-values of each GO category are displayed in the graphs next to the respective 
bar. 
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Table 3-1. Summary of the cellular processes upregulated (red arrow) and downregulated (green arrow) in 
the mistranslating cell lines in the three passages.  
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3.3.3 Long term gene expression deregulation in mistranslating cells  
 
To identify gene expression alterations during the successive passages of our cell lines 
the genes that were up and downregulated between each time point for each cell line were 
identified. For instance, to identify genes up and downregulated from P1 to P15 in tRNASer(S) 
cells we calculated the fold change of tRNASer(S) in P15 relative to tRNASer(S) in P1. 
Significantly altered genes were considered in our analysis (p<0.05) if fold change was above 
1.5 or below -1.5. The same approach was used for our control cell line (Mock). We then 
removed the deregulated genes that appeared in our control cell (Mock P1-P15) from the list 
tRNASer(S) P1-P15 (Figure 3-5). This was done for our four cell lines (tRNASer(S), 
tRNASer(A), tRNASer(L), tRNASer(H)) between the three time points, P1-P15, P15-P30 and P1-
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P30. With this strategy we could identify genes that were specifically deregulated in each cell 
line, in response to PSE and excluded from the analysis genes whose deregulation was due to 
cell evolution in culture.  
 
 
 
 
Figure 3-5. Diagram showing the experimental design used to obtain the list of tRNASer(S) genes used 
in the transcriptional analysis of cell evolution. 
 
 
From P1 to P15, all cell lines deregulated approximately 4% of their genes, except for 
tRNASer(L) which deregulated 2.5% (Figure 3-6 A). The percentage of upregulated genes was 
higher than that of downregulated genes in tRNASer(S) (2.3% up; 1.5% down), tRNASer(L) 
(1.7% up; 0.8% down) and tRNASer(H) (1.8% up;1.5% down) cells. tRNASer(A) cells had more 
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genes downregulated (2.5%) than upregulated (1.2%) (Figure 3-6 A). From P15-P30, 
tRNASer(H) cells showed higher percentage of deregulated genes (6.9%) followed by 
tRNASer(L) (5.8%), tRNASer(A) (4.1%) and tRNASer(S) cells (2.5%) (Figure 3-6 B). 
tRNASer(L) and tRNASer(H) cells had higher number of upregulated genes (2% and 5.5%, 
respectively). During the evolution in culture, from P1 to P30, the cell lines that had more 
genes deregulated were tRNASer(L) and tRNASer(H) (5.6% and 4.9%) (Figure 3-6 C). 
tRNASer(S) and tRNASer(A) cell lines showed lower percentage of deregulated genes (2.8% and 
3.8%, respectively) (Figure 3-6 C). Regarding the percentage of deregulated genes, the pattern 
is very similar in P15-P30 and P1-P30.  
 
A                                                                B 
 
 
 
 
 
 
 
 
                         C 
 
 
 
 
 
 
 
Figure 3-6. The percentage of deregulated genes in each cell line between passages. A - P1-P15; B – 
P15-P30; C- P1-P30 
 
 
3.3.4 Gene Ontology categories deregulated during evolution  
 
To complete gene expression deregulation analysis in each time point, we also studied 
each cell line between the time points P1-P15, P15-P30 and P1-P30. Deregulated genes were 
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also annotated in GO categories using DAVID Bioinformatics Resources 6.5.  As before, we 
discuss the GO categories that were potentially relevant to understand the adaptation to PSE 
during evolution. The Categories chosen in DAVID annotation tool were the following: 
OMIM_DISEASE, GOTERM_BP_FAT (Biological Process), GOTERM_CC_FAT (Cellular 
Compartment), GOTERM_MF_FAT (Molecular Function) and KEGG_PATHWAY.  
Table 2-1 shows the GO categories upregulated from P1 to P15 and from P15 to P30. 
During the initial part of the evolution, genes involved in carbohydrate catabolic process and 
glycolysis were upregulated in tRNASer(S) and tRNASer(A) cell lines, respectively. This may 
indicate that these two cell lines require glucose to boost ATP production during adaptation to 
PSE. The tRNASer(A) cell line also showed upregulation of mitosis from P1 to P15, which 
correlates with an increase in cell proliferation capacity of this cell line (Chapter 2, Figure 2-7). 
Also, between P1 and P15, tRNASer(L) and tRNASer(H) cell lines showed upregulation of genes 
related to cell adhesion, while tRNASer(L) cell line, upregulated ER genes. In particular stress 
related genes such as DNAJC3, which encodes a homolog of Hsp40, involved in the UPR. p53 
signaling pathway was another category upregulated in this cell line that contained genes 
involved in regulation of the cell cycle and apoptosis (such as CASP8, which encodes caspase 
8). Between P15 and P30, genes involved in transcription process were up-regulated in 
tRNASer(S), tRNASer(A) and tRNASer(L) cells. Also, signaling pathways were upregulated in 
tRNASer(A) and tRNASer(L) cells. Specifically, in tRNASer(L) cell line, there was upregulation 
of genes related to MAPK signaling, namely MAP3K4, which encodes a kinase that modulates 
the UPR.  
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Table 3-2. GO categories upregulated in mistranslating cell lines during evolution in culture.  
 
 
Regarding downregulated categories, from P1 to P15 (Table 3-3), in tRNASer(S) cells 
the p53 signalling pathway was visible, where annotated genes are involved in DNA damage 
repair and cell cycle arrest. From P1 to P15, tRNASer(H) cells dowregulated ER genes, namely 
HSP90B1 and DNAJB11, which are two molecular chaperones, and cell motility and migration 
genes. As shown before, this cell line upregulated genes related to ER stress in P1 (Figure 3-2 
D), but between P1 and P15 there was downregulation of ER genes, such as molecular 
chaperones. Results described in Chapter 2, showed that the levels of some chaperones were 
decreased in the end of evolution in tRNASer(H) cell line. Also, Chapter 2 data showed that 
tRNASer(H) cells had lower capacity to form colonies in culture compared with Mock in P15. 
This was probably due to downregulation of several genes involved in cell motility and 
migration.  
Between P15 and P30 (Table 3-3), tRNASer(S) cells dowregulated genes involved in 
cAMP biosynthesis, which plays important roles in signaling processes. In tRNASer(A) cells 
regulation of growth and a KEGG pathway related to the extracellular matrix were 
downregulated. tRNASer(L) cells showed downregulation of categories related to cell adhesion 
and plasma membrane, but also chromatin assembly and disassembly. In this last category, 
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several histone coding genes, which play a central role in transcription regulation, DNA repair, 
DNA replication and chromosomal stability, were annotated. Finally, in tRNASer(H) cells 
processes involved in regulation of cell division and differentiation, protein polyubiquitination 
and regulation of the actin cytoskeleton were downregulated from P15 to P30.  
 
Table 3-3. GO Categories downregulated in mistranslating cell lines during evolution 
 
 
The Figure 3-4 shows a summary of the main processes altered between P1 and P15 
and P15 and P30.  Each cell line shows a specific transcriptional response although some 
processes are common to some cells, such as transcription and cell adhesion. In tRNASer(H) 
cells, it is interesting to note that some categories related to the ER and the response to 
proteotoxic stress (polyubiquitination of proteins) were downregulated. This may indicate that 
adaptation and survival of tRNASer(H) cells in the last part of evolution does not rely on 
activation of PQC mechanisms.  
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Table 3-4. GO categories that are deregulated in mistranslating cell lines between P1 and P15 and at later 
stages (between P15 and P30). 
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From P1 to P30 (Table 3-5), we could observe upregulation of genes related to 
glycolysis and gluconeogenesis in tRNASer(S) cells, similarly tRNASer(A) cells upregulated 
categories involved in metabolism and energy, such as regulation of glycogen biosynthetic 
process. In tRNASer(L) cells several GO categories were upregulated, in particular, cell cycle, 
transcription and carbohydrate catabolic process. Gluconeogenesis and fatty acid metabolism 
were upregulated in tRNASer(H) cells. 
A common category was downregulated between P1 and P30, namely extracellular 
region (Table 3-6). In tRNASer(H) cells genes involved in migration, cell division and the 
cytoskeleton were also downregulated. An interesting category that was downregulated in 
tRNASer(H) cell line was L-serine biosynthetic process. Since in these cells Ser is 
misincorporated at non-cognate codon sites it is likely that decrease in Ser synthesis decreases 
PSE.  
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Table 3-5. GO categories upregulated in mistranslating cell lines during evolution in culture (P1-P30).  
 
Table 3-6. GO categories downregulated in mistranslating cell lines during evolution in culture (P1-P30).  
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3.4 Discussion  
 
To understand the molecular bases of the phenotypes induced by PSE in human cells 
we have analyzed the transcriptional profile of mistranslating cells described previously. We 
wanted to unveil possible pathways and mechanisms of gene expression reprogramming by 
PSE. Our results showed that transcriptional responses were different between cell lines and 
culture passage number. Many upregulated genes were annotated into categories related to ER 
and ER stress response, as we would expect. However, mistranslating cell lines deregulated 
several genes involved in energy metabolism, transcription, chromosome, signaling pathways 
(p53, MAPK) and many other processes, indicating that other mechanisms could be important 
to adaptation to PSE.  
We have observed that the expression of our mutant tRNAs or overexpression of the 
Wt tRNASer in HEK293 cells leads to the degerulation of a small percentage of genes, always 
below 8%. In C. albicans mistranslating strains the number of deregulated genes in cDNA 
microarrays was correlated with the level of Leu misincorporation (75,230). While low-level 
mistranslation (0.64%) deregulated only 2% of genes, high levels of mistranslation (20% to 
80%) deregulated approximately 16.9% to 26.2% of the C. albicans genes (75,230). Since the 
expression of our mutant tRNAs decreases abruptly from P1 to P15, possibly leading to a sharp 
decrease in Ser misincorporation levels, it was not surprising that a low percentage of 
deregulated genes was observed in our cells. Also, we have to take into consideration that 
before the first evolution time point (P1), HEK293 cells expressed the mutant tRNAs during 5 
passages. This was necessary to select the cells that expressed the mutant tRNAs stably.  
Due to the structural differences between the amino acids Ser and Leu and the 
phenotypes observed, specially the accumulation of protein aggregates in tRNASer(L) cells in 
P15, we were expecting higher percentage of deregulated genes in this cell line. In fact, 
tRNASer(L) cells in P1 had the lowest percentage of deregulated genes (2.1%), relative to the 
other cell lines (Figure 3-1 A). Only in P30 the percentage of deregulated genes increased 
(5.9%) (Figure 3-1 C). Also from P1 to P15, tRNASer(L) cells had the lowest number of 
deregulated genes (2.5%), which increased from P15 to P30 (5.8%) (Figure 3-6). From P1 to 
P30, tRNASer(L) cells had higher percentage of deregulated genes comparatively to the other 
cell lines, suggesting that the impact of mistranslation is higher in this cell line (Figure 3-6 C). 
The overexpression of the Wt tRNASer had higher impact in transcriptional deregulation 
comparatively to other cell lines, particularly in P1 and P15 (7.4% and 4.9% of deregulated 
genes, respectively) (Figure 3-1). This is not surprising since previous studies show that 
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overexpression of a specific tRNA in human cells can modulate protein expression  (159,204). 
In any case, this cell line had the lowest percentage of deregulated genes (2.8%) between P1 
and P30 (Figure 3-6 C).  
In the previous chapter, we used cDNA microarrays and selected genes that are known 
to be involved in the response to misfolded proteins in human cells. From these, only a few 
genes were deregulated. The analysis of the GO categories, in this chapter, allowed us to 
identify other genes that also participate in response to misfolded proteins. In particular, ER 
stress response genes. The UPR is a very complex cellular process that includes changes in 
expression of many genes and different cell lines and individuals show variability in these 
genes expression patterns (231). Dombroski et al., exposed B cells to tunicamycin or 
thapsigargin and observed that among the top 100 genes that showed the most significant 
variation in fold change in response to ER stress, only 40% were known “UPR genes” (231). 
In our data set we have identified several genes belonging to the classic UPR pathway, for 
example; DNAJB11, HERPUD1, HSP90AB1 and DERL3. Other genes that do not participate 
in UPR, but are usually upregulated in cases of proteotoxic stress were also identified (231). 
This was the case of PCK2, which encodes phosphoenolpyruvate carboxykinase 2 
(mitochondrial), which was upregulated in tRNASer(S) cells in P1, and annotated in 
carbohydrate biosynthetic process category (Figure 3-2 A). These results complement our 
previous data on the PQC mechanisms activated in response to PSE. The activation and 
synchronization throughout time of these mechanisms in all cell lines supports the hypothesis 
that PQC mechanisms are essential for cells to maintain homeostasis and to survive (232–234).  
Besides PQC mechanisms, several other genes were deregulated in our cells. Genes 
involved in glycosis process were upregulated in tRNASer(S) cells from P1 to P30 (Table 3-5) 
and in tRNASer(A) cells from P1 to P15 (Table 3-2). A previous study correlated ER stress in 
hematopoietic cells with a relative inability of these cells to use extracellular glucose, resulting 
in reduced glycolysis and Kreb’s cycle activity (235), however in cancer cells, where PQC 
mechanisms are usually upregulated (including UPR), there is increased glucose uptake and 
glycolysis (236–239). Glycolysis is a source of ATP and plays a key role in cell survival and 
adaptation of proliferating cells (236,239). In cells producing misfolded proteins, maintenance 
of ATP levels is essential since many PQC systems are ATP dependent, such as some 
chaperones, the UPS, and mechanisms of folding and degradation in the ER (175,237,240–
242). Increasing glycolysis could help tRNASer(S) and tRNASer(A) cells to fold and degrade 
misfolded proteins and, even increase proliferation rate (Chapter 2, Figure 2-7). In a previous 
evolutionary study, using mistranslating strains of S. cerevisiae, it was observed that evolved 
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cell lines had an accelerated protein turnover. In response to this high-energy demand, glucose 
uptake was increased due to the selective duplication of hexose transporter genes. These cells 
were only able to thrive in nutrient-rich environments because of its exceptionally high energy 
demands (196).  
Usually the control of glycolysis and energy production in proliferating cells, for 
example cancer cells, primarily resides at the transport and phosphorylation steps. For 
example, in upregulation of glucose transporters and hexokinases (239). However, in 
mammals, some tissues such as liver, kidney and gastrointestinal tract have gluconeogenic 
enzyme activity (243). Since our HEK293 cells are human embryonic kidney cells, it is not 
surprising that we could see upregulation of genes related to gluconeogenesis in tRNASer(S) 
and tRNASer(H) cell lines from P1 to P30 (Table 3-5), suggesting that these cell lines increase 
glucose production.  
Cell signaling pathways, such as p53 and MAPK, were also deregulated in our cell 
lines. p53 signaling pathway was downregulated in tRNASer(S) cells from P1 to P15 (Table 3-
3), but is was upregulated in tRNASer(L) cells also in P1 to P15 (Table 3-2). This pathway is 
activated in cells in response to various forms of stress, but mainly genotoxic stress. p53 
targeted genes are involved in cell-cycle arrest, DNA repair or apoptosis if the damage is 
irreparable (244). In the case of tRNASer(S) cells, genes belonging to this pathway were 
downregulated, possibly to avoid cell-cylce arrest and apoptosis. On the other hand, in 
tRNASer(L) cells, the p53 pathway was upregulated. The upregulation of genes involved in 
control of the cell cycle and apoptosis effectors (such as CASP8, which encodes caspase 8) can 
possibly explain the phenotype observed in this cell line, a decrease in the number of viable 
cells from P1 to P15 (Chapter 2, Figure 2-6). The connection between misfolded proteins 
accumulation and p53 signaling pathway activation is still poorly understood. It its known, 
however, that severe or prolonged proteotoxic stress induces activation of cell death through 
apoptosis and p53 signaling pathway may be involved (245,246).  
In tRNASer(L) cells there was also upregulation of MAPK signaling pathway, from P15 
to P30 (Table 3-2). Recent evidences show that mitogen-activated protein kinase (MAKP) 
signaling pathways have a role in the response to ER stress (247). Indeed, some MAPK 
pathways are activated in response to ER stress (such as JNK and p38) (247). One of the genes 
upregulated in tRNASer(L) cells encodes mitogen-activated protein kinase kinase 4 (MKK4), 
which can activate JNK, leading to apoptosis, and modulate UPR via p38-dependent 
phosphorylation of CHOP and ATF6 (247–249). MAKP signaling may be involved, in this 
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way, in the response to the accumulation of misfolded proteins and consequent ER stress in the 
tRNASer(L) cell line.  
Genes involved in lipid metabolism were downregulated in our mistranslating cell lines 
(Table 3-1). In addition to its activities in the processing of secreted and membrane proteins, 
the ER is a major site of synthesis of membrane lipids in eukaryotic cells, particularly 
phospholipids and sterols (250). It is not surprising though, that accumulation of misfolded 
proteins in the ER lead to alterations in lipid metabolism. In C. elegans, acute ER stress 
(caused by tunicamycin) cause adaptative changes in the expression of several genes involved 
in phospholipids metabolism and phosphatidylcholine, the most abundant ER membrane lipid. 
The induction of these genes may reflect demands for ER expansion (250–252). Indeed, 
elements of the UPR are involved in lipids biosynthesis, for example, XBP-1 promotes 
transcription of genes involved in fatty acid and cholesterol biosynthesis (253). Despite these 
results, we have observed downregulation of lipid metabolism categories. Possibly, the 
induction of genes involved in lipid metabolism could be relevant in severe and acute stress, 
but not in prolonged adaptation to PSE.  
Our cell lines showed several transcriptional alterations that go beyond activation of 
PQC mechanisms. Specially, tRNASer(S) and tRNASer(A) cells showed transcriptional 
activation of genes that can explain adaptation to PSE and survival. Together, this and Chapter 
2 data, raises the hypothesis that these advantageous features could be important in different 
microenvironments, for example if these cells transform in an in vivo situation. A previous 
study using NIH3T3 mistranslating cells, showed that expression of mutant tRNAs lead to 
increased cell transformation in vivo, UPR and cancer-related pathways activation 
(unpublished data, Annex E), which may indicate that low levels of PSE in mammalian cells 
could be advantageous in specific conditions.  
 
 
3.5 Conclusions 
 
The microarray analysis carried out in this chapter complemented our previous study 
on the activation of PQC mechanisms in cells that produced aberrant proteins. It was also 
possible to unveil new pathways (p53 and MAPK) and adaptation mechanisms (increase in 
gluconeogenesis/ glycolysis) involved in the response to PSE during human cell evolution in 
culture.  
As we would expect, the different mistranslating cell lines created have different 
transcriptional profiles, and the majority of these results can be correlated with our previous 
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phenotypes observed in Chapter 2. The most interesting cell lines, regarding evolutionary 
adaptation, were the tRNASer(S) and tRNASer(A) cells. Despite activation of several PQC 
mechanisms, transcriptional analysis showed alterations in many other categories, for example 
cell proliferation, cell adhesion, glycolysis, suggesting that PSE may even have positive effects 
in human cells. Another interesting feature is that misincorporation of Ser at Ala codons 
(tRNASer(A)) is an error that occurs at the physiological level due to chemical similarity 
between the two amino acids. It will be interesting to determine in future studies if human cells 
are better adapted to Ser-Ala misincorporations than to other non-phisiological errors.   
 
 
3.6 Materials and Methods  
 
3.6.1 Cell culture 
  
Human embryonic kidney 293 (HEK293) were grown in Minimum Essential Medium 
(Gibco, Cat.41090-028) supplemented with 10% fetal bovine serum (FBS) (Sigma, 
Cat.F1051), 1% of Pen/Strep (Gibco, Cat.15070-063) and 1% of non-essential amino acids 
(Gibco, Cat.11140-050) in a humidified atmosphere at 37ºC in the presence of 5% CO2.  
 
 
3.6.2 Mistranslating cell lines used 
 
HEK293 cells stably transfected with an empty vector (Mock), and with the plasmid 
carrying tRNAAGA
Ser(S), tRNAAGC
Ser(A), tRNAAAG
Ser(L) or tRNAGTG
Ser(H) genes were used in 
this study in the passages 1, 15 and 30 (see Methods from Chapter 2).   
 
 
3.6.3 Total RNA extraction  
 
RNA was extracted using Trizol®Reagent (Thermo Fisher Scientific, Cat.15596026). 
The content of one well from a 6 well plate, with around 5x105cells, was collected for each 
experimental condition. Purification of RNA was done using DNaseI, Amplification Grade kit 
(Invitrogen, Cat.18068015), following manufacturer’s instructions. RNA was then precipitated 
with a standard Phenol/Chlorophorm/Isoamylalchohol (25:24:1) (Acros Organics, 
Cat.327111000) extraction protocol and conserved at -80ºC. RNA concentration was 
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determined using NanoDrop1000 (Thermo Scientific). RNA quality was verified using Agilent 
2100 Bioanalyser.  
 
 
3.6.4 Gene expression microarrays  
 
Gene expression microarrays profiling was performed using the Agilent protocol for 
One-Color Microarray Based Gene Expression Analysis Low Input Quick Amp Labeling v6.9 
(Agilent Technologies). RNA quality determination was performed using 2100 Bioanalyser 
(Agilent Technologies) and the Agilent RNA 6000 Nano kit (Agilent Technologies, Cat.5067-
1512). 100ng of total RNA were used to synthesize labeled cDNA (with Cyanine 3-CTP) using 
Agilent T7 Promoter Primer and T7 RNA polymerase Blend (Agilent Technologies, Cat.5190-
2305). cDNA was purified with RNAeasy mini spin columns (Quiagen, Cat.74104). Dye 
incorporation was quantified using Nanodrop 1000 Spectophotometer. 600ng of labeled cDNA 
were hybridized in Sure Print G3 Human Gene Expression 8x60k v2 microarrays (Agilent 
Technologies, Cat.G4851B). Hybridizations were carried out using Agilent gasket slides in a 
rotating oven for 17h at 65ºC. Slides were then washed following manufacturer’s instructions 
and scanned in an Agilent G2565AA microarrays scanner. Probes signal values were extracted 
using Agilent Feature Extraction Software.  
The microarray raw data was submitted to the GEO database and has been given the 
following accession number: GSE93854.  
 
 
3.6.5 Statistical analysis  
 
Data were normalized using median centering of signal distribution with Biometric 
Research Branch BRB-Array tools v3.4.o software (217,218). Each gene’s measured intensity 
was median normalized to correct for differences in the labeling efficiency between samples 
using the most variable probe (set) measured by IQR across arrays. Median normalized values 
were then divided by its value in the control sample in order to obtain the M values (Log2 
intensity ratios) and Fold Change. Microarrays statistical analysis was carried out using Mev 
software (TM4 Microarray Software Suite) (219,220). T-test (calculated based on Welch 
approximation; p-value based on permutations; alpha critical p-value=0.05) was performed to 
identify genes that showed differences in expression between our control (Mock) and our 
samples.  
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3.6.6 Gene expression deregulation analysis  
 
Significant genes that present a fold change above 1.5 or bellow -1.5 (between each 
cell line and the control) were considered as differentially expressed and used for our analysis. 
GO term enrichment analysis were carried out using DAVID Bioinformatics Resources 6.7, an 
online database (254,255).  
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4. Genome alterations of 
HEK293 mistranslating cells  
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4.1 Abstract 
 
In the previous chapters, we characterized mistranslating cell lines regarding their 
phenotypes, activation of protein quality control (PQC) mechanisms and transcriptional 
profiles. Some molecular mechanisms involved in adaptation of these cells to protein synthesis 
errors (PSE) were identified, but the genomic mutations that permit that adaptation were not 
identified. In this chapter, we tackle this question to better understand the biology of PSE. For 
this, we took advantage of next-generation sequencing tools, namely whole-exome sequencing.  
The exomes of our cell lines Mock, tRNASer(S), tRNASer(A), tRNASer(L) and 
tRNASer(H) were sequenced at the end of the evolution experiment (P30), to identify variants 
such as single nucleotide polymorphisms (SNPs) and small Insertions and Deletions (INDELs) 
that accumulated in the coding genome.  
We were able to identify mutations which were absent in the Mock cell line, in genes 
that may be important for the adaptation to PSE. Mutated genes were mainly involved in 
mRNA binding, transcription by RNA polymerase II, cytoskeleton and Endoplasmic 
Reticulum (ER).  
 
 
4.2 Introduction  
 
Next-generation sequencing (NGS) technologies are able to tackle the complexity of 
the human genome and provide a variety of tools to understand how human genome sequence 
variants underlie phenotypes and diseases (256).   
Whole-genome sequencing provides the most comprehensive view of genomic 
information and associated biological implications (256). However, it remains expensive on a 
large scale and poses considerable challenges in the analysis and interpretation of the data. 
Whole-exome sequencing targets only a subset of the genome, namely the protein coding 
region, and also some non-protein coding elements (e.g. microRNA, long intergenic noncoding 
RNA, etc.) (257). Since the size of the genomic material used in genetic analysis (~1% of the 
human genome) is reduced, also the costs of genome analysis are lower comparatively to 
whole-genome sequencing. This permits sequencing higher number of samples, allowing for 
higher breadth and depth of genomic studies (256,258).  
Therefore, whole-exome sequencing has become the method of choice for 
identification of causative mutations of human diseases, or to discover functional variation of 
traits and drug responses (257,259). Examples of diseases where exome sequencing has been 
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used to detect causative variants include Alzheimer’s disease, amyotrophic lateral sclerosis, 
and a number of cancer predisposition mutations (147,257,260–264). Especially in cancer, 
exome sequencing proved to be an important tool to study clonal evolution and response to 
therapeutic drugs (265–268).  
Although most mutations are deleterious, they also provide the raw material for 
adaptation and evolution. In fact, stressors can induce mutagenesis adaptive programs that fuel 
evolution of microbial pathogenesis and antibiotic-resistance, tumor progression and 
chemotherapy resistance (269,270).  
Stress-induced genomic instability has been studied in a variety of organisms such as 
bacteria, yeast and human cancer cells. Alterations in the genome include small changes (of 1 
nucleotide), deletions and insertions, gross chromosomal rearrangements and copy-number 
variations (269). For example, in yeast cells, proteotoxic stress caused by transient Hsp90 
inhibition, potentiates adaptation through induction of aneuploidy. This form of stress-
inducible mutation in eukaryotes was capable of fueling rapid phenotypic evolution and drug 
resistance (271). Also, in cancer cells, aneuploidy is a form of mutation that may contribute to 
oncogenesis, metastasis and the development of chemotherapy resistance (272,273).  
Previous studies have reported alterations at the genomic level of cells exposed to PSE 
for several generations. In these experiments, PSE were produced by an engineered 
tRNACAG
Ser that misincorporated serine (Ser) at leucine (Leu) sites encoded by the CUG 
codon. In yeast CUG codons are distributed over 89% of its protein coding genes and since Ser 
and Leu are chemically different from each other, these mistranslation events generated protein 
misfolding and proteotoxic stress (196). During evolution for ~250 generations, the fitness of 
mistranslating strains increased and large-scale chromosomal duplication and deletion events 
were observed. Indeed, 431 independent mutational events, namely SNPs and large genomic 
rearrangements were detected. Several functional units were repeatedly mutated in the 11 
clones sequenced, such as rRNA maturation, transcription initiation and elongation and the 
ubiquitin-proteasome system. Large scale duplication events were enriched in genes involved 
in ribosomal biogenesis, rRNA processing, superoxide dismutase 1 (SOD1) gene and protease 
core complex assembly. Since these chromosomal rearrangements were observed at the same 
breakpoints in all of the sequenced clones, it is likely that such mutational events confer 
adaptive advantage to the carrying cells (196). Also, in C. albicans mistranslating strains 
evolved for ~100 generations, full genome resequencing identified various strain specific 
single nucleotide polymorphism (SNPs) and one SNP in the deneddylase (JAB1) gene in all 
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strains. This gene is part of a complex, which mediates degradation of a variety of cellular 
proteins and may play a role in tolerance and adaptation to PSE in C. albicans (274).  
In the previous chapters, we saw that human cells adapt relatively well to the 
expression of mutant tRNAs and to overexpression of the Wt tRNASer. We observed the 
accumulation of misfolded proteins and in some cases protein aggregates (tRNASer(L)) that 
activated PQC mechanisms (Chapter 2). We were also able to identify transcriptional 
alterations in these cells that may explain survival and adaptation, beyond PQC mechanisms, 
such as alterations in metabolic pathways (glycolysis/gluconeogenesis) and signaling pathways 
(p53 and MAKP) (Chapter 3). In order to understand those phenotypes, we sequenced the 
whole-exome of our cell lines, Mock, tRNASer(S), tRNASer(A), tRNASer(L) and tRNASer(H) in 
the last point of the evolution experiment (P30). Our hypothesis was that mistranslating cells 
accumulated adaptive mutations to overcome the stress imposed by PSE.  
With the application of high quality criteria, we were able to detect several alterations 
in mistranslating cell lines, but the majority was common to our Mock control cell line. A 
small number of alterations (SNPs and Insertions), detected in our cell lines, were different 
from the Mock cell line and occurred in genes that are mainly were involved in mRNA 
binding, transcription from RNA polymerase II, and in some cases, cytoskeleton and 
Endoplasmic Reticulum. Some of the alterations could be correlated to our previous 
phenotypes and probably confer advantages to these mistranslating cells in culture.  
 
 
4.3 Results 
 
4.3.1 Whole-exome sequencing of evolved mistranslating HEK293 cells   
 
Our previous data suggested that our cell lines adapt relatively well to PSE probably by 
accumulating mutations in the genome. In order to clarify this hypothesis, we have sequenced 
the whole-exome of the Mock, tRNASer(S), tRNASer(A), tRNASer(L) and tRNASer(H) cell lines 
at the end of the evolution (P30).  
For exome sequencing, genomic DNA was extracted from those cell lines, and the 
samples were sequenced using a HiSeq2000 instrument (Illumina) with 75bp paired-end reads. 
After sequencing, images were acquired using Illumina Genome Analyzer Sequencing Control 
Software and analyzed. FASTQ files with base calls, quality metrics and read calls were 
generated. Sequences were then aligned to the Human Genome Reference and single 
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nucleotide polymorphisms (SNPs) and small insertions or deletions (INDELs) were detected. 
Several quality criteria were applied during the analysis and will be referred in the text, but the 
final criteria to identify variants and annotated genes was: unique variants (defined by 
chromosome, coordinate and reference), variant quality (Q) ≥100, genotype quality (GQ) ≥90 
and number of reads≥40. This was done to ensure identification of high quality variants.  
 
 
4.3.2 Variants Lost, Shared and Gained  
 
Table 4-1 shows the number of variants detected in each cell line, relative to the 
Human Reference Genome (HRG). The cell lines that had the highest number of mutations 
relative to the HRG were tRNASer(A) and tRNASer(L), with 2.030.408 and 2.066.886 variants, 
respectively. tRNASer(H) had the lowest number of variants (1.307.461). After the application 
of the first quality criteria: unique variants, defined by chromosome, coordinate and reference, 
variant quality (Q) ≥20, genotype quality (GQ) >20, the number of variants decreased. The 
tRNASer(A) and tRNASer(L) cell lines had higher number of variants, 306.719 and 298.472, 
respectively, while tRNASer(S) cell line had the lower value, 173.980 variants.  
 
Table 4-1. Number of variants in each cell line (vs. Homo sapiens) with no criteria and with the application 
of the first set of quality criteria. 
Cell line Total number of variants 
Number of unique variants 
(chromosome, coordinate, 
reference) Q ≥20, GQ>20 
Mock  1.897.546 273.515 
tRNASer(S) 1.797.217 173.980 
tRNASer(A) 2.030.408 306.719 
tRNASer(L) 2.066.886 298.472 
tRNASer(H) 1.307.461 199.064 
 
 
The number of variants (unique variants, Q≥20, GQ>20) was normalized to the sum of 
mapped reads of each condition, because differences in variants number can be due to 
sequencing efficiency.  In fact, when the values of variants were normalized (Figure 4-1), we 
could see that Mock and tRNASer(S) cells had the same number of variants, 2,09. tRNASer(A) 
and tRNASer(L) cells had also the same number of variants, 2,14. tRNASer(H) had the lower 
value, 1,64 variants.  
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Figure 4-1. Number of variants (unique variants, Q≥20, GQ>20) in each cell line (vs. Homo sapiens) 
normalized to the total number of mapped reads in each cell line (x1000). 
 
 
We then selected the variants (unique variants, Q≥20, GQ>20) with a coverage of reads 
equal or above 20 and compared each cell line with our control, the Mock cell line. Variants 
identified by this comparison were categorized in:  
Lost variants (Lost) – are present in Mock, but absent in tRNASer(S) or tRNASer(A) or 
tRNASer(L) or tRNASer(H);  
Gained variants (Gained) – are absent in Mock, but present in tRNASer(S) or 
tRNASer(A) or tRNASer(L) or tRNASer(H); 
Shared variants (Shared) – present in Mock and tRNASer(S) or tRNASer(A) or 
tRNASer(L) or tRNASer(H).  
The following patterns were observed: in tRNASer(S) and tRNASer(H) cells there was 
higher number of Lost variants, 164.410 and 170.420 variants, respectively; while in 
tRNASer(A) and tRNASer(L) cells the highest number of variants were categorized as Gained, 
188.428 and 181.700 variants, respectively (Figure 4-2 A). Normalization of these values 
resulted in the same pattern (Figure 4-2 B). Shared variants were similar in the four cell lines 
(Figure 4-2 A). Normalization of the values showed that the tRNASer(S) cell line had higher 
number of Shared variants, 1,31 (Figure 4-2 B). 
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Figure 4-2. Number of variants (unique variants, Q≥20, GQ>20, number of reads≥20) in each cell line 
vs. Mock, categorized as “Shared”, “Lost” and “Gained”. A – Total number of variants; B – Number of 
variants normalized to the total number of mapped reads for each cell line (x1000).     
 
 
In order to increase the sensitivity of variants detection, we analyzed the variants 
Shared, Lost and Gained with new criteria. According to previous results of Meynert et al., 40x 
mean on target depth is required to obtain 95% overall estimated sensitivity for heterozygous 
SNPs (275). Using this value as reference (Table 4-2), we compared the number of variants 
Shared, Lost and Gained (relative to Mock), using a coverage of at least 20 reads, and using a 
coverage of at least 40 reads (non-normalized values). The number of variants decreased when 
we analyzed variants with coverage of a minimum of 40 reads, relatively to the analysis carried 
out with at least 20 reads. The numbers of Lost and Gained variants were similar in each cell 
line. The number of Shared variants in all cell lines was higher than Lost or Gained variants.  
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Table 4-2. Number of variants Shared, Lost or Gained relative to Mock, with a minimum of 20 or 40 reads 
(non-normalized values).  
Mock vs. 
Shared Lost Gained 
#unique 
variants  
Q ≥20, 
GQ>20, 
reads≥20  
#unique 
variants,  
Q ≥20, 
GQ>20,  
reads≥40 
#unique 
variants  
Q ≥20, 
GQ>20, 
reads≥20 
#unique 
variants,  
Q ≥20, 
GQ>20,  
reads≥40 
#unique 
variants  
Q ≥20, 
GQ>20, 
reads≥20 
#unique 
variants,  
Q ≥20, 
GQ>20,  
reads≥40 
tRNASer(S) 109.105 31.884 164.410 2.219 64.875 1.977 
tRNASer(A) 118.291 50.504 155.224 2.097 188.428 2.317 
tRNASer(L) 116.772 49.187 156.743 2.133 181.700 2.261 
tRNASer(H) 103.095 43.649 170.420 3.462 95.969 2.124 
 
 
The values of variants obtained with a minimum of 40 reads were normalized to the 
total number of mapped reads for each cell line. The number of variants Shared was much 
higher than the number of Lost or Gained variants in all cells lines (Figure 4-3), suggesting that 
the majority of the alterations accumulated during evolution are not related to PSE, since these 
alterations were also present in our control cell line (Mock). The number of Lost and Gained 
variants decreased with the application of this new criterion, meaning that Lost and Gained 
variants previously identified had lower coverage and higher level of associated error. In 
tRNASer(S) and tRNASer(H) cells there was higher number of Lost variants (0,27 and 0,28, 
respectively) relatively to the number of Gained variants (tRNASer(S): 0,24 and tRNASer(H): 
0,17).  In tRNASer(A) and tRNASer(L) cells the pattern observed was the opposite, the number 
of Gained variants (0,16 for both cases) was higher than Lost variants (0,15 for both cases). 
tRNASer(S) and tRNASer(H) cells showed higher values of Lost or Gained variants relatively to 
tRNASer(A) and tRNASer(L) cells (Figure 4-3 B). 
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Figure 4-3. Number of variants (unique variants, Q≥20, GQ>20, number of reads≥40) in each cell line 
relative to Mock, normalized to the total number of mapped reads for each cell line (x10000). A – 
Variants categorized as Shared, Lost or Gained for each cell line. B – Highlight of Lost and Gained variant 
categories. 
 
 
Since after the application of the second criterion we still had high numbers of variants 
we decided to apply a final set of criteria to select variants and reduce scoring error levels. We 
used high quality variants, unique variants, Q≥100, GQ≥90, with a number of reads≥40. As 
expected the application of the new criteria reduced the number of variants. The number of 
Lost variants in tRNASer(A) and tRNASer(L) cells (559 and 558 variants, respectively) was very 
similar to the number of Gained variants (601 and 557 variants, respectively) (Table 4-3). 
tRNASer(S) and tRNASer(H) cells had a different pattern since the number of Lost variants 
(1494 and 1360 variants, respectively) was higher than the number of Gained variants (557 and 
602 variants, respectively) (Table 4-3).  
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Table 4-3. Number of high quality (HQ) variants Lost or Gained in comparison with Mock, with a minimum 
of 40 reads or with the minimum of 40 reads with the application of the new quality criteria (Q≥100, GQ≥90) 
(non-normalized values). 
Mock vs. 
Lost Gained 
#unique variants,  
Q ≥20, GQ>20,  
reads≥40 
#unique variants,  
Q ≥100, GQ>90,  
reads≥40 
#unique variants,  
Q ≥20, GQ>20,  
reads≥40 
#unique variants,  
Q ≥100, GQ>90,  
reads≥40 
tRNASer(S) 2.219 1.494 1.977 557 
tRNASer(A) 2.097 559 2.317 601 
tRNASer(L) 2.133 558 2.261 557 
tRNASer(H) 3.462 1.360 2.124 602 
 
 
Table 4-3 values of high quality variants (unique variants, Q≥100, GQ≥90, with 
number of reads≥40) were normalized to the total number of mapped reads for each cell line. 
Figure 4-4 shows the final distribution of Lost and Gained variants in our cell lines. The 
patterns already identified were similar for our cell lines.  In tRNASer(A) and tRNASer(L) cells 
the number of Lost variants (0,039 and 0,040 variants, respectively) was similar to the number 
of Gained variants (0,042 and 0,040 variants, respectively). In tRNASer(S) and tRNASer(H) 
cells the number of Lost variants (0,179 and 0,112 variants, respectively) was higher than the 
number of Gained variants (0,067 and 0,049 variants, respectively).  
 
 
Figure 4-4. Number of Lost and Gained HQ variants (unique variants, Q≥100, GQ≥90, with a number 
of reads≥40) in each cell line comparatively to Mock, normalized to the total number of mapped reads 
for each cell line (x10000). 
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To better understand the relevance of the previous patterns we have determined the 
ratio of Gained/Lost variants relative to Mock in each cell line (Figure 4-5). We can observe 
that tRNASer(S) had the lowest value (0,37), followed by tRNASer(H) cells (0,44), meaning that 
these two cell lines, have a tendency to lose variants that were present in Mock. tRNASer(L) 
ratio of Gained/Lost variants was 1, while tRNASer(A) ratio was 1,08 indicating that in these 
cell lines the number of Lost and Gained variants was identical or very similar. Until the 
introduction of these new criteria (Q≥100, GQ≥90) we had higher number of Gained variants 
relative to Lost variants in tRNASer(A) and tRNASer(L) cell lines.  
 
 
Figure 4-5. Ratio of Gained/Lost HQ variants (unique variants, Q≥100, GQ≥90, with a number of 
reads≥40) in each cell line comparatively to Mock. 
 
 
We then analyzed the distribution of Lost and Gained variants per chromosome. The 
ratio of Ganeid/Lost variants was in most of the cases lower or equal to 1, but there were some 
exceptions (Figure 4-6). In tRNASer(S) and tRNASer(H) cell lines there was a variant loss trend, 
relative to the Mock cell line, in all chromosomes. In the tRNASer(S) cell line in chromosomes 
1, 12, 13 and 19 the ratio of Gained/Lost variants was higher than 1 and in the chromosome 19, 
the ratio Gained/Lost was around 2. This increase in gained variants was observed throughout 
chromosome 19. The genes that accumulated variants in this chromosome did not belong to 
any relevant functional Gene Ontology (GO) category. However, we can highlight USE1 gene 
that contained an upstream variant. This gene encodes a SNARE protein that may be involved 
in targeting and fusion of Golgi-derived retrograde transport vesicles with the endoplasmic 
reticulum (ER). In chromosome 19, ZNF480, ZNF805, ZNF766 genes that encode zinc finger 
proteins and are involved in transcriptional regulation, also accumulated mutations.   
In tRNASer(A) cell line there was accumulation of Gained variants in chromosome 6. 
The ratio Gained/Lost variants was around 4. The genes in chromosome 6 that accumulated 
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mutations were annotated in the GO category of “extracellular matrix structural constituent” 
(p-value=2.6E-2). Two genes that encode collagen molecules were annotated in this category, 
COL12A1 and COL19A1. Other genes also accumulated alterations, but were not annotated in 
any GO category, namely: 
- TBP, which encodes a transcription factor that functions at the core of the DNA-
binding multiprotein factor TFIID, playing a role in the activation of eukaryotic 
genes transcribed by RNA polymerase II. This gene accumulated a frameshit 
variant with predicted high impact in the protein structure; 
-  HSF2, which encodes a DNA binding protein that specifically binds to heat shock 
promoter elements and activates transcription. In this case an intronic mutation was 
detected;  
- POLH, which encodes a DNA polymerase involved in DNA repair, accumulated 
two intron variants;  
- MRPL18, which encodes a mitochondrial ribosomal protein, accumulated an intron 
variant;  
- ECT2L, which encodes the protein epithelial cell transformin sequence 2 oncogene-
like, accumulated an intron variant. This gene was also downregulated in our 
microarray data set, namely from P1 to P30 in tRNASer(A) cell line.  
 Finally, in tRNASer(L) cells, there was a strong decrease in Gained variants in 
chromosome 13, relative to the other cell lines. 
 
 
Figure 4-6. Ratio of Gained/Lost HQ variants (unique variants, Q≥100, GQ≥90, number of reads≥40) 
per chromosome, in each cell line, comparatively to Mock. 
 
 
Chapter 4 – Genome alterations of HEK293 mistranslating cells 
 
145 
 
4.3.3 SNPs, INDELs and variants quality criteria 
 
We identified next the type of alterations (SNPs or INDELs) that were present in the 
exome of our cell lines in P30. Whole-exome sequencing analysis allows identification of 
SNPs, namely Transitions and Transversions, and small Insertions and Deletions (INDELs). 
Transitions are interchanges of two-ring purines (A↔G) or of one-ring pyrimidines (C↔T) 
(Figure 4-7). Transversions are interchanges of purine for pyrimidine bases, which involve 
exchange of one-ring and two-ring structures (Figure 4-7).  
 
 
Figure 4-7. Representative scheme of Transitions and Transversions (adapted from (276)). 
 
 
Table 4-4 shows the number of variants; Transitions or Transversions for each cell line, 
using the different quality criteria already described. The number of Transitions was higher 
than the number of Transversions, for all cell lines and independently of the quality criteria 
used. This is not surprising since, in humans transition mutations are at least twice as likely as 
transversion mutations, resulting in many SNPs that are A/G or C/T (277). tRNASer(A) and 
tRNASer(L) cell lines had higher number of Transitions and Transversions, relative to 
tRNASer(S) and tRNASer(H) cells. tRNASer(S) cell line had the lowest values of Transitions and 
Transversions. 
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Table 4-4. Number of variants (Transitions or Transversions) for each cell line, using different quality 
criteria. 
# Variants (not normalized) 
Type Cell Line 
No 
Criteria 
#unique 
variants 
Q≥20, 
GQ≥20, 
Number of 
reads≥20 
#unique 
variants 
Q≥20, 
GQ≥20, 
Number of 
reads≥40 
#unique 
variants 
Q≥100, 
GQ≥90, 
Number of 
reads≥40 
TRANSITIONs 
tRNASer(S) 173.438 44.010 23.293 20.245 
tRNASer(A) 223.954 52.490 35.392 31.630 
tRNASer(L) 218.596 51.396 34.259 30.537 
tRNASer(H) 178.217 48.739 31.594 28.225 
TRANSVERSIONs 
tRNASer(S) 145.552 21.000 10.377 8.211 
tRNASer(A) 213.875 25.881 15.870 13.019 
tRNASer(L) 212.901 25.589 15.626 12.885 
tRNASer(H) 169.791 24.152 14.051 11.585 
 
We then, normalized the values of Transitions and Transversions to the number of 
reads for each cell line, using the last quality criteria applied (unique variants, Q≥100, GC≥90 
and number of reads≥40). With the normalization of the values we could observe that 
tRNASer(S) had slightly more Transitions than the other cell lines (0,81) (Figure 4-8). This was 
probably due to a technical problem; since the sequencing of this cell line was less efficient 
than the other cell lines (tRNASer(S) had around 83 million reads while the other cell lines had 
above 120 million reads). When we normalized tRNASer(S) variants to the total number of 
reads there was an apparent higher number of variants. The number of Transversions was very 
similar in all mistranslating cells, the average of Transversions was around 0.3. Once again, it 
was clear that the number of Transitions was higher than the number of Transversions, in all 
cell lines (Figure 4-8).  
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Figure 4-8. Number of Transitions and Transversions (unique variants, Q≥100, GQ≥90, number of 
reads≥40), for each cell line, relative to Mock, normalized to the total number of mapped reads for 
each cell line (x10000). 
 
 
Next, the number of variants; Transitions and Transversions, and Insertions or 
Deletions was categorized in Gained, Shared or Lost, relative to our control, the Mock cell line 
(Figure 4-9). When we introduce the more stringent criteria the number of Gained and Lost 
variants was very low in all cell lines. This happened for all variant types, Transitions, 
Transversions, Insertions and Deletions. The decrease in Gained and Lost variants with the 
introduction of quality criteria was due to variants of low quality, the low genome quality and 
also the decreased number of reads (low coverage). In all cell lines, genomic alterations were 
mainly Shared with the control, and only a very low number were specific of each cell line.  
 
A 
 
 
Figure 4-9.► 
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  C 
 
   D 
 
Figure 4-9. Number of variants with no criteria (columns) or with application of the maximum quality 
criteria (unique variants, Q≥100, GQ≥90, number of reads≥40) (dots) that were Gained, Shared or 
Lost for each cell line relative to Mock, normalized to the total number of mapped reads for each cell 
line (x10000). A – Transitions; B – Transversions; C – Insertions; D – Deletions 
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4.3.3 SNPs and Insertions annotated to genes  
 
 SNPs (Transitions and Transversions) and some Insertions with high quality (unique 
variants, Q≥100, GQ≥90, number of reads≥40) were annotated to genes in order to identify 
biological functions that can be affected and explain adaptation to PSE. Overall, 10.198 high 
quality INDELs were detected, however only 1.438 were annotated to genes. This is due to a 
technical problem, since paired-end reads and depth coverage approaches frequently miss 
small INDELs, and are unable to predict the breakpoints accurately (278). For this reason, we 
could not identify the genes with Deletions and the majority of Insertions. For each cell line, 
we identified genes that accumulated Transitions, Transversions and Insertions, relative to 
Mock, and also cross checked these data with our previous microarray data, whenever 
possible.  
 The number of annotated and identified (DAVID Bioinformatic Resources 6.7) genes 
in our cell lines that have Transitions, Transversions or Insertions in their sequence is 
presented in Table 4-5.  
 
Table 4-5. Number of annotated and identified (DAVID Bioinformatic Resources 6.7) genes in our cell lines 
that have Transitions, Transversions or Insertions in their sequence. 
Mistranslating cell 
lines 
#Genes with 
Transitions 
#Genes with 
Transversions 
#Genes with 
Insertions 
tRNASer(S) 17 12 24 
tRNASer(A) 20 22 42 
tRNASer(L) 13 20 32 
tRNASer(H) 14 23 38 
 
 
In tRNASer(S) cell line, 17 genes with Transitions were annotated and identified, 
namely ROS1 (containing an intron variant) which codes a cell growth or differentiation factor 
receptor and CDK19 (containing an intron variant), which encodes a component of the 
Mediator co-activator complex, required for transcriptional activation by DNA binding 
transcription factors that regulate RNA polymerase II. Two genes that encode proteins that 
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bind to mRNA poly(A) tails, PABPC1 (containing a missense variant) and PABPC1P5 
(containing an upstream gene variant) also had Transitions in tRNASer(S) cell line (Table 4-6). 
One of the 20 genes that accumulated Transitions in tRNASer(A) cells was HSF2 (containing an 
intron variant). This gene encodes the heat shock transcription factor 2 that induces the 
transcription of genes in response to alterations in the protein-degradative machinery. In the 
tRNASer(L) cell line, genes with Transitions were annotated to the GO category “transcription 
from RNA polymerase II promoter”. One of them is HSF2 (containing an intron variant). The 
tRNASer(H) cell line had 14 genes with Transitions, namely DNASE1L1 (containing a 
downstream gene variant), which encodes a deoxyribonuclease protein very similar to DNaseI 
(Table 4-6).  
The genes that accumulated Transitions in our mistranslating cell lines were mainly 
involved in RNA polymerase II transcription, indicating that transcription plays an important 
role in the response to proteotoxic stress in the evolved cell lines. HSF2 presented alterations 
in two of our cell lines, tRNASer(A) and tRNASer(L). HSF2 is ubiquitously expressed in 
mammanlian tissues and is activated by the downregulation of the ubiquitin-proteasome 
pathway (UPS). When activated, the response is similar to the activation of HSF1 and leads to 
upregulation of molecular chaperones, likely due to accumulation of misfolded proteins (279). 
Our previous data from Chapter 2 indicated that the levels of HSP27, HSP60 and HSP70 
chaperones seem to be downregulated in our cells. This may indicate that sustained activation 
through time of molecular chaperones is not beneficial and alterations in HSF2 gene could 
have an effect in this process.  
 
Table 4-6. Examples of genes with Transitions in mistranslating cell lines.  
Mistranslating cell lines Examples of genes with Transitions 
tRNASer(S) 
ROS1 (ROS proto-oncogene1, receptor tyrosine kinase) 
CDK19 (cyclin dependent kinase 19) 
PABPC1 (poly(A) binding protein cytoplasmic 1) 
PABPC1P5 (poly(A) binding protein cytoplasmic 1 pseudogene 5) 
tRNASer(A) HSF2 (heat shock transcription factor 2) 
tRNASer(L) HSF2 (heat shock transcription factor 2) 
tRNASer(H) DNASE1L 1 (desoxyribonuclease 1 like 1) 
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Regarding the genes with Tranversions, 12 were identified in tRNASer(S) cell line, in 
genes such as PABPC3 (containing a missense variant) and ZNF75D (Table 4-7). PABPC3 
gene encodes a protein that binds to the poly(A) tail of mRNA and may be involved in 
cytoplasmic regulatory processes of mRNA metabolism, while the ZNF75D gene encodes a 
zinc finger protein involved in transcriptional regulation. tRNASer(A) cell line had 22 genes 
with Transversions. Within these there are zinc finger proteins (ZNF676, ZNF75D and 
ZC3H12D). The ZC3H12D gene product may function as an RNase, regulating levels of target 
RNAs. Also, the genes TBX18 (containing an intron variant) and ZYG11B (containing a 
missense variant) had Transversions in tRNASer(A) cell line. TBX18 encodes a transcriptional 
regulator involved in developmental process, and ZYG11B encodes a protein that is part of an 
E3 ubiquitin ligase complex, probably acting as a target recruitment subunit (Table 4-7).  
In tRNASer(L) cell line, the genes that accumulated Transversions were annotated in 
GO categories such as “mRNA binding” and “transcription regulation”. The “mRNA binding” 
category includes the KHDRBS2 gene (containing an intron variant), which encodes an RNA-
binding protein that plays a role in the regulation of alternative splicing and influences mRNA 
splice selection and exon inclusion. In the second category, “transcription regulation” we 
found two genes that encode zinc finger proteins, both involved in transcriptional regulation, 
ZNF75D and ZNF441. Also, MED23 gene was found in this category. The protein encoded by 
MED23 gene is required for transcriptional activation subsequent to the pre-initiation complex 
and is a component of the Mediator complex that functions as a coactivator involved in the 
regulated transcription of nearly all RNA polymerase II-dependent genes (Table 4-7). In 
tRNASer(H) cell line 23 genes had Transversions and some of them were annotated in the GO 
category “mRNA binding”, such as KHDRBS2. Two genes that encode zinc finger proteins 
involved in transcriptional regulation also had Transversions, ZNF75D and ZNF774 (Table 4-
7).  
The accumulation of Transversions occurred in genes involved mainly in RNA binding 
and transcription. In tRNASer(S) alterations in the potential RNase gene, ZC3H12D, could be 
related with the alterations of tRNASer expression. The gene ZYG11B, encodes a substrate-
recognition subunit of a CUL-2-based complex (E3 ubiquitin ligase complex) that regulates 
cell division and transcription (280). Alterations in this gene seem to be important in 
tRNASer(A), since its expression is upregulated in our microarray data (P15-P30). Therefore, it 
may be important for cell division and proliferation of tRNASer(A) cells. In tRNASer(L) cells, 
alterations that occurred at the genomic level in MED23 gene may explain the up-regulation in 
P30.  
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Table 4-7. Example of genes with Transversions in mistranslating cell lines.  
Mistranslating 
cell lines 
Examples of genes with Transversions 
tRNASer(S) 
PABPC3 (poly(A) binding protein cytoplasmic 3) 
ZNF75D (zinc finger protein 75D) 
tRNASer(A) 
ZNF676 (zinc finger protein 676) 
ZNF75D (zinc finger protein 75D) 
ZC3H12D (zinc finger CCCH-type containing 12D) 
TBX18 (T-box 18) 
ZYG11B (zyg-11 family member B, cell cycle) 
tRNASer(L) 
KHDRBS2 (KH RNA binding domain containing, signal transduction associated 
2) 
ZNF75D (zinc finger protein 75D) 
ZNF441 (zinc finger protein 441) 
MED23 (mediator complex subunit 23) 
tRNASer(H) 
KHDRBS2 (KH RNA binding domain containing, signal transduction associated 
2) 
ZNF75D (zinc finger protein 75D) 
ZNF774 (zinc finger protein 774) 
 
 
Regarding genes that contained Insertions in tRNASer(S) cells, 24 were identified and 
annotated in GO categories, including “cytoskeletal part” and “microtubule cytoskeleton”. 
Other genes not annotated in these categories were for example, EIF3A (containing two 
downstream gene variants) (Table 4-8). This gene encodes the eukaryotic translation initiator 
factor 3 subunit A. In tRNASer(A) cell line genes with Insertions were annotated in categories 
such as “transcription cofactor activity” and “alternative splicing”. The first category included 
TCERG1 (containing a downstream gene variant) and MYSM1 (containing an intron variant) 
genes (Table 4-8). TCERG1 gene encodes a transcription factor that binds to RNA polymerase 
II and inhibits elongation of transcripts from target promoters. The MYSM1 gene encodes a 
metalloprotease that specifically deubiquitinates monoubiquitinated histone H2A, a specific 
tag for epigenetic transcriptional repression, thereby acting as a coactivator. In addition to 
these, PSMD9 (containing a downstream gene variant), encodes a protein that acts as a 
regulatory subunit of the 26S proteasome. Also in tRNASer(L) cell line, genes that accumulated 
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Insertions were mainly involved in alternative splicing, such as MYSM1 and cytoskeletal 
protein binding. The genes TRNT1, DNAJC14, POLR3G PSMD9 and CIDEB also had 
Insertions in tRNASer(L) cells (Table 4-8). The TRNT1 gene encodes a protein that adds and 
repairs the conserved 3´-CCa sequence of tRNAs; the DNAJC14 gene encodes an Hsp70 co-
chaperone that regulates the export of target proteins from the ER to the cell surface; POLR3G 
gene encodes a specific peripheric component of RNA polymerase III, which synthesizes small 
RNAs and tRNAs and CIDEB gene encodes a protein that activates apoptosis. Finally 
regarding tRNASer(H) cell line, 38 genes had Insertions. Some were annotated in the GO 
category “endoplasmic reticulum”, such as DNAJC14 (Table 4-8).  
The number of genes with Insertions was higher than the number of genes with 
Transitions or Transvertions. These genes were mainly involved in transcription processes, 
alternative splicing and cytoskeleton. It is interesting to note that tRNASer(A) cells accumulated 
alterations in genes that belong to the ubiquitin-proteasome system, which may indicate that 
these mutations can be important to the activity of this system. A component of polymerase III 
was mutated in tRNASer(L) cells, POLR3G, which may influence tRNA synthesis in this cell 
line. We wonder if this mutation is involved in the dowregulation of the mutant tRNA. Also, 
the mutation detected in CIDEB gene in tRNASer(L) cells may explain its uperegulation in our 
microarray data set (P1-P30 and M30-L30). The respective protein is involved in apoptosis, 
but we did not observe significant alterations in cell death in tRNASer(L) cells in P30. Genes 
that belong to the “endoplasmic reticulum” category accumulated insertions in tRNASer(H) 
cells, namely DNAJC14 which may prevent the the activation of Hsp70 and the export of 
misfolded proteins to cells surface.  
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Table 4-8. Example of genes with Insertions in mistranslating cell lines.  
Mistranslating cell lines Examples of genes with Insertions  
tRNASer(S) EIF3A (eukaryotic translation initiation factor 3 subunit A ) 
tRNASer(A) 
TCERG1 (transcription elongation regulator 1) 
MYSM1 (Myb like, SWIRM and MPN domains 1) 
PSMD9 (proteasome 26S subunit, non-ATPase 9) 
tRNASer(L) 
MYSM1 (Myb like, SWIRM and MPN domains 1) 
TRNT1 (tRNA nucleotidyl transferase 1) 
DNAJC14 (DnaJ heat shock protein family (Hsp40) member C14) 
POLR3G (RNA polymerase III subunit G) 
PSMD9 (proteasome 26S subunit, non-ATPase 9) 
CIDEB (cell death-inducing DFFA-like effector b) 
tRNASer(H) DNAJC14 (DnaJ heat shock protein family (Hsp40) member C14) 
 
 
4.4 Discussion  
 
Whole-exome sequencing analysis was performed to understand the genomic 
alterations in our cell lines in P30. Our hypothesis was that these cells accumulated adaptive 
mutations to survive or counteract the negative effects of PSE. In addition to adaptive 
mutations, our results show alterations in some genes that could be related to the phenotypes 
that we have observed in previous chapters, for example mutations in DNAJC14 gene among 
others. Genes involved in RNA binding and Transcription from RNA polymerase II showed 
higher level of alterations in our cell lines, indicating that genomic alterations were mainly 
related to the transcription process.  
In C. albicans, amino acid misincorporations lead to alterations in genome structure, 
detected by whole-genome sequencing. C. albicans has the ability to incorporate Ser (~97%) 
and Leu (~3%) at CUG codons. Engineered C. albicans strains that misincorporate increasing 
levels of Leu at protein CUG sites showed high number of genotype changes at polymorphic 
sites, and 80% of Leu misincorporation results in complete loss of heterozygosity in a large 
region of chromosome V (75). In the affected region of chromosome V most of the ORFs had 
no known function, but the known genes were involved in the stress response, antifungal drug 
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resistance and pathogenesis, which is in line with the acquired resistance to antifungals (75). 
Whole-exome sequencing is a good tool to study alterations in the coding part of the genome, 
but unlike whole-genome sequencing, it is very limited to unveil genomic structural variants 
(281). 
The identification of Indels represents a challenge in the analysis of NGS data. In our 
study, we could identify and annotate some Insertions, but no Deletions. Due to the short 
sequence reads produced by NGS, Insertions and Deletions involving large DNA segments are 
difficult to accurately align. For example, when the size of the Indel is greater than half of the 
sequence read length, the NGS reads containing the mutant sequence may fail to align properly 
(278,282).  
The majority of variants detected in mistranslating cell lines were also present in Mock. 
This could be due to the low quality of Gained and Lost variants, as described in the results. 
One of the major complications with NGS data is the identification of high quality variants and 
for this reason during the bioinformatic analysis the quality criteria was increased (275,283).  
In tRNASer(A) and tRNASer(L) cell lines the HSF2 gene had the same single nucleotide 
variation (SNV) in its intron, suggesting that this gene may be relevant to adaptation to PSE. 
Heat shock factors (HSFs) are transcriptional regulators of genes encoding molecular 
chaperones and several other stress proteins and for this reason are essential for organisms 
survival (284). HSF2 depends on HSF1 for its stress-related functions, it is recruited to HSP 
gene promoters only in the presence of HSF1 and can positively or negatively modulate HSPs 
expression (284). Previous studies revealed that HSF2 is able to modulate HSP70, HSP27, 
HSP40 and HSP90 expression in stress situations, but is also important for normal levels of 
constitutive expression of HSE-containing genes (285–287). Protein chaperones levels 
decreased in P30 in our cell lines (Chapter 2), and in tRNASer(A) and tRNASer(L) this decrease 
may be correlated with the mutation found in HSF2 gene. Although HSF1 is the major 
regulator of Hsps expression and no impact in the protein structure can be atributed to the 
variant found in HSF2 gene, we can not exclude alteration in expression of HSF2 mediated by 
this mutation, but further studies are needed to clarify the importance of this alteration in these 
mistranslating cell lines. Particularly in the case of Hsp70, which is downregulated in 
tRNASer(A) and tRNASer(L) cells, it is well decribed that HSF2 is able to form heterotrimers 
with HSF1, bind to hsp70.1 promoter and increase Hsp70 expression in response to heat shock 
and during proteasome inhibition in mouse embryonic fibroblasts (MEFs) (285). Also 
DNAJC14 gene accumulated a 3’ UTR variant in tRNASer(L) and tRNASer(H) cells. The J 
protein encoded by this gene is a co-chaperone of Hsp70 and has a J domain that interacts and 
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stimulates Hsp70 ATPase activity (91). In addition, DNAJC14 is bound to ER and modulates 
transport of client proteins from this organelle to the plasma membrane (288,289). During ER 
stress, DANJC14 can bind to client misfolded proteins and in cooperation with Hsc70 targeting 
them to unconventional secretion, a mechanism suggested to relieve the protein burden in the 
ER (289). Although this may not be an adaptive mutation and the impact of the downstream 
variant found in DNAJC14 gene, is not known, in tRNASer(L) cell line we do not exclude that 
this alteration may prevent ER stress alleviation leading to accumulation of protein aggregates 
(Chapter 2). Previous exome sequencing analyses have identified several mutions in DNAJC 
genes (DNAJC13, DNAJC6 and DNAJC5) that may be implicated in protein aggregation 
diseases such as Parkinson’s disease (290).  
The tRNASer(A) cell line presented a ratio of Gained mutations higher than the other 
cell lines, especially in chromosome 6. This cell line adapts rather well to PSE, through 
activation of the ubiquitin-proteasome system, increasing protein synthesis rate and also 
increasing the expression of genes involved in glycolysis (Chapters 2 and 3). One of the genes 
that accumulated mutations was POLH that encodes the DNA polymerase eta, involved in 
DNA repair.  This polymerase has the ability of repairing damage from ultraviolet radiation 
and oxidative stress (291), suggesting that PSE may increase mutation rate. This is interesting 
because cancer cells speed their growth by acquiring mutations in genes that normally fix 
DNA damage, fueling the evolution of cancer (292,293).  
The tRNASer(S) cell line had mutations in some genes involved in translation, such as 
poly(A) binding proteins and the eukaryotic translation initiation factor; EIF3A. The eIF3a 
protein participates in translation of global mRNAs, but also regulates the translation of a 
subset of mRNAs that may be involved in cell proliferation, cell cycle control, cell 
differentiation and DNA repair (294,295). In many cancers, such as lung, breast and prostatic 
cancers, mutations in EIF3A gene are associated with susceptibility to tumor growth (296,297). 
Despite these connections with disease, previous studies using mistranslating cell lines do not 
report mutations in protein synthesis machinery components. The effect of these mutations 
should be elucidated in future studies.  
Transcription factor genes accumulated a significant number of mutations in our 
mistranslating cell lines. This phenomenon was already observed in S. cerevisiae evolved 
mistranslating strains, where genes belonging to the category: transcription initiation and 
elongation also accumulated mutations (196).  
One of the limitations of this work was the analysis of only one biological replicate. It 
would be important to complement this analysis with several biological replicates to 
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distinguish the variants that occur in all replicates and are specific for the adaptation of each 
cell line to PSE. One alternative could be the sequencing of single-cells (298). This approach is 
important to overcome key issues, such as population heterogeneity. In fact, this technique has 
been used to characterize some types of cancer  (299,300). Also, our study would benefit from 
sequencing cells in P1 to identify the alterations that were present in the lines at the beginning 
of the evolution experiment (196,274). 
 
 
4.5 Conclusions  
 
Whole-exome sequencing, allowed us to detect genomic alterations that accumulated 
during evolution in the exome of mistranslating cell lines. The cell line that had more 
mutations was tRNASer(A) and the majority of mutations in our cells occurred in genes 
involved in mRNA binding and RNA polymerase II transcription. Also, genes annotated in 
categories such as cytoskeleton and endoplasmic reticulum accumulated mutations. We were 
able to identify genes that could be related to the phenotypes described in Chapter 2; such as 
the mutations that occur in HSF2 gene in tRNASer(A) and in tRNASer(L) cells and mutations in 
DNAJC14 gene in tRNASer(L) cells, or may explain adaptation; such as mutations in POLH 
and EIF3A genes in tRNASer(A) and tRNASer(S) cells, respectively. Nevertheless, how these 
mutations contribute to adaption to PSE remains to be clarified.  
Future studies involving sequencing of evolved and non-evolved single-cells would be 
extremely useful to reduce population heterogeneity and identify mutations that are relevant to 
adaptation to PSE.  
 
 
4.6 Materials and Methods  
4.6.1 Cell Culture  
 
Human embryonic kidney 293 (HEK293) were grown in Minimum Essential Medium 
(Gibco, Cat.41090-028) supplemented with 10% fetal bovine serum (FBS) (Sigma, 
Cat.F1051), 1% of Pen/Strep (Gibco, Cat.15070-063) and 1% of non-essential amino acids 
(Gibco, Cat.11140-050) in a humidified atmosphere at 37ºC in the presence of 5% CO2.  
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4.6.2 Evolution of cells in culture 
 
After transfection and plasmid selection, cells were kept in culture dishes (60mm) and 
subcultured ever 3 days using the same dilution (1/6) untill passage 30. Cell culture conditions 
were the same during evolution.  
 
 
4.6.3 Mistranslating cell lines used 
 
HEK293 cells stably transfected with an empty vector (Mock), and with the plasmid 
carrying tRNAserAGA(S), tRNA
Ser
AGC(A), tRNA
Ser
AAG(L) or tRNA
Ser
GTG(H) genes were used in 
this study in passage 30 (see Methods from Chapter 2).   
 
 
4.6.4 DNA Extraction  
 
Genomic DNA extraction was carried out using the Genomic-tip 100/G kit (Qiagen) 
according to manufacturer’s protocol. Quantification and quality assessment were performed 
using the Picogreen fluorescence bases quantification assay.  
 
 
4.6.5 Exome Capture Nimblegen v3 and Illumina sequencing  
 
Library preparation for exome sequencing was done using the capture kit “SeqCap EZ 
Human Exome Library v3” (Roche NimbleGen) that covers a total of 64 Mb. The insert size of 
the libraries was between 150 and 300 nucleotides. The initial DNA fragmentation was done 
using a Covaris S2 instrument. After library preparation, quality of libraries was checked using 
a capillary instrument, Bioanalyzer 2100(Agilent) to measure the size of the library and real 
time PCR to calculate its concentration. In order to load different libraries in the same lane of 
sequencing different adaptors were used (1-12).  
Libraries were sequenced using a HiSeq2000 instrument (Illumina) with paired end 
reads of 2x75pb read length. For each sample was generated more than 50 fold average 
coverage. More than 80% of the filtered reads had a quality value higher than Q30 (Phred 
score).  
Samples were sequenced in CNAG (Centre Nacional D’anàlisi Genòmica) in 
Barcelona in collaboration with Marta Gut, Mónica Bayés, Lídia Águeda and Sergi Beltran.  
Chapter 4 – Genome alterations of HEK293 mistranslating cells 
 
159 
 
4.6.6 Alignment and analysis of sequences 
 
After sequencing, images were acquired using Illumina Genome Analyzer Sequencing 
Control Software and analyzed. FASTQ files with base calls, quality metrics and read calls 
were generated. BWA (Burrows-Wheeler Aligner) software package was used for mapping 
sequences against the human reference genome (GRCh38) (301). SAMtools (Sequence 
Alignment/Map) was used for variant call and to generate VCF files (302). We also used 
PERL scripts developed in house and data stored in MySQL databases. For statistical analysis, 
we used the R software. Several quality criteria were applied during the analysis, but the final 
criteria to identify variants and annotated genes was: unique variants (defined by chromosome, 
coordinate and reference), variant quality (Q) ≥100, genotype quality (GQ) ≥90 and number of 
reads≥40. This was done to ensure the identification of high quality variants.  
Alignment of sequences and analysis was done by Patrícia Oliveira from 
IPATIMUP/I3S from Porto.  
 
 
4.6.7 Gene Ontology analysis 
 
Genes that presented variants with high quality (unique variants; defined by 
chromosome, coordinate and reference, variant quality (Q) ≥100, genotype quality (GQ) ≥90 
and number of reads≥40) were annotated using in GO categories using DAVID Bioinformatics 
Resources 6.7, an online database (254,255).  
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5.1 General Discussion 
 
Protein synthesis is essential for life and maintenance of its fidelity is critical. 
Although cells possess several mechanisms to ensure fidelity and proteome homeostasis, errors 
are an intrinsic characteristic of protein synthesis and destabilize the proteome (51). Many 
different studies have shown that protein synthesis errors (PSE) are associated with 
degenerative phenotypes and disease (32,69,86). Surprisingly, recent studies suggest that PSE 
may be also advantageous depending on environmental conditions and physiology 
(67,75,196,228).  
 In our study, we wanted to understand the long-term effects of PSE in human cells in 
culture, namely the cellular stress responses pathways that are activated and the connections 
between them. For this, we used mutant tRNAs that introduce random errors in the proteome 
and created five stable cell lines: Mock (control), tRNASer(S) (overexpressing the Wt tRNASer), 
tRNASer(A), tRNASer(L) and tRNASer(H) (Figure 2-1). This allowed us to create different 
proteome destabilization strategies to clarify if specific amino acid substitutions in proteins 
would produce different phenotypes. A previous study using similar Ser tRNAs transfected 
transiently into HEK293 cells showed severe alterations in cell death and activation of the UPS 
and UPR (165), suggesting that HEK293 cells or other types of human cells, could be 
important to understand the effects of PSE. Activation of the UPS and UPR were proportional 
to the severity of the errors being accumulated in the whole proteome, for example 
incorporation of Ser at isoleucine (Ile) codons sites strongly activated PQC, while 
incorporation of Ser at lysine (Lys) codon sites had a much lower impact on cells (165). In our 
study, we have observed that cells overexpressing the Wt tRNASer and mistranslating cell lines 
were also able to activate different PQC mechanisms, depending on the type of error 
introduced in the proteome (Figure 2-21).  
 Two of our cell lines, tRNASer(S) and tRNASer(A), activated the ATF6 branch of the 
UPR wich may explain their adaptation capacity to stress caused by PSE (Figure 2-18). When 
cells are under ER stress, ATF6 is cleaved and the cytosolic fragment (ATF6f) controls 
directly the expression of genes encoding ERAD components and XBP-1 (124). In addition, 
ATF6 has been associated with tolerance to chronic ER stress, since it leads to the expression 
of several genes that preserve ER function, including protein folding, protein degradation and 
maintenance of general ER homeostasis (303). In tRNASer(S) cell line, in P15, ATF6f levels 
increased (Figure 2-18 A) and consequently the expression of genes involved in protein folding 
(ERO1LB, PDIA4, DNAJC3, HYOU1, GRP94), protein trafficking/ER homeostasis (ATP2A2, 
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NUCB2) and biosynthesis (PDXK), among others, was upregulated (Figure 3-3 A). Recent 
studies suggest that activation of the ATF6 pathway could correct the aberrant ER proteostasis 
of pathologic destabilized protein mutants involved in protein misfolding diseases (304,305). 
For example, in HEK293 cells expressing Wt and mutant forms of the protein rhodopsin, 
ATF6f was able to significantly reduce abnormal rhodopsin aggregates, while the levels of Wt 
proteins were not affected (306). Increasing ATF6 activation  also attenuates aggregation of 
amyloidogenic proteins that can form extracellular aggregates (305). In tRNASer(S) and 
tRNASer(A) cell lines where ATF6f levels increased (Figure 2-18), there was accumulation of 
ubiquitinated proteins (Figure 2-11), but protein aggregates were not observed (Figure 2-10). 
Therefore, it is likely that activation of the ATF6 branch of the UPR, and the expression of 
targeted genes, was essential to maintain protein homeostasis and avoid the accumulation of 
aggregated proteins.  
The UPR branches can interact with each other. In ER stress situations the ATF6 
pathway can induce XBP1 expression, which can be spliced by IRE1α to induce transcription 
of ER chaperones and ERAD components (119). In addition, the unspliced XBP-1 (XBP-1u) 
can negatively regulate the XBP-1 spliced form (XBP-1s), benefiting cell survival (307). In 
tRNASer(S) cell line there was increased ATF6f (Figure 2-18) and XBP1u (Table 2-1). Whether 
XBP1u increased the level of the active transcription factor or induced a negative feedback is 
an important issue to address in future studies to clarify the importance of XBP-1 in adaptation 
of tRNASer(S) cells to PSE.  
Cells respond to various forms of stress by inhibiting or downregulating protein 
synthesis through phosphorylation of the translation initiation factor eIF2α. If the ER is 
exposed to stress, eIF2α is phosphorylated by PERK. The shutting down of protein synthesis, 
allows cells to recover from stress or result in cell death if the damage is beyond repair 
(308,309). Some mRNAs, such as ATF4 mRNA are efficiently translated when eIF2α is 
phosphorylated, through a mechanism that involves delayed translation re-initiation (310). 
Increased translation of ATF4 is required to increase the expression of genes that facilitate the 
adaptation of cells to stress (121,309). One of these genes encodes GADD34 that exerts a 
negative feedback loop by directly interacting with the catalytic subunit of type 1 protein 
serine/threonine phosphatase (PP1). Activation of PP1’s results in dephosphorylation of eIF2α 
allowing for translational recovery (311). In our tRNASer(A) cells, ER stress leads to 
downregulation of eIF2α-P (Figure 2-19 A), in P30, due to the upregulation of GADD34 
(Figure 2-20 A), exerting a protective effect by preventing shutdown of protein synthesis. 
Studies with GADD34 knockout mice showed that GADD34 promotes the recovery from 
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protein synthesis inhibition induced by ER stress leading to increased cell survival (312). Also, 
in cells expressing mutant huntingtin protein, overexpression of GADD34 increased cell 
viability and induced cytoprotective autophagy (313). In line with this, in our tRNASer(A) cells, 
ATG16L1, which encodes a protein component of a large complex essential for autophagy, was 
upregulated, from P15 to P30 (Table 2-1). 
The activation of PQC mechanisms was concomitant with decreased expression of the 
mutant tRNAs (Figure 2-3). We were not able to elucidate how tRNA expression decreased, 
but it is likely that their transcription was downregulated or, for some unknown reason, they 
were targeted to degradation. Changes in endogenous tRNA abundance are regulated by a 
translational program where tRNA expression profiles vary depending on the differentiation or 
proliferation status of cells (314). One of the pathways that may be involved in tRNA 
expression regulation is the mammalian target of rapamycin (mTOR), since it controls tRNA 
and ribosome biogenesis (315,316) by interacting with Maf1, a known repressor of Pol III 
transcription. Other regulators of Pol III include the tumor suppressors retinoblastoma protein 
and p53 (317,318). The role of these factors in the expression of the mutant tRNAs should be 
studied in the future.  
Since expression of our tRNAs imbalances the pool of serine tRNAs in the cell lines, it 
will be interesting to determine tRNAs levels during evolution. Indeed, expression of other 
serine tRNAs, that compete for the active site of SerRS, and other tRNAs that compete in the 
A-site of the ribosome with the mutant tRNAs carrying the correct amino acid (tRNAAGC
Ala; 
tRNAAAG
Leu and tRNAGTG
His) are likely to be affected. Upregulation of these tRNAs could be 
important to decrease the level of PSE and amino acids misincorporation. Breast cancer cells, 
not only overexpress tRNAs, but also perturb expression of isoacceptor tRNAs to optimize 
codon usage of tumor-promoting genes (158,316). Similarly, our mistranslating cells may be 
able to decrease mistranslation levels by adjusting tRNAs pool. In tRNASer(S) cells, 
overexpression of tRNASer (Figure 2-3) also leads to overexpression of several genes that 
encode aaRS, such as AlaRS, AspRS, GlyRS, IleRS, MetRS, TrpRS and TyrRS (Figure 3-3 
A), indicating that deregulation of a tRNASer also influences the expression of other 
components of the protein synthesis machinery. How alterations in aaRS expression can be 
involved in adaptation to PSE should be addressed in future studies, especially because aaRS 
can have several non-canonical functions, namely in signaling pathways (p53 and mTOR), 
immune response and translational control, and are associated with tumorigenesis (37,319). 
Whole-exome sequencing allowed us to identify several mutations that were present in 
evolved cell lines in P30. Although most variants found are modifiers (there is no evidence of 
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impact in proteins structure), some of them can be correlated with the phenotypes observed. 
For example, mutations in EIF3A gene in tRNA(S) cells (Table 4-8) can be associated with up 
regulation of cell proliferation genes (Figure 3-4 A) and increased proliferation (Figure 2-7 A) 
in P30. This gene codes for the largest subunit of eIF3, which binds to the 40S ribosome and 
promotes the loading of the ternary complex of Met-tRNA/eiF2-GTP, forming the 43S 
preinitiation complex and can also assist eIF4 to recruit mRNAs to this complex. The eIF3a 
subunit regulates various genes involved in DNA repair, proliferation, differentiation and cell 
cycle, and is overexpressed in breast, cervical, esophageal and lung cancers (320–322). In 
addition to these, two SNPs (rs10787899 and rs3824830) have been identified as risk factores 
for the development of breast and pancreas adenocarcinomas (323). Several genes involved in 
transcription had mutations in our cell lines. Two examples were MED23 (Table 4-7) and 
HSF2 (Table 4-6) genes in tRNA(L) cells. MED23 encodes a subunit of the Mediator complex 
that transduces regulatory information from transcription regulators to the RNA polymerase II 
apparatus, namely heat shock factors (HSF) mediated transcriptional activation (324,325). In 
stress conditions, trimerized HSF proteins bind to heat shock promoters and recruit MED23 to 
induce chaperones transcription by Pol II (325,326). Interestingly, another gene involved in 
induction of molecular chaperone transcription also had a mutation in this cell line, namely 
HSF2 gene. Although further investigations will be needed to clarify the role of these genes, 
the mutations detected are likely responsible for the downregulation of chaperones observed in 
tRNA(L) cell line. Even though mRNA levels of chaperones were not altered in our study 
(Chapter 3), we observed downregulation of protein levels of HSP27, HSP60 and HSP70 
(Chapter 2) in P30.   
Depending on the type of error introduced in the proteome of our cell lines, some 
interesting phenotypes were observed. The tRNASer(S) and tRNASer(A) cells had increased 
proliferation (Figure 2-7) accompanied by upregulation of genes involved in glycolysis 
(Chapter 3), showing high capacity to deal with PSE, while tRNASer(L) and tRNASer(H) cells, 
were not able to increase proliferation rate at the end of evolution and showed accumulation of 
protein aggregates and decreased proliferation in P15, respectively (Figure 2-21). In the case of 
tRNASer(S) cells, it is not surprinsing to observe these phenotypes since tRNA overexpression 
is frequently associated to proliferating phenotypes and serine tRNAs are the most 
overexpressed in breast tumors (158,314). tRNA imbalance can affect translation rate, fidelity 
and/or protein folding (327). In the case of cancer cells, overexpression of specific tRNAs can 
form “inducible” pathways with their direct target transcripts, enriched for their cognate 
codons, since these target transcripts can be more effectively translated (159). The tRNAs 
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carrying the amino acid Ser, might potentiate post-translational regulation of proteins involved 
in signal transduction, because Ser is a target for kinases and phosphatases, although the 
mechanism had been not identified (158). But, increase in the abundance of the tRNA pool 
may also accelerate elongation rate, compromising the folding of proteins, especially if there is 
an increase in low-abundance tRNAs. These tRNAs usually pair with slow-translating codons, 
thus facilitating co-translational folding (328).  
In general, translational errors can occur during the discrimination of the correct amino 
acid by aaRS or during decoding in the ribosomes (329). In the case of aaRSs, errors are more 
likely to occur between amino acids with similar structure, for example between Ser and Ala. 
Such errors are usually reduced by the aaRS editing mechanisms, leading to the hydrolysis of 
misactivated or mischarged amino acids, before or after atachement to the tRNAs (31,32,330). 
If an editing error occurs, for example in AlaRS, this synthetase can aminoacylate tRNAAla 
with Gly or Ser and these amino acids are incorporated into proteins in Ala sites (330,331). 
Therefore, in tRNASer(A) cell line, the expression of the mutant tRNAAGC
Ser, originates a type 
of error that is more likely to occur physiologically than Ser-for-Leu or Ser-for-His 
misincorporations, which are much more disruptive to the proteome and may influence cells 
phenotypes and adaptation.  
Previous work from our lab showed that, NIH3T3 mouse embryo fibroblast cells stably 
transfected with the Wt tRNASer (tRNAAGA
Ser) and a mutant tRNA that misincorporates Ser at 
Ala codons (tRNAAGC
Ser) were angiogenic and tumorigenic, in the chorioallantoid membrane 
assays (CAM) and nude mice (unpublished data, Annex E, Figure 2). Tumor analyses showed 
strong selection of the mutant tRNA expression suggesting that mistranslation is advantageous 
for tumor growth (unpublished data, Annex E, Figure 1 and 2). In fact, these cell lines could 
activate the UPR and cancer-associated pathways. Moreover, tumors derived from cells 
expressing the mutant tRNA showed low levels of phosphorylated eIF2α due to GADD34 
upregulation (unpublished data, Annex E, Figures 3-5). These results are consistent with our 
data in tRNASer(A) cell line (Chapter 2) and show that PSE are likely relevant in cancer. 
Deregulation of the protein synthesis machinery has been associated to cancer, but the 
mechanism by which these alterations may lead to disease are still poorly understood 
(16,161,332,333). One clue unveiled in this thesis is the increase in protein turnover that 
allows tRNASer(A) cells (Figures 2-9 and 2-12) to thrive and may be relevant in a cancer 
microenvironment. This was already reported in yeast cells with high PSE levels (196). But, 
this increase in protein turnover has an energetic cost that requires upregulation of glycolysis 
(Chapter 3).  
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The tRNASer(L) cells accumulated protein aggregates in P15, but not in P30 (Figure 2-
10). It was interesting that these cells could erase protein aggregates by activating PQC 
mechanisms. Another factor that may contribute to the dilution of protein aggregates may be 
cell division. A recent study showed that in cells that divide asymmetrically, such as S. 
cerevisiae, aggregated proteins are retained by the mother cell, through association with the 
mother-cell mitochondria. This asymmetric cell division results in an aging mother cell and a 
daughter cell free of aggregates and rejuvenated (334,335). Since dividing cells are able to 
erase protein aggregates, probably PSE and consequently accumulation of misfolded proteins 
can have different effects depending on the type of cells. Neurons, for instance, are probably 
not able to counteract PSE, in the same way dividing cells do, which will ultimately lead to cell 
death (69).  
Previous work and our study show that PSE may have important consequences to the 
biology of eukaryotic cells, but we still do not yet understand the full impact of PSE in the 
proteome. PSE rates have been determined using specific proteins and biochemical or genetic 
reporters (75,76,167,195,228), but these methods have several disadvantages because they only 
measure one type of error at a time and do not provide a global picture of the amino acid 
misincorporations tolerated by cells. Mass spectrometry has also been used to search for 
specific types of amino acids misincorporations (336). Recently, our group was able to detect 
Ser misincorporations using mass spectrometry, in mice tumors originated from NIH3T3 cells 
that expressed the mutant tRNAAGC
Ser, the same that we used in this work to create the 
tRNASer(A) cell line. In comparison with Mock (empty plasmid), this cell line had more 
misincorporations in the two codons that are decoded by the tRNAAGC
Ser (GCT and GCC) 
(unpublished data, Annex E, Supplementary Figure 3). This technique is being improved to 
detect misincorporations and is very promising, since it may allow to obtain a global view of 
PSE in human cells in different pathologies or physiological conditions.  
We have demonstrated that human cells can tolerate PSE in long term evolution 
experiments. Although the level of error was not quantified in our cell lines, we demonstrated 
that the mutant tRNAs were expressed and since previous studies showed that these tRNAs are 
fully functional in HEK293 cells (165,337), we are confident that the phenotypes described in 
this thesis represent cells responses to PSE.  
The main alterations detected in the different cell lines used in this thesis are 
summarized in Figure 5-1. All cell lines accumulated ubiquitinated proteins in P15, but not in 
P30, and tRNASer(L) was the only one that showed accumulation of protein aggregates. Two 
interesting mechanisms were identified in tRNASer(A) and tRNASer(L) cells that could explain 
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adaptation. In tRNASer(A) cells (physiological error) there was increased protein turnover and 
activation of UPR, namely increase in fragmented ATF6 and decreased phosphorylation of 
eIF2α by GADD34. In tRNASer(L) cells (non-physiological error) there was decreased protein 
synthesis rate due to the phosphorylation of eIF2α (Figure 5-1). At the transcriptional level, 
there was upregulation of genes involved in ER function and ER stress, and in some cases, 
pathways, such as glycolysis (Figure 5-1). Mutations in these cells occurred mainly in genes 
involved in RNA binding and transcription.  
Further investigations are needed to obtain a global picture of the underlying adaptation 
to PSE, but our study provides the first evolutionary view of human cell adaptation to different 
types of PSE.   
 
 
 
 
Figure 5-1. Summary of the main alterations detected during evolution of cells expressing the Wt 
tRNASer and mistranslating cell lines [adapted from Servier Medical Art image bank (338)].  
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5.2 Future Perspectives  
 
Our data unveiled several new issues that should be addressed and clarified in future 
studies.  
1) Quantification of Ser misincorporations at non-cogante sites in proteins. This issue 
should be addressed for each cell line at each passage. Mass spectrometry 
identification of proteins containing higher level of PSE, would help better 
understand the phenotypes of the mistranslating cell lines. 
2) Other cell or animal models should be used to identify common mechanisms of 
adaptation to PSE. Mutations in other tRNA isoacceptors and overexpression of 
other Wt tRNAs affecting different codons could help understand the diversity of 
stress responses to PSE. Overexpression of Wt tRNAs is very interesting and 
physiologically more relevant because alterations in the expression of protein 
synthesis components are usually associated with disease (159).  
3) It would be interesting to inhibit the proteasome and/or protein synthesis rate of 
tRNASer(A) cells and determine if such cells would accumulate protein aggregates. 
Also, understanding if protein turnover is important to overcome the effects of PSE 
would help understand adaptation to PSE. Since genes involved in glycolysis are 
upregulated, in this cell line, testing whether these cells have a higher glucose 
comsumption could reveal if adaptation to PSE requires higher ATP production. 
4) Validation of the deregulation of MAPK and p53 pathways and the consequences 
of the mutations found in EIF3A, MED23, HSF2 and other genes would help unveil 
the cellular networks that regulate proteotoxic stress induced by mistranslation.  
5) Quantification of amino acids misincorporations in different pathologies would 
help understand the biomedical relevance of the PSE phenomenon.  
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Annex B – List of genes with Transitions in mistranslating cell lines  
 
tRNASer(S) - PABPC1P5, ROS1, RP1-179P9.3, GPR6, CGB8, SASH1, RP11-236F9.2, CGB5, 
SLC25A14, PABPC1, CTB-60B18.17, CLUHP10, TRBV6-5, TRBV7-4, KRTAP9-9, RNU6-
55P, MBNL2, RNA5SP37, SNRPEP6, NDUFV2, RP11-21J18.1, NDUFV2-AS1, HDDC2, 
GJE1, RNU6-1239P, POTEM, CTD-2311B13.5, USP17L18, USP17L17, CDK19, DAB2IP, 
LCN1P2 
tRNASer(A) - CGB8, SASH1, CGB5, CTB-60B18.17, RP11-301A5.2, NKAIN2, UPK3BP1, 
DCBLD1, POTEE, ARID4A, RNU6-55P, C17orf98, SNRPEP6, TUBB8P10, FAM166AP5, 
RP11-96F8.1, RSU1P2, CUBNP3, RP11-285G1.15, IGHVII-1-1, RP11-747H12.5, RPL7AP34, 
PTP4A1, PRELID1P1, IL22RA2, ADAT2, MTRF1L, RP1-101K10.6, NDUFV2, RP11-21J18.1, 
NDUFV2-AS1, HDDC2, STAC, RWDD1, HSF2, RPL23AP50, RNU6-437P 
tRNASer(L) - ANKRD20A9P, RP1-163M9.7, POTEF, CDC27P1, ANKRD30BL, ARFGEF3, 
PBOV1, CLUHP10, TRBV6-5, TRBV7-4, UPK3BP1, ARID4A, TMEM183A, KRT16P1, RNU6-
55P, C17orf98, STAC, RWDD1, HSF2, LRRC10B, MIR4488, COLEC12, RP1-142L7.9, GJE1 
tRNASer(H) - PRB1, ADGRE5, PRB2, TNPO1P2, DYTN, ANKRD20A9P, GRK7, KRT31, 
CTB-60B18.17, CLUHP10, RP11-301A5.2, TRBV6-5, TRBV7-4, RP11-364B14.1, NECAP1, 
RNU6-537P, RP11-347H15.1, RP11-69M1.6, MAPK10, RP11-288H12.3, RP11-104G3.2, 
GLIDR, ABCD1, BCAP31, DNASE1L1, RPL10, XX-FW83563B9.5, TMEM183A, KRT16P1, 
RP11-23F23.3, RNU6-55P, MBNL2, RNA5SP37, C17orf98, SNRPEP6 
 
Annex C – List of genes with Transversions in mistranslating cell lines  
 
tRNASer(S) - OR8U1, VWF, FRG1GP, FANCD2, NBPF20, CTD-3157E16.2, PABPC3, 
FOXE1, MAN1A1, ZNF75D, RNU7-195P, NIFKP8, RBMX, SNAP91, PFN1P3, RP11-
1281K21.2, CBWD5, PPP1R14C, RP13-210D15.8, CSPG4P12, CHEK2 
tRNASer(A) - SIM1, PDXDC2P, KCNJ12, ZYG11B, FRG1GP, PSPC1P1, NBPF20, CTD-
3157E16.2, PCSK6-AS1, ZNF890P, RP11-419C5.2, CTB-109A12.1, ZC3H18, KLF3, SAMD5, 
MAN1A1, ADGB, ZNF75D, ZNRF2P2, RP11-419C5.3, ZNF676, SEPP1, C17orf53, BCRP2, 
KB-1592A4.15, TBX18, FRK, SHANK3, RPS13P2, PFN1P3, RP11-1281K21.2, CBWD5, 
IGKV1-8, RPL12P4, CTD-2366F13.2, RP3-335E1.1, STX7, ZC3H12D, PPP1R14C, RP13-
210D15.8, OR10AH1P, LSM1, RNU6-323P, NPM1P8 
tRNASer(L) - PDXDC2P, OR8U1, MZT1, ZNF441, HSPA8P8, CTD-2060L22.1, ITM2A, 
ETFA, TYRO3P, RP11-419C5.2, CTB-109A12.1, KHDRBS2, MAN1A1, ZNF75D, MED23, 
RNU7-195P, RP11-419C5.3, CTD-2561J22.2, CTD-2561J22.1, SEPP1, OPHN1, C17orf53, 
TTC39B, SUMO2P4, RPS13P2, PPP1R14C, RP13-210D15.8, NPM1P8, CDK17, RNU6-80P, 
MIR2113, RP11-436D23.1, HEY2, RP11-624M8.1, FBXO5 
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tRNASer(H) - ZNF774, CTBP2P4, KCNJ12, OR8U1, GABARAPL3, B3GNTL1, MAP4K4, 
TTLL12, PLXNA4, PARP12, ARR3, RAB41, PDZD11, PCSK6-AS1, ZNF890P, KHDRBS2, 
ZNF75D, RNU7-195P, PABPC1P5, SLC9B1P4, BPI, CTD-2308N23.2, SEPP1, PABPC1P9, 
BRAFP1, RNA5SP283, LINC01410, RP11-23F23.3, RPS13P2, PPP1R14C, RP13-210D15.8, 
OR10AH1P, LSM1, RNU6-323P, TSPO, RARRES2P1, AGGF1P3, RP11-489M13.2, CCNJL, 
RP11-826N14.1, ZNRF2P1 
Annex D – List of genes with Insertions in mistranslating cell lines  
 
tRNASer(S) - OLFM1, APP, DISP3, DENND2D, CHI3L2, RIIAD1, NANOS1, EIF3A, 
MRPL23, VEZT, LRRK1, MYOM1, ZNF805, CTC-444N24.8, LINC00461, WRN, PTPRD, 
MYSM1, MSH4, IFI44, RP4-641G12.3, PPP1R13B, ZFYVE21, MUC16, GNA12, AMZ1, 
STAU2, RP11-463D19.1, DNHD1, C12orf56, RPS11P6, ABCC13 
tRNASer(A) - SNRPC, CTBP2P1, MYSM1, DNHD1, C12orf56, RPS11P6, ABCC13, PADI6, 
ST6GALNAC3, STX6, RP11-46A10.5, RP11-46A10.8, FAM13C, STYK1, SNORD114-7, 
SNORD114-10, SNORD114-11, SNORD114-9, SNORD114-13, SNORD114-12, SNHG23, 
ALOX15, DNAH2, SPACA3, MPND, AC007292.3, AC007292.4, EIF1P6, ALK, CLIP4, 
PDCL3, CST1, SH3BGR, TMPRSS2, TMEM110, TMEM110-MUSTN1, MIR8064, RP11-
894J14.2, CRYBG3, NUP54, TCERG1, GPR151, OFCC1, RP11-23J9.4, CCDC180, PSMD9, 
WDR66, RP11-87C12.2, FN3KRP, RP11-388C12.1, AC024361.1, LRP5L, CTA-246H3.11, 
L3MBTL2, RP4-756G23.5, ZNF717, MIR4273, RTN4, EML6 
tRNASer(L) - MYSM1, ABCC13, PSMD9, WDR66, RP11-87C12.2, FN3KRP, RP11-388C12.1, 
AC024361.1, LRP5L, CTA-246H3.11, L3MBTL2, RP4-756G23.5, ZNF717, MIR4273, A2ML1, 
RP11-259O18.5, CIDEB, NOP9, DHRS1, SAMD4A, MYH10, NDEL1, NEB, CXADR, 
AP000345.1, TRIOBP, TRNT1, IL5RA, PDHB, PXK, RP11-802O23.3, NKD2, LYSMD3, 
POLR3G, TSPYL1, DSE, RP1-93H18.1, ADAM9, NOL6, MIR6851, ORMDL2, DNAJC14, 
SARNP, RP11-762I7.5, CST2 
tRNASer(H) - CPT1A, OLFM1, MSH4, IFI44, RP4-641G12.3, PPP1R13B, ZFYVE21, 
MUC16, GNA12, AMZ1, STAU2, RP11-463D19.1, ABCC13, RTN4, EML6, ORMDL2, 
DNAJC14, SARNP, RP11-762I7.5, CST2, NVL, ART1, ART5, TRPC2, OR9G4, OR9G3P, 
RP11-100N3.2, MIR6128, KCNA6, GALNT8, RP11-234B24.4, OR7E47P, RP1-288H2.2, CIT, 
TDRD3, KHNYN, SDR39U1, AQR, RP11-83J16.1, ARIH1, RP11-1006G14.4, BLM, SLC5A11, 
RTTN, KIAA2012, DGKD, RNF114, ISY1, ISY1-RAB43, PRKAA1, STEAP2 
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Abstract 
The upregulation of protein synthesis, deregulation of tRNA expression and amino acid 
starvation are common features of human cancer. The occurrence of any of these mechanisms, 
or their concomitance, raises the hypothesis that translational fidelity is compromised in tumors. 
However, little is known about the relevance of protein synthesis errors (mistranslation) in 
cancer initiation and development. To clarify this issue, we expressed mutant tRNAs that 
misincorporate amino acids in non-cognate codons in mouse NIH3T3 cells and assessed their 
tumorigenic capacity in vitro and in vivo. These tRNAs were well tolerated, but in transformed 
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cells, stimulated angiogenesis and produced fast growing tumors in mice. Their expression 
increased sharply during tumor development, highlighting unanticipated advantages of mutant 
tRNAs in cancer growth. Since mistranslation diversifies the proteome, produces high 
phenotypic variation and drug resistance in various eukaryotic cell models, we postulate that 
tRNA decoding adds an important layer of complexity to tumor characterization. 
 
Significance Statement: Increased rate of protein synthesis is normally associated with cell 
proliferation and cancer. In this study, we go beyond classical translational regulation studies to 
show important mRNA mistranslation effects on tumor growth, activation of the unfolded 
protein response and cancer signaling pathways in mice. Since protein synthesis errors diversify 
the proteome, produce cell population heterogeneity and genome instability, our work highlights 
unanticipated roles of tRNA misreading in tumor heterogeneity and evolution. 
 
Introduction  
Cancer is a multifactorial disease driven by accumulation of DNA mutations, 
chromosomal aberrations and epigenetic alterations (1). Transcriptional, post-transcriptional and 
translational deregulation is also well established; however little is known about the contribution 
of protein synthesis errors to tumor initiation and growth. Eukaryotic cells translate mRNAs 
(messenger RNAs) with basal error levels of 10−3 to 10−4 amino acid misincorporations per 
codon, after protein quality control (PQC) (2,3). Cells cope relatively well with this level of 
aberrant protein synthesis and it is unclear (controversial) whether such errors play any role in 
cell degeneration, aging or disease (4–7). Recent reports show, however, that small increase in 
translational errors leads to accumulation of misfolded proteins (4,8–10), saturation of PQC, 
proteotoxic stress, re-wiring of chaperone-clients interaction networks, and wide deregulation of 
cellular functions (9). Since translational fidelity depends mainly on tight regulation of tRNAs, 
aminoacyl-tRNA synthetases (aaRSs), RNA modifying enzymes, translation elongation factors, 
ribosome function and amino acid supply (11), we hypothesize that the deregulation of these 
translational factors in tumors (12–19) has profound effects on cancer biology and etiopathology. 
Indeed, aaRS are normally upregulated to sustain the high rate of protein synthesis and cell 
proliferation in tumors (20). Although the available methods for tRNA prediction assign the 
tRNA identity solely based on the anticodon, making it difficult to detect mutations in the 
anticodon, there are already some reports associating mitochondrial tRNA mutations with cancer 
(21–23).  
Activation of the unfolded protein response (UPR) is consistent with deregulation of 
tRNA expression, and processing, amino acid starvation and aberrant protein synthesis (24–27). 
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Mistranslated proteins sequester BiP, activate the UPR sensors PERK, IRE-1 and ATF6 and 
upregulate molecular chaperones and the ubiquitin-proteasome system (24). Tumor cells 
highjack these endoplasmic reticulum (ER) adaptive measures to thrive (28), explaining, at least 
in part, the UPR association with malignancy and aggressiveness of several types of cancer (29–
31). 
With this work, we aimed at disentangling the role of mRNA mistranslation from other 
protein synthesis and protein quality control confounding effects. Our main objective was to 
clarify if mistranslation alone is sufficient to sustain cell transformation, tumor growth and UPR 
activation. Geslain et al. developed a method for inducing protein synthesis errors using mutant 
tRNAs that introduce serine (Ser) in non-cognate codons in transiently transfected human cells 
(32). Taking advantage of this model, we constructed mutant tRNAs that misincorporate Ser at 
alanine (Ala) and leucine (Leu) codons, and stably expressed them in the near-normal NIH3T3 
cell line. We also created a cell line that expresses the normal Ser tRNA to see alterations caused 
by tRNA pool deregulation. In our model, there were no visible effects on cell viability, but cell 
transformation, angiogenesis, tumor growth, activation of the UPR and other cancer-related 
pathways, were clearly visible. Remarkably, expression of the mutant tRNAs was sharply 
selected in tumors, indicating that some types of mistranslation might be advantageous during 
tumor growth. 
 
Results 
 
Mistranslation in mammalian cell lines 
 
The construction of mutant tRNAs that misincorporate Ser at Ala-GCU,GCC 
(tRNASer(Ala)), and Leu-CUU,CUC (tRNASerLeu) codons (Fig.1A, left panel) was possible due 
to the inability of the seryl-tRNA synthetase (SerRS) to recognize the anticodon of tRNASerAGA, 
i.e., introduction of mutations in this structural domain do not interfere with serylation (32,33). 
Those anticodons were chosen to test putative phenotypic diversity arising from Ser 
misincorporation at chemically distinct protein sites. Mutant tRNA genes and the Wt tRNASer 
(tRNASerAGA) were cloned into the pIRES2-DsRed and transfected into NIH3T3 cells. Cell lines 
stably expressing these tRNAs were then selected for phenotypic characterization (Fig.1A, right 
panel). Cells transfected with the empty vector (Mock) was used as a control. Transfection 
efficiency was determined by Real-Time PCR, using the pIRES2 DsRed gene as a readout probe. 
The data showed 100% efficiency for all cell lines but the tRNASer(Leu) cell line, where 72% 
efficiency was observed. 
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The incorporation of the mutant tRNA genes in the transfected cells was confirmed by 
Polymerase Chain Reaction (PCR) and Sanger DNA sequencing of genomic DNA samples 
extracted from the selected cell lines (Fig. S1A). tRNA expression was determined using a 
primer extension assay (SNaPshot analysis) that detected each mutant tRNA and the endogenous 
copies of the tRNASer gene (n=12 genes). The cellular level of the endogenous tRNASer was 19.4-
fold higher than the mutant tRNAAGC
Ser(Ala) and 49.5-fold higher than the tRNAAAG
Ser(Leu) 
(Fig.1B). This low expression level was expected to influence cell behavior, as previous reports 
showed that modest deregulation of  endogenous tRNAs is sufficient to produce phenotypic 
effects in mammalian cells (17). 
 
Cellular consequences of mRNA mistranslation  
 
We used cell viability, proliferation and apoptosis assays to evaluate the phenotypic 
consequences of the mutant tRNAs and misexpression of Wt tRNASer. Trypan Blue staining 
showed no impact on viability (Fig.S1B) and the Annexin V Apoptosis assay showed a basal 
necrosis level (≤1% of cells) and low percentage of cells in late (ca. 5% of cells) and early 
apoptosis (7-8% of cells) (Fig.1C). Cell proliferation was also not significantly affected 
(Fig.S1C) and cell cycle progression demonstrated a similar pattern in all cell lines (Fig.S1D). 
These data suggested that NIH3T3 cells are highly tolerant to the mutant tRNAs and 
misexpression of Wt tRNASer, however there seems to be an effect on cell transformation, as 
measured by the foci formation assay. Mutant tRNA expressing cell lines produced more foci 
than the negative control cells (Mock) (Fig.1D), suggesting that mutant tRNAs were able to 
transform NIH3T3 cells. 
 
Effect of mutant tRNAs and misexpression of Wt tRNASer in tumor formation in vivo 
 
 To clarify whether mutant tRNAs or the misexpression of Wt tRNASer could induce 
angiogenesis and tumorigenesis in vivo, we used the chick chorioallantoic membrane assay 
(CAM). Only tRNASer(Ala) cells, produced larger tumors and had stronger angiogenic response 
in the CAM assay (Fig.2A). These results were further confirmed by inoculating cells expressing 
K-rasV12, the mutant tRNAs (tRNASer(Ala) or tRNASer(Leu)) or misexpressing the Wt tRNASer 
(tRNASer(WT)), on the left dorsal flank of at least five mice (for each cell line) and control cells 
(Mock) on the corresponding right dorsal flank of every mice. Within 14 to 21 days post-
inoculation (p.i.), tumors were produced by cells expressing K-rasV12 (5/5 mice), tRNASer(Ala) 
(6/6 mice) and tRNASer(Leu) (5/5 mice) (Fig.2B, upper panel). At day 27 p.i., 12/21 (57.1%) 
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mice inoculated with Mock cells and 5/5 mice inoculated with tRNASer(WT) cells developed 
small similar size tumors. At this stage, tumors produced by cells expressing tRNASer(Ala) were 
the largest. At day 31 p.i., the experiment was terminated. tRNASer(Ala) and K-rasV12 tumors 
were similar in size distribution and were different from Mock tumors (p<0.01) (Fig.2B, upper 
and middle panel). 
Histological characterization of resected tumors unveiled high grade sarcomas with high 
proliferative index, as determined by Ki67 labeling (Fig.2B, lower panel, Fig.S2C). 
Histopathological analysis of murine organs (ganglion, lung, kidney, liver, bladder, pleura and 
stomach), collected at day 31 p.i., revealed the presence of lung metastases in K-rasV12 expressing 
tumors, and no metastases in all other mice. Therefore, the expression of mutant tRNA in 
tRNASer(Ala) cells accelerated tumor growth, in agreement with the CAM assay results, but Ser 
misincorpoartion at Leu codons and misexpression of tRNASer also induced formation of smaller 
tumors. 
DNA extracted from tumors, from both CAM and mice experiments, were sequenced 
and genomic incorporation of all plasmids was validated (Fig.S2A,B). tRNA expression in mice 
tumors was determined using the primer extension assay described above. Surprisingly, 
expression levels of mutant tRNAs were much higher in tumors than in the corresponding cell 
lines, i.e., 8 and 8.4 fold higher for the tRNASer(Ala) and tRNASer(Leu), respectively (Fig.2C). 
In other words, the mutant tRNAs were advantageous for tumor development (Fig.1B,2C). 
We analysed the Soluble (SF) and Insoluble Fraction (IF) of proteins from tumors derived from 
our cell lines to confirm misincorporations by Mass Spectrometry. Overall, we detected more 
proteins with misincorporations (AlaSer and LeuSer) in the SF of tumor proteins. Both in 
SF and IF, tRNASer(Ala) derived tumor presented more distinct proteins with misincorporations 
than the rest of the tumors (Fig. S3A). We further investigated whether the misincorporations 
detected corresponded to the anticodons of our tRNAs. In the IF, the misincorporations detected 
did not correspond to our tRNAs, occurring randomly in Ala or Leu codons. However, in the 
SF, there was increased incorporation of Ser at Ala sites in the tRNASer(Ala) cells (Fig. S3B). 
This proves that our mutant tRNA is being recruited by the ribosome and that it is able to induce 
incorporation of Ser at the correspondent Ala sites (GCC and GCU). Using this approach, we 
could not detect an increase of LeuSer misincorporations. Since this misincorporation disrupts 
protein conformation, probably proteins that are being formed are also being degraded by the 
proteasome or autophagy, being this misincorporation difficult to detect. 
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Impact of mutant tRNAs and misexpression of Wt tRNASer in the UPR 
 
Since the UPR is frequently activated, highly relevant in cancer and an end point of 
protein mistranslation (34), we have tested whether it was also activated in our model. For this, 
we have monitored biomarkers of the three UPR branches, namely IRE-1, PERK and ATF6. 
Activation of the IRE-1 pathway was determined by measuring splicing levels of the XBP-1 
transcription factor, using RT-PCR. Comparing to Mock tumors, its activation was increased 7% 
and 14% in tRNASer(Ala) and tRNASer(Leu) tumors, respectively (Fig.S4). tRNASer(Ala) and 
tRNASer tumors showed higher levels of ATF6 activation than Mock tumors (3.1- and 2.15-fold, 
respectively) (Fig.3A,C). We next assessed the phosphorylation status of eIF2α, the downstream 
target of PERK, to clarify whether these tRNAs affected translation initiation rate. The levels of 
eIF2α-P (the inactive form of eIF2α) were 77% lower in tRNASer(Ala) tumors, comparing to 
Mock, and did not change in other tumors (Fig.3B,C). This raised the hypothesis that PERK 
could be downregulated or, alternatively, the regulatory subunit of the PP1 phosphatase 
GADD34 could be upregulated. Western blot analysis showed 6-fold upregulation of GADD34 
(Fig.3B,C), confirming that the fast growth rate of tRNASer(Ala) tumors was likely due to 
upregulation of protein synthesis through dephosphorylation eIF2α by the GADD34-PP1 
complex. 
 
The effect of misreading tRNAs in cancer-associated signaling pathways 
 
Serine, threonine and tyrosine tRNAs are among the most overexpressed tRNAs in breast 
cancer (16). Since these amino acids can be phosphorylated, their misincorporation at non-
cognate sites may cause aberrant phosphorylation and alteration of signaling transduction 
pathways (16). This lead us to hypothesize that Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt 
signaling pathways could be affected in our model system, promoting unrestrained cellular 
growth, proliferation and tumor formation (35). Indeed, global serine phosphorylation was 
increased in tRNASer(Ala) and tRNASer(Leu) tumors (1.53 and 1.71 fold, respectively) (Fig.4A), 
confirming that cell signaling could be deregulated. We then analyzed the activation of Akt, 
ERK1/2 and p38 in the same tumors and observed activation of the Akt pathway in all of our 
tumors (Fig.4B), and downregulation of the ERK1 (64%) and ERK2 (54%) pathways in 
tRNASer(Leu) tumors (Fig.S5A,C). p38 was downregulated 82% in tRNASer(WT) relative to 
Mock, but was unchanged in the other tumors (Fig.S4B,C). Therefore, tumorigenesis induced 
by mutant tRNAs and misexpression of tRNASer is likely associated with activation of the Akt 
pathway, while growth rate differences between tumors could be linked to differential activation 
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of ERK1/2. 
 
Microenvironment effects in mistranslation outcomes  
 
Since the expression of mutant tRNAs and misexpression of tRNASer were highly 
tolerated and did not activate the UPR or cancer-associated pathways in vitro (data not shown), 
we reasoned that external stimuli would be necessary to expose the phenotypes observed in vivo. 
To clarify this issue, we treated cell lines expressing Mock, tRNASer and the mutant tRNAs with 
the pro-inflammatory tumor necrosis factor alpha (TNF-α) for 30 min and 4 hours, and used Akt 
and p38 phosphorylation as phenotypic readouts (Akt-P/Akt and p38-P/p38) (Fig.5 and S6). The 
p38 pathway was activated in tRNASer(Leu) cells after 30 minutes and persisted up to 4 hours of 
exposure (3.43 and 2.1-fold change, respectively). A slight activation was also observed in 
tRNASer(Ala) cells at 30 minutes, but was lost after 4h (Fig.5). The Akt pathway was only 
significantly activated in tRNASer(Ala) cells after 30 minutes (2.6-fold change) (Fig.5A). Despite 
the lack of complete data overlap between tumors and cell lines, these responses indicated that 
the microenvironment is crucial for tRNA mediated activation of cancer-related pathways and 
tumorigenesis. 
  
Discussion 
 
Imbalance of tRNA pools promotes the formation of non-cognate tRNA-aaRS pairs 
leading to tRNA mischarging (36). Pavon et al. reported an increase of certain tRNAs associated 
with malignant phenotypes and Gingold et al. reported enrichment of tRNAs required for the 
fast and accurate translation of proliferation associated genes in cancer (16,17,37). These studies 
support the role of protein synthesis regulation and translational fidelity effects in tumors. 
Moreover, mistranslation has clear impact on proteome and phenotypic diversification, drug 
tolerance and resistance in other biological models (7,38), suggesting that it may interfere with 
tumor growth, heterogeneity and response to therapy. To disentangle protein synthesis rate and 
regulation from mRNA mistranslation effects on cancer, we have expressed several mutant 
tRNAs and misexpress the Wt tRNASer in near-normal NIH3T3 cells. Such tRNAs were tolerated 
in vitro and did not produce visible effects on cell viability, apoptosis, proliferation and cell cycle 
progression, contrary to previous reports using transient models, but promoted angiogenesis and 
tumor growth in vivo (32). In particular, tRNASer(Ala) cells, produced tumors that grew as fast 
as K-rasV12 tumors. Previous studies have shown that Ser misincorporation at Ala codon sites, 
arising from a single mutation that prevents Ser vs Ala discrimination by the editing site of the 
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AlaRS, induces rapid loss of purkinge cells, ataxia and premature death in mice (39). These 
apparently contradictory phenotypic outcomes suggest that mistranslation effects are cell type 
dependent, i.e., mistranslation in purkinge cells leads to apoptosis while in other cells leads to 
transformation and neoplasia. Indeed, the higher expression of mutant tRNAs in our mice tumors 
(Fig.2C), compared to the levels detected in cell lines (Fig.1B) indicates that mistranslation is 
adaptive in tumor contexts. Our group has previously shown that mistranslation in yeast 
increases tolerance to stress and allows for growth in presence of lethal doses of drugs and 
chemicals (40,41). These yeast cells also adapt very fast to mistranslation by altering genomic 
architecture, increasing protein synthesis, protein degradation and glucose uptake (10). Thus, the 
deleterious effects of mutant tRNA expression are rapidly mitigated through genomic, metabolic 
and proteomic changes, allowing mistranslating cells to thrive in specific microenvironments. 
The tRNASer(Ala) expressing tumors showed low levels of eIF2α-P, due to GADD34 
upregulation and activation of cancer-associated pathways. This is highly relevant since 
decreased levels of eIF2α-P are sufficient to trigger NIH3T3 transformation (42). ATF6 and 
IRE-1 activation have also been documented in tumors (30,43), where the former is associated 
with cellular protection and growth (44). Furthermore, UPR coupled with induced tumor 
dormancy protects neoplasic cells from apoptosis and permits recurrence once favorable growth 
conditions are restored (45). Microenvironment signaling may also be responsible for 
accentuating this phenotype when cells are inoculated, allowing them to adapt and thrive. It is 
well established that tumor development needs genetic and epigenetic changes as well as 
cooperation of microenvironment components to promote adaptation and growth (46). Common 
adaptive responses include enhanced plasticity, cell motility, resistance to apoptosis and survival 
in hostile environments characterized by hypoxia, acidity, amino acid deprivation, inflammatory 
cytokines delivery, and induction of the UPR (47,48). Importantly, PERK activity and eIF2α-P 
levels are reduced in mouse breast tumors, where Akt is activated, and in cells exposed to ER or 
oxidative stress (49). In line with these results, tumors expressing mutant tRNAs showed 
concomitant activation of the Akt pathway, low levels of eIF2α-P and UPR induction. We 
postulate that this conjugation of factors may drive apoptosis evasion, cell survival and potentiate 
tumor growth (Fig.6). 
Although remarkable progress is being made on the elucidation of the molecular basis 
of cancer, the etiology of most cancers is still unknown. In the past few years, new molecular 
links between cancer and translation deregulation have been unraveled, highlighting this setting 
as etiopathogenic (50). Our model supports this link by disclosing that mutant tRNAs are 
upregulated and selected for in tumors and are sufficient to promote fast tumor growth. Since 
mistranslation leads to random amino acid misincorporation into proteins, producing highly 
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heterogeneous and unstable proteomes, the tumor mistranslation landscape, and the effects of 
proteome alterations on tumor heterogeneity and resistance to anti-cancer drugs will be 
fascinating future avenues of research. 
 
Methods 
 
Experimental procedures are briefly described here and detailed description is provided 
in SI text. A DNA fragment of the gene encoding human tRNAAGA
Ser (Chr6 tRNA#5) and its 
flanking region was amplified by PCR from genomic DNA and cloned into the vector pIRES2-
DsRed. Site-directed mutagenesis was performed to change the anticodon of tRNAAGA
Ser to other 
anticodons. A mouse Embryo Fibroblast cell line (NIH3T3) (American Type Culture Collection) 
was transfected with 1µg DNA plasmid using Lipofectamine 2000 (Invitrogen), following 
manufacturer’s instructions. Stably transfected cell lines were established with 1000µg/ml G418 
for 1 month. Cells were transfected with the empty vector (Mock), the plasmid with the wild-
type tRNASer(WT) and the mutant tRNAAGC
Ser(Ala) and tRNAAAG
Ser(Leu). To confirm the 
expression of mutant tRNAs in cell lines and tumors we amplified the cDNA of interest by PCR. 
PCR products were analyzed on 2% agarose gels and bands were excised and purified using 
Ilustra™ GFX™ PCR DNA and Gel Band purification Kit (GE). SNaPshot reactions were 
performed using SNaPshot Multiplex Ready Reaction Mix (Applied Biosystems). Samples were 
then sequenced and analyzed using Peak Scanner software (Applied Biosystems). To access the 
tumorigenic ability of Mock, tRNASer(WT), tRNASer(Ala) and tRNASer(Leu) cells, the chicken 
embryo chorioallantoic membrane (CAM) model and tumor induction assay in mice were 
preformed. Two rings were placed in each CAM, one was filed with Mock cell suspension and 
the other with tRNA transfected cells (1x106 cells). After 3 days, the CAM was excised, 
photographed ex ovo in a stereoscope at 20x magnification (Olympus SZX16, DP71 camera). 
The number of new vessels was counted and tumor area was determined using Cell^A Olympus 
program. Regarding the mice, 6-8 weeks-old male nude mice were used for in vivo experiments, 
in accordance with the Guidelines for the Care and Use of Laboratory Animals, directive 
2010/63/EU. Each mouse was injected in the right flank with Mock cells and in the left flank 
with tRNASer(WT), tRNASer(Ala) and tRNASer(Leu) cells. Mice were weighted and tumor width 
and length were measured. Tumor volumes were calculated assuming ellipsoid growth patterns. 
Regarding the Mass Spectrometry approach, complete lanes were cut of SDS-PAGE gels, 
destained with 25 mM ammonium bicarbonate/50% acetonitrile and dried under vacuum 
(SpeedVac®, Thermo Savant, USA). The dried gel pieces were rehydrated with 10 µg/mL 
trypsin (Promega V5111) and digested overnight at 37 °C. Tryptic peptides were extracted from 
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the gel with 10% formic acid/ 50% acetonitrile and were then dried under vacuum. Separation 
of tryptic peptides by nano-HPLC was performed on the module separation Proexeon EASY-
nLC 1000 from Thermo equipped with a 50-cm EASY C18 column with particle size 2-µm.  
Each sample was separated over a gradient of 5-32 % ACN in 90 at 250 nl/min. Peptide cations 
were converted to gas-phase ions by electrospray ionization and analyzed on a Thermo Orbitrap 
Fusion Lumos. Precursor scans were performed from 300 to 1,500 m/z at 120K resolution (at 
445 m/z) using a 1 x 105 AGC target. Precursors selected for tandem MS were isolated at 1 Th 
with the quadrupole, fragmented by HCD with normalized collision energy of 30, and analyzed 
using rapid scan in the ion trap. The maximum injection time for MS2 analysis was 50 ms, with 
an AGC target of 1 x 104. Precursors with a charge state of 2-5 were sampled for MS2. Dynamic 
exclusion time was set at 60 seconds, with a 5ppm tolerance around the selected precursor. The 
raw files were searched directly against the Mus musculus database using PatternLab (Version 
4.0.0.48). Search criteria included a static modification of +57.0214 Da on cysteine residues, 
variable modification of +15.9949 Da on oxidized methionine, +15.994915 on Ala and -
26.052036 on Ile/Leu.  
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Figures:  
 
 
 
Figure 1. Schematic model and in vitro phenotypic effects of mutant tRNAs. A) Schematic model. 
Domains highlighted in grey are important for tRNASer recognition by SerRS. Left panel) The human 
tRNAAGASer gene (Chr6 tRNA#5), was cloned into pIRES2-DsRed plasmid and mutant constructs were 
generated by site-directed mutagenesis (green: Ala(AGC) and red: Leu(AAG)). Right panel) Serylated mutant 
tRNAs misincorporate Ser at the non-cognate codons indicated.  B) Expression of mutant tRNAs on stably 
expressing cells was confirmed using SNaPshot. Samples were sequenced and analyzed using Peak Scanner 
software. The endogenous copies of tRNASer were 32 and 49.5-fold more expressed then the mutant tRNAs in 
tRNASer(Ala) and tRNASer(Leu) cells, respectively. Grey: Non-mutated tRNASer; Black: mutant tRNAs. C) 
Percentage of cells in necrosis, late and early apoptosis were determined by flow cytometry using AnnexinV-
FITC (1:100) and Propidium iodide (2.5µg/ml) staining. D) The number of foci arising from NIH3T3 cells was 
counted after 13-21 days after transfection. Data represents average ± SEM (n=2-3) and was analyzed using 
One-way ANOVA followed by Dunnett’s using Mock cell line as control. There are no significant differences 
among cell lines (p˃0.05).  
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Figure 2. Impact of mistranslation on angiogenesis and tumor formation in vivo. A) CAM assay. 
Upper panel) Representative images of tumors and vessels produced by Mock, tRNASer(WT), tRNASer(Ala) 
and tRNASer(Leu) cell lines. Lower panel, left) Quantitative evaluation of new vessels’ formation. Lower 
panel, right) Relative tumor area. Data represents percentage relative to Mock. Graphics depict average ± 
SEM (n=12-14). Data was analyzed using two-tailed paired Student’s t test (*p˂0.05; **p<0.01). B) 
Tumorigenic capacity of mistranslating cells in mice. Upper panel) Kinetics of tumor growth determined after 
inoculation of Mock, tRNASer(WT), tRNASer(Ala) and tRNASer(Leu) cells and K-rasV12 expressing cells 
(positive control). Middle panel) Quantitative evaluation of tumor area at 31 days p.i.. Graphics depict the 
average ± SEM (n=5-10). Data was analyzed using One-way ANOVA followed by Dunnett’s (**p˂0.01; 
***p<0.001). Lower panel) Photographs of representative tumors, H&E and Ki67 staining (40x amplification) 
from each condition. C) Expression of tRNASer and mutant tRNAs in mice tumors measured by SNaPshot. 
Samples were sequenced and analyzed using Peak Scanner software. Expression of the mutant tRNAs in 
tRNASer(Ala) and tRNASer(Leu) cells were 4 and 5.9-fold lower than the endogenous tRNASer, respectively. 
Grey: Non-mutated tRNASer; Black: Mutant tRNASer. 
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Figure 3. Activation of the UPR in vivo. A) Activation of ATF6 in tumors harboring the wild-type 
and mutant tRNAs. Total ATF6 and ATF6 fragment were detected by immunoblotting. B) eIF2α-P and 
GADD34 levels in each tumor lysate were analyzed by immunoblotting and relative expression values are 
shown. β-tubulin was used as loading control. C) Representative immunoblots for total ATF6, ATF6 fragment, 
total eiF2α, eIF2α-P, GADD34 and β-tubulin for each membrane. Graphics depict average ± SEM (n=3). Data 
was analyzed using One-way ANOVA followed by Dunnett’s and significant p-values are shown (*p˂0.05; 
***p<0.001).  
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Figure 4. Classical cancer-associated pathways activated in mice tumors. A) Evaluation of total phosphoserine 
levels in tissue lysates from mice tumors. B) Relative activation ratio of Akt in tumor lysates compared to the 
Mock and representative immunoblots of Akt-P, total Akt and β-tubulin (loading control) from tumor lysates. 
Graphics depict average ± SEM (n=3). Data was analyzed using One-way ANOVA followed by Dunnett’s and 
significant p-values are shown (*p˂0.05; **p<0.01).  
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Figure 5. Pathways activated by TNFα induction. A) Treatment of cells misexpressing the Wt tRNASer 
and expressing mutant tRNAs with TNFα (30ng/ml) for 30 minutes. Upper panel) Relative activation ratios 
of p38 in cell lines exposed to TNFα. Middle pannel) Relative activation ratios of Akt in cell lines exposed to 
TNFα. Lower panel) Representative immunoblots of p38-P, total p38, Akt-P and total Akt in cell lines. β-
tubulin was used as a loading control. B) Treatment of cells misexpressing the Wt tRNASer and expressing 
mutant tRNAs with TNFα (30ng/ml) for 4 hours. Upper panel) Relative activation ratios of p38 in cell lines 
exposed to TNFα. Middle panel) Relative activation ratios of Akt in cell lines exposed to TNFα. Lower panel) 
Representative Immunoblots of p38-P, total p38, Akt-P and total Akt in cells lines. β-tubulin was used as a 
loading control. Data represents average ± SEM (n=3), was analyzed using One-way ANOVA followed by 
Dunnett’s and relevant p-values are displayed (*p˂0.05; **p<0.01).  
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Figure 6. Representation of the stress response induced by mutant tRNAs and tRNASer misexpression. 
The expression of these tRNAs in NIH3T3 cells in combination with microenvironment stimuli in vivo induces 
ER stress and activation of the Akt pathway. These events lead to UPR activation, increasing cell capacity to 
survive, evade apoptosis and increased protein synthesis rate, especially in tRNASer(Ala) cells where eIF2α-P 
is downregulated due to GADD34 overexpression. Overall these molecular mechanisms culminate in tumor 
growth. Adapted from Servier Medical Art collection (http://www.servier.com).  
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Supplementary Figures:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Integration of pIRES2-DsRed and exogenous tRNAs in NIH3T3 cells and 
its phenotypic effects. A) Agarose gel (1%) of the PCR product obtained by amplification of genomic DNA 
from cell lines across the fragment of pIRES2-DsRed plasmid containing the tRNA insert. NTC represents the 
negative control. This is a cropped figure. NTC was at the end of the gel and there were three more samples 
which were excluded from the paper. (B) To access the cell viability, cells were grown for 48h and then stained 
with Trypan blue (0.4%). Number of viable cells was then registered and normalized to the Mock cell line. (C) 
To check if there were differences in proliferation, stable cell lines were grown in 10 mm cover slips for 48h 
and incubated with BrdU for 1h. Cover slips were incubated with1:10 mouse anti-BrdU  and 1:500 goat anti-
mouse Ig Alexa Fluor® 488. Total number of cells was counted using DAPI staining. Number of proliferating 
cells was determined and normalized to the Mock cell line. (D) For cell-cycle analysis we performed flow 
cytometry (Propidium Iodide (1mg/ml) staining). The percentage of cells detected in each phase of the cell 
cycle (G0/G1; S; G2/M) is shown in the graph. Data represents average ± SEM (n=3). Statistical significance 
was determined using ONE-way ANOVA with Dunnett’s post-test. Results were not statistically significant (p 
˃ 0.05). 
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Supplementary Figure 2. Presence of the plasmid pIRES2-DsRed and exogenous tRNAs in the 
tumors (CAM and mice) and histological analysis of representative tumors. (A) Agarose gel of the PCR 
product obtained by amplification of genomic DNA from tumors, extracted from chicken embryo 
chorioallantoic membrane (CAM) model, across the fragment of pIRES2-DsRed plasmid containing the tRNA 
insert. NTC represents the negative control. (B) Agarose gel of the PCR product obtained by amplification of 
genomic DNA from tumors, extracted from mice model, across the fragment of pIRES2-DsRed plasmid 
containing the tRNA insert. NTC represents the negative control. (C) Histological analysis. (Upper panel) 
Hematoxylin and eosin staining staining (H&E) on paraffin-embedded tumor tissues showing high grade 
sarcomas (40x amplification). (Lower panel) Immunohistochemical analysis with anti-Ki67 antibody (1:400) 
on paraffin-embedded tumor tissues presenting high level of proliferation in all tumors (40x amplification). 
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 Supplementary Figure 3. Mass Spectrometry Analysis of protein fractions isolated from tumors 
derived from our cell lines. (A) Number of proteins that have at least one amino acid misincorporation 
AlaSer or LeuSer. (Left panel) Venn diagram showing the number of proteins with amino acid 
substitutions (AlaSer and LeuSer) in the soluble protein fraction. (Right panel) Venn diagram showing 
the number of proteins with amino acid substitutions (AlaSer and LeuSer) in the insoluble protein fraction. 
(B) Analysis of codons that correspond to the misincorporated amino acids (Left panel) Number of Ser 
misincorporations in Ala and Leu codons in the protein soluble fraction. The Ala codons, GCT and GCC, and 
the Leu codons, CTT and CTC correspond to the anticodons of our mutant tRNAs (tRNAAGCSer(Ala) and 
tRNAAAGSer(Leu)) (Right panel) Number of Ser misincorporations in Ala and Leu codons in the protein 
insoluble fraction.  
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Supplementary Figure 4. Activation of XBP-1 in tumors expressing mutant tRNAs and the Wt serine 
tRNA.  Left panel) The presence of unspliced (un), hybrid (H) and spliced (s) XBP-1 forms was checked by 
RT-PCR. Actin β was used as a loading control. Right panel) Activation of XBP-1 was determined using the 
formula: 100x[XBP-1s+0.5 XBP-1H]/[XBP-1s+XBP-1H+XBP-1un]. Graphics depict average ± SEM (n=3). 
Data was analyzed using One-way ANOVA with Dunnett’s post-test and significant p-values are shown 
(*p˂0.05). 
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Supplementary Figure 5. Classical cancer-associated pathways modulated in mice tumors. (A) 
ERK1/2 relative activation ratio among tumor lysates. (B) Relative activation ratios of p38 in tumor lysates. 
(C) Representative immunoblots of ERK1/2-P, ERK1/2, p38-P, total p38 and the respective β-tubulin (loading 
control) from tumor lysates. Graphics depict average ± SEM (n=3). Data was analyzed using One-way 
ANOVA with Dunnett’s post-test and significant p-values are shown (*p˂0.05; **p<0.01). 
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Supplementary Figure 6. TNFα induction assay – results from non-treated cells (negative 
controls). (A) Negative controls of cells treated with with TNFα for 30 minutes. (Upper panel) Relative 
activation ratios of p38 in the cell lines not exposed to TNFα. (Middle panel) Relative activation ratios of Akt 
in the cell lines not exposed to TNFα. (Lower panel) Representative immunoblots of phosphorylated p38, p38, 
phosphorylated Akt and total Akt in cells lines that were not treated with TNFα. β-tubulin was used as a loading 
control. (B) Negative controls of cells treated with TNFα for 4 hours. (Upper panel) Relative activation ratios 
of p38 in the cell lines not exposed to TNFα. (Middle panel) Relative activation ratios of Akt in the cell lines 
not exposed to TNFα. (Lower panel) Representative immunoblots of phosphorylated p38, p38, phosphorylated 
Akt and total Akt in cells lines that were not treated with TNFα. β-tubulin was used as a loading control. Data 
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represents average ± SEM (n=3). Statistical significance was determined using unpaired two-tailored Student’s 
t-test. Results are not statistically significant (p ˃ 0.05), showing that there are no differences among cell lines 
when they are not exposed to any stimuli in vitro. 
  
 
 
 
 
 
 
 
 
